



ARUNJYOTI BIO VENTURES LTD.

To,

Date: 20.07.2026

BSE Limited
P.J. Towers, Dalal Street
Mumbai — 400001

Dear Sir/Madam,

Sub: Submission of Notice of the 40th Annual General Meeting and Annual Report for the Financial Year 2025-26 pursuant to Regulations 30 and 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Unit: Arunjyoti Bio Ventures Limited (Scrip Code 530881)

With reference to the subject cited above and pursuant to Regulations 30 and 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the Notice of the 40th Annual General Meeting and the Annual Report of the Company for the Financial Year 2025-26.


The 40th Annual General Meeting ("AGM") of the Company is scheduled to be held on Wednesday, August 12, 2026, at 11:00 A.M. (IST) through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM").

The cut-off date for the same is Wednesday, 05th August 2026.

This is for the information and records of the Exchange, please.

Thanking you.

Yours sincerely,
For Arunjyoti Bio Ventures Limited


Pabbathi Badari Narayana Murthy
Whole-Time Director
(DIN: 01445523)



Encl: as above

ARUNJYOTI BIO VENTURES LIMITED

**40th
ANNUAL REPORT
2025-26**

ARUNJYOTI BIO VENTURES LIMITED

CORPORATE INFORMATION

BOARD OF DIRECTORS

- | | |
|--|--|
| 1. Mr. Pabbathi Badari Narayana Murthy | - Whole-time Director (DIN: 01445523) |
| 2. Mr. Dathvik Pabbathi | - Whole-time Director (DIN: 09629913) |
| 3. Mr. Nadimpalli Vishal | - Whole-time Director & CFO
(DIN: 02745303) |
| 4. Ms. Dhanalakshmi Guntaka | - Independent Director (DIN: 09363100) |
| 5. Mr. Srikar Ranga | - Independent Director (DIN: 02965183) |
| 6. Mr. Vijaya Rama Lakshmana Murthy Mylavarapu | - Independent Director (DIN: 07788466) |

COMPANY SECRETARY AND COMPLIANCE OFFICER:

Ms. Swati Jain

REGISTERED OFFICE:

Door No.1-98/1/JSIC/6F/604-B6th Floor,
Jain Sadhguru Capital Park, Beside Image Gardens,
Madhapur, Shaikpet, Telangana - 500081
E-mail id: cenport@gmail.com

STATUTORY AUDITORS:

PKF Sridhar & Santhanam LLP
Chartered Accountants
Office Unit 609,
6th Floor, Jain Sadhguru Images Capital Park
Plot No: 1-98/4/1 – 1328 & 29
Near Metro Pillar No 1765
Madhapur
Hyderabad
Telangana, India 500 081.

INTERNAL AUDITORS:

M/s. K.S. Ramakrishna & Co.
Chartered Accountants

BANKERS:

ICICI Bank
Axis Bank

AUDIT COMMITTEE:

- | | |
|---|---------------|
| Ms. Dhanalakshmi Guntaka | - Chairperson |
| Mr. Srikar Ranga | - Member |
| Mr. Vijaya Rama Lakshmana Murthy Mylavarapu | - Member |

NOMINATION & REMUNERATION COMMITTEE:

- | | |
|---|---------------|
| Mr. Vijaya Rama Lakshmana Murthy Mylavarapu | - Chairperson |
| Mr. Srikar Ranga | - Member |
| Ms. Dhanalakshmi Guntaka | - Member |

ARUNJYOTI BIO VENTURES LIMITED

STAKEHOLDERS RELATIONSHIP COMMITTEE:

Ms. Dhanalakshmi Guntaka	- Chairperson
Mr. Dathvik Pabbathi	- Member
Mr. Vijaya Rama Lakshamana Murthy Mylavarapu	- Member

INDEPENDENT DIRECTORS:

Mr. Vijaya Rama Lakshamana Murthy Mylavarapu
Mr. Srikar Ranga
Ms. Dhanalakshmi Guntaka

REGISTRAR & SHARE TRANSFER AGENTS:

Venture Capital and Corporate Investments Private Limited
"AURUM", 4th & 5th Floors, Plot no. 57,
Jayabheri Enclave Phase II, Gachibowli,
Hyderabad-500032, Telangana.

LISTED AT	:	BSE Limited
ISIN	:	INE485K01022
WEBSITE	:	www.abvl.co.in
INVESTOR E-MAIL ID	:	cenport@gmail.com
CORPORATE IDENTITY NUMBER	:	L01400TG1986PLC062463

ARUNJYOTI BIO VENTURES LIMITED

NOTICE

NOTICE is hereby given that the 40th Annual General Meeting of the Members of Arunjyoti Bio Ventures Limited will be held on Wednesday, the 12th day of August 2026 at 11:00 a.m. through Video Conferencing/ Other Audio Visual Means (OAVM) to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and adopt the Audited Balance Sheet as at 31st March, 2026 and the Statement of Profit and Loss for the year ended as on that date along with Cash Flow Statement and notes appended thereto together with the Directors Report and Auditor's Report thereon.
2. To appoint a director in place of Mr. Nadimpalli Vishal who retires by rotation and being eligible, offers himself for re-appointment.

SPECIAL BUSINESS:

3. **TO APPOINT M/S. VIVEK SURANA & ASSOCIATES., PRACTICING COMPANY SECRETARIES AS SECRETARIAL AUDITORS FOR A TERM OF UPTO 5 (FIVE) CONSECUTIVE YEARS.**

To consider and if thought fit, to pass, with or without modification(s), the following resolution as an Ordinary Resolution:

“RESOLVED THAT pursuant to the provisions of Regulation 24A & other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) read with Circulars issued thereunder from time to time and Section 204 and other applicable provisions of the Companies Act, 2013, if any read with Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (“the Act”), M/s. Vivek Surana & Associates., Practicing Company Secretaries be and is hereby appointed as Secretarial Auditors of the Company for a period of 5 consecutive years, from April 1, 2026 to March 31, 2031 (‘the Term’), on such terms & conditions, including remuneration as may be determined by the Board of Directors.”

“RESOLVED FURTHER THAT approval of the Members is hereby accorded to the Board to avail or obtain from the Secretarial Auditor, such other services or certificates or reports which the Secretarial Auditor may be eligible to provide or issue under the applicable laws at a remuneration to be determined by the Board.”

“RESOLVED FURTHER THAT the Board be and is hereby authorized to do all such acts, deeds, matters and things as may be considered necessary, desirable or expedient to give effect to this resolution and for matters connected therewith or incidental thereto.”

4. TO CHANGE THE NAME OF THE COMPANY AND CONSEQUENT ALTERATION OF ARTICLES OF ASSOCIATION AND MEMORANDUM OF ASSOCIATION:

To consider and if thought fit, to pass with or without modification(s), the following resolution as a Special Resolution:

“RESOLVED THAT pursuant to the provisions of Sections 4, 5, 13, 14 and all other applicable provisions, if any, of the Companies Act, 2013 read with the relevant rules there under (including any statutory modifications or re-enactment thereof, for the time being in force) and Memorandum of Association and Articles of Association of the Company and necessary subject to the approval of the Central Government, Registrar of Companies, Hyderabad, under Ministry of Corporate Affairs and Regulation 45 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, consent of the members be and is hereby accorded to change the name of the Company from **“ARUNJYOTI BIO VENTURES LIMITED” to “PASURA INDUSTRIES LIMITED”**.

“RESOLVED FURTHER THAT consequent to the aforesaid change of name of the company, the Name Clause of the Memorandum of Association be and is hereby altered by substituting existing clause I with the following new clause I:

I. The name of the Company is “PASURA INDUSTRIES LIMITED”.

“RESOLVED FURTHER THAT in the Articles of Association, the name **“ARUNJYOTI BIO VENTURES LIMITED”** be and is hereby substituted by **“PASURA INDUSTRIES LIMITED”**.

“RESOLVED FURTHER THAT the Board be and is hereby authorized to make, sign, execute and file necessary applications, forms, papers, documents and furnish information as may be considered necessary or expedient including appointing attorney/s or authorized representatives under appropriate Letter/s of Authority/ies, to appear before the office of the Ministry of Corporate Affairs / Registrar of Companies, Stock Exchange where securities of the Company are listed and other Regulatory or Statutory Authority/ies, as may be required from time to time and do all such acts, deeds, matters and things as may be considered necessary to give effect to the above resolution.”

5. RATIFICATION OF THE LOAN GIVEN TO PASURA XPRESS LLP, A RELATED PARTY

To consider and if thought fit, to pass, with or without modification(s), the following resolution as a Special Resolution:

“RESOLVED THAT pursuant to Section 185 and all other applicable provisions, if any, of the Companies Act, 2013, read with the relevant Rules thereof (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) and based on the approval of the Audit Committee and Board of Directors, the consent of the members be and is hereby accorded to ratify the loan extended to **Pasura Xpress LLP**, being an entity in which one or more Directors of the Company are interested, up to an aggregate amount not exceeding **Rs. 1,00,00,000 (Rupees One Crore Only)**, on such terms and conditions as may be determined by the Board from time to time.

RESOLVED FURTHER THAT the Board be and is hereby authorised to take all such actions and to give all such directions as may be necessary or desirable and also to settle any question or difficulty that may arise in regard to the proposed investments or loans or guarantees or securities and to do all such acts, deeds, matters and things and to execute all such deeds, documents and writings as may be necessary, desirable or expedient in connection therewith.”

6. APPROVAL OF WAIVER OF RECOVERY OF EXCESS MANAGERIAL REMUNERATION PAID TO MR. PABBATHI BADARI NARAYANA MURTHY, WHOLE-TIME DIRECTOR FOR THE FINANCIAL YEAR 2025-26

To consider and if thought fit, to pass, with or without modification(s), the following resolution as a Special Resolution:

“RESOLVED THAT pursuant to the provisions of Section 197(10) and other applicable provisions, if any, of the Companies Act, 2013, read with the applicable Rules made thereunder (including any statutory modification(s), amendment(s) or re-enactment(s) thereof for the time being in force), and pursuant to the recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors, consent of the members be and is hereby accorded for the waiver of recovery from Mr. Pabbathi Badari Narayana Murthy, Whole-time Director, of the excess remuneration of ₹9,71,432 (Rupees Nine Lakhs Seventy-One Thousand Four Hundred and Thirty-Two only) paid during the financial year 2025-26.”

“RESOLVED FURTHER THAT the Members hereby note that the remuneration approved by the members was implemented and paid as a net remuneration, with the income-tax liability thereon being separately borne by the Company and consequently, the income-tax paid by the Company on behalf of Mr. Pabbathi Badari Narayana Murthy formed part of his remuneration in accordance with the provisions of the Companies Act, 2013, resulting in the aggregate managerial

remuneration exceeding the amount approved by the members by ₹9,71,432 (Rupees Nine Lakhs Seventy-One Thousand Four Hundred and Thirty-Two only).”

“RESOLVED FURTHER THAT members after considering the facts and circumstances of the case, are satisfied that the excess remuneration was neither attributable to any fraud nor to any wilful default on the part of Mr. Pabbathi Badari Narayana Murthy, but arose solely on account of the tax liability borne by the Company on the net remuneration paid to him, and accordingly approved the waiver of recovery of the said excess remuneration in terms of Section 197(10) of the Companies Act, 2013.”

“RESOLVED FURTHER THAT the Board of Directors of the Company (which term shall be deemed to include any Committee thereof and any person(s) authorised by the Board in this behalf) be and is hereby authorised to do all such acts, deeds, matters and things as may be necessary, desirable or expedient to give effect to this Resolution and to settle any questions, difficulties or doubts that may arise in connection therewith.”

7. APPROVAL OF WAIVER OF RECOVERY OF EXCESS MANAGERIAL REMUNERATION PAID TO MR. NADIMPALLI VISHAL, WHOLE-TIME DIRECTOR AND CFO FOR THE FINANCIAL YEAR 2025-26

To consider and if thought fit, to pass, with or without modification(s), the following resolution as a Special Resolution:

“RESOLVED THAT pursuant to the provisions of Section 197(10) and other applicable provisions, if any, of the Companies Act, 2013, read with the applicable Rules made thereunder (including any statutory modification(s), amendment(s) or re-enactment(s) thereof for the time being in force), and pursuant to the recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors, consent of the members be and is hereby accorded for the waiver of recovery from Mr. Nadimpalli Vishal, Whole-time Director and CFO, of the excess remuneration of ₹15,47,800 (Rupees Fifteen Lakhs Forty Seven Thousand and Eight Hundred only) paid during the financial year 2025-26.”

“RESOLVED FURTHER THAT the Members hereby note that the remuneration approved by the members was implemented and paid as a net remuneration, with the income-tax liability thereon being separately borne by the Company and consequently, the income-tax paid by the Company on behalf of Mr. Nadimpalli Vishal formed part of his remuneration in accordance with the provisions of the Companies Act,

2013, resulting in the aggregate managerial remuneration exceeding the amount approved by the members by ₹15,47,800 (Rupees Fifteen Lakhs Forty Seven Thousand and Eight Hundred only).”

“RESOLVED FURTHER THAT members after considering the facts and circumstances of the case, are satisfied that the excess remuneration was neither attributable to any fraud nor to any wilful default on the part of Mr. Nadimpalli Vishal, but arose solely on account of the tax liability borne by the Company on the net remuneration paid to him, and accordingly approved the waiver of recovery of the said excess remuneration in terms of Section 197(10) of the Companies Act, 2013.”

“RESOLVED FURTHER THAT the Board of Directors of the Company (which term shall be deemed to include any Committee thereof and any person(s) authorised by the Board in this behalf) be and is hereby authorised to do all such acts, deeds, matters and things as may be necessary, desirable or expedient to give effect to this Resolution and to settle any questions, difficulties or doubts that may arise in connection therewith.”

8. INCREASE IN THE REMUNERATION OF MR. PABBATHI BADARI NARAYANA MURTHY, WHOLE-TIME DIRECTOR OF THE COMPANY

To consider and if thought fit, to pass, with or without modification(s), the following resolution as a Special Resolution:

“RESOLVED THAT pursuant to the provisions of Section 197 read with Part I and Section I of Part II of Schedule V and other applicable provisions, if any, of the Companies Act, 2013 (including any statutory modification or re-enactment thereof), applicable clauses of Articles of Association of the Company and on recommendation of the Nomination & Remuneration Committee and Board of Directors, consent of the Members be and is hereby accorded for revision in the remuneration and perquisites payable to Mr. Pabbathi Badari Narayana Murthy, Whole Time Director of the Company with effect from 01.04.2026 for his remaining tenure as per the details below:

a) Salary: Rs. 8,00,000/- per month.

b) Leave Travel allowance – Rs. 10,00,000 per annum for self and family

“RESOLVED FURTHER THAT in the event of losses or inadequacy of profits in any financial year during his tenure the Company shall pay to Mr. Pabbathi Badari Narayana Murthy (DIN: 01445523) remuneration by way of salaries and allowances as specified above as minimum remuneration and in accordance with the limits specified under the Companies Act, 2013 read with Schedule V to the Companies Act 2013,

or such other limit as may be prescribed by the Government from time to time”.

“RESOLVED FURTHER THAT the Board be and is here by the authorized to do all such acts, deeds, matters and things as in its absolute discretion, it may consider necessary, expedient or desirable including filing of forms with the Registrar of Companies, Telangana and to settle any question or doubt that may arise in relation thereto and in order to give effect to the foregoing Resolution, or as may be otherwise considered fit by it in the best interest of the Company.”

9. INCREASE IN THE REMUNERATION OF MR. NADIMPALLI VISHAL, WHOLE-TIME DIRECTOR AND CFO OF THE COMPANY

To consider and if thought fit, to pass, with or without modification(s), the following resolution as a Special Resolution:

“RESOLVED THAT pursuant to the provisions of Section 197 read with Part I and Section I of Part II of Schedule V and other applicable provisions, if any, of the Companies Act, 2013 (including any statutory modification or re-enactment thereof), applicable clauses of Articles of Association of the Company and on recommendation of the Nomination & Remuneration Committee and Board of Directors, consent of the Members be and is hereby accorded for revision in the remuneration and perquisites payable to Mr. Nadimpalli Vishal, Whole Time Director and CFO of the Company, with effect from 01.04.2026 for his remaining tenure as per the details below:”

a) Salary: Rs. 5,00,000/- per month.

b) Leave Travel allowance – Rs. 10,00,000 per annum for self and family

“RESOLVED FURTHER THAT in the event of losses or inadequacy of profits in any financial year during his tenure the Company shall pay to Mr. Nadimpalli Vishal remuneration by way of salaries and allowances as specified above as minimum remuneration and in accordance with the limits specified under the Companies Act, 2013 read with Schedule V to the Companies Act 2013, or such other limit as may be prescribed by the Government from time to time.”

“RESOLVED FURTHER THAT the Board be and is here by the authorized to do all such acts, deeds, matters and things as in its absolute discretion, it may consider necessary, expedient or desirable including filing of forms with the Registrar of Companies, Telangana and to settle any question or doubt that may arise in relation thereto and in order to give effect to the foregoing Resolution, or as may be otherwise considered fit by it in the best interest of the Company.”

10. INCREASE IN THE REMUNERATION OF MR. DATHVIK PABBATHI, WHOLE-TIME DIRECTOR OF THE COMPANY

To consider and if thought fit, to pass, with or without modification(s), the following resolution as a Special Resolution:

“RESOLVED THAT pursuant to the provisions of Section 197 read with Part I and Section I of Part II of Schedule V and other applicable provisions, if any, of the Companies Act, 2013 (including any statutory modification or re-enactment thereof), applicable clauses of Articles of Association of the Company and on recommendation of the Nomination & Remuneration Committee and Board of Directors, consent of the Members be and is hereby accorded for revision in the remuneration and perquisites payable to Mr. Dathvik Pabbathi, Whole Time Director of the Company, with effect from 01.04.2026 for his remaining tenure as per the details below:”

a) Salary: Rs. 5,00,000/- per month.

b) Leave Travel allowance – Rs. 10,00,000 per annum for self and family

“RESOLVED FURTHER THAT in the event of losses or inadequacy of profits in any financial year during his tenure the Company shall pay to Mr. Dathvik Pabbathi remuneration by way of salaries and allowances as specified above as minimum remuneration and in accordance with the limits specified under the Companies Act, 2013 read with Schedule V to the Companies Act 2013, or such other limit as may be prescribed by the Government from time to time.”

“RESOLVED FURTHER THAT the Board be and is here by the authorized to do all such acts, deeds, matters and things as in its absolute discretion, it may consider necessary, expedient or desirable including filing of forms with the Registrar of Companies, Telangana and to settle any question or doubt that may arise in relation thereto and in order to give effect to the foregoing Resolution, or as may be otherwise considered fit by it in the best interest of the Company.”

**For and on behalf of the Board
Arunjyoti Bio Ventures Limited**

**Sd/-
Pabbathi Badari Narayana Murthy
Whole-time Director
(DIN: 01445523)**

**Place: Hyderabad
Date: 09.07.2026**

ARUNJYOTI BIO VENTURES LIMITED

NOTES:

1. In pursuance of Regulation 36 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard on General Meetings, details in respect of the Directors seeking appointment/ re-appointment at the AGM, form part of this Notice.
2. Ministry of Corporate Affairs vide General Circular No.03/2025 dated September 22, 2025, has permitted the holding of the Annual General Meeting ("AGM") through Video Conference/Other Audio Visual Means, without the physical presence of the Members at a common venue. Pursuant to the provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the Circulars issued by MCA and SEBI, the AGM of the Company is being conducted through Video Conferencing (VC)/ Other Audio-Visual Means (OAVM).
3. The Deemed Venue of the 40th AGM of the Company shall be its Registered Office.
4. Since the AGM will be held through VC/OAVM (e-AGM), the Route Map for venue of AGM is not annexed to the Notice.
5. Members attending the AGM through VC/OAVM shall be counted for the purpose of reckoning the quorum of the AGM under Section 103 of the Act.
6. In compliance with the MCA Circulars and SEBI Circular, Notice of the AGM along with Annual Report for the financial year 2025-26 is being sent only through electronic mode to those Members whose email addresses are registered with the Company/ Depositories/ R&T Agent. Members may note that the Notice will also be available on the Company's website www.abvl.co.in, website of the Stock Exchange i.e., BSE Limited at www.bseindia.com. The AGM Notice is also disseminated on the website of CDSL (agency for providing the Remote e-Voting facility and e-voting system during the AGM i.e. www.evotingindia.com).
7. In case of joint holders, the Member whose name appears as the first holder in the order of names as per the Register of Members of the Company will be entitled to vote at the AGM.

ARUNJYOTI BIO VENTURES LIMITED

8. To avoid fraudulent transaction(s), the identity/ signature of the Members holding shares in electronic/ demat form is verified with the specimen signatures furnished by NSDL/ CDSL and members holding shares in physical form is verified as per the records of the R&T Agent of the Company. Members are requested to keep the same updated.
9. Pursuant to the provisions of the Act and other applicable Regulations, a Member entitled to attend and vote at the AGM is entitled to appoint a proxy to attend and vote on their behalf and the proxy need not be a Member of the Company. However since this AGM is being held pursuant to the MCA/SEBI Circulars through VC/OAVM, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of proxies by the Members will also not be available for the AGM and hence the Proxy Form and Attendance Slip are not annexed to the Notice.
10. Corporate/institutional Members (i.e. other than individuals, HUF, NRI, etc.) are required to send a scanned copy (PDF/ JPG format) of the relevant Board Resolution/Authority Letter / Power of Attorney etc. together with attested specimen signature of the duly authorised signatory(ies) who is /are authorised to vote, to the Scrutinizer through e-mail at cenport@gmail.com.
11. Recent circular requires submission of Aadhaar/PAN number by every participant in securities market. Members holding shares in demat form are, therefore, requested to submit Aadhaar card/PAN details to the Depository Participants with whom they have demat accounts. Members holding shares in physical form can submit their Aadhaar card/PAN details to the Company/ Registrar and Share Transfer Agents (Venture Capital Corporate Investments Private Limited)
12. Members holding shares in the same name under different ledger folios are requested to apply for Consolidation of such folios and send therelevant share certificates to Venture Capital Corporate Investments Private Limited., Share Transfer Agents of the Company for their doing the needful.
13. Members are requested to send their queries at least 5 days before the date of meeting so that information can be made available at the meeting.
14. In respect of shares held in physical mode, all shareholders are requested to intimate changes, if any, in their registered address immediately to the registrar and share transfer agent of the Company

ARUNJYOTI BIO VENTURES LIMITED

and correspond with them directly regarding share transfer/transmission /transposition, Demat/Remat, change of address, issue of duplicate shares certificates, ECS and nomination facility.

15. In terms of Section 72 of the Companies Act, 2013, a member of the Company may nominate a person on whom the shares held by him/her shall vest in the event of his/her death. Members desirous of availing this facility may submit nomination in prescribed Form-SH-13 to the Company/RTA in case shares are held in physical form, and to their respective depository participant, if held in electronic form.
16. Members holding shares in the electronic form are requested to inform any changes in address/bank mandate directly to their respective Depository Participants.
17. The company has appointed M/s. Vivek Surana & Associates, Practicing Company Secretaries, as scrutinizer of the company to scrutinize the voting process.
18. Since securities of the Company are traded compulsorily in dematerialized form as per SEBI mandate, members holding shares in physical form are requested to get their shares dematerialized at the earliest.
19. The Members can join the e-AGM 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice.
20. The Register of Directors' and Key Managerial Personnel and their shareholding maintained under Section 170 of the Companies Act, 2013, the Register of Contracts or arrangements in which the Directors are interested under Section 189 of the Companies Act, 2013, will be available for inspection at the AGM.
- 21. THE INTRUCTIONS FOR SHAREHOLDERS FOR REMOTE E-VOTING AREAS UNDER:**

THE INTRUCTIONS OF SHAREHOLDERS FOR REMOTE E-VOTING:

Step 1: Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

Step 2 : Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.

ARUNJYOTI BIO VENTURES LIMITED

- (i) The voting period begins on Sunday, 09.08.2026 at 09:00 a.m. and ends on Tuesday, 11.08.2026 at 05:00 p.m. During this period shareholders' of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date (record date) of Wednesday, 05.08.2026 may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.
- (ii) Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.
- (iii) Pursuant to SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 09.12.2020, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.
- (iv) Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.
- (v) In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to all the demat account holders, by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

Step 1 : Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

In terms of SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

ARUNJYOTI BIO VENTURES LIMITED

Pursuant to abovesaid SEBI Circular, Login method for e-Voting for **Individual shareholders holding securities in Demat mode CDSL/NSDL** is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in Demat mode with CDSL Depository	1) Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login to Easi / Easiest are requested to visit cdsi website www.cdslindia.com and click on login icon & My Easi New (Token) Tab. 2) After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly. 3) If the user is not registered for Easi/Easiest, option to register is available at cdsi website www.cdslindia.com and click on login & My Easi New (Token) Tab and then click on registration option. 4) Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.

Individual Shareholders
holding securities in
demat mode with **NSDL
Depository**

- 1) If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: <https://eservices.nsdl.com> either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period.
- 2) If the user is not registered for IDeAS e-Services, option to register is available at <https://eservices.nsdl.com>. Select "Register Online for IDeAS "Portal or click at <https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp>
- 3) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period.
- 4) For OTP based login you can click on <https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp>. You will have to enter your 8-digit DP ID, 8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile

ARUNJYOTI BIO VENTURES LIMITED

	number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.
Individual Shareholders (holding securities in demat mode) login through their Depository Participants (DP)	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	Helpdesk details
Individual Shareholders holding securities in Demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 21 09911
Individual Shareholders holding securities in Demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at : 022 - 4886 7000 and 022 - 2499 7000

ARUNJYOTI BIO VENTURES LIMITED

Step 2 : Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.

- (i) Login method for Remote e-Voting for Physical shareholders and shareholders other than individual holding in Demat form.
- 1) The shareholders should log on to the e-voting website www.evotingindia.com.
- 2) Click on “Shareholders” module.
- 3) Now enter your User ID
 - a. For CDSL: 16 digits beneficiary ID,
 - b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
 - c. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.
- 4) Next enter the Image Verification as displayed and Click on Login.
- 5) If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier e-voting of any company, then your existing password is to be used.
- 6) If you are a first-time user follow the steps given below:

	For Physical shareholders and other than individual shareholders holding shares in Demat.
PAN	Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.
Dividend Bank Details OR Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login. If both the details are not recorded with the depository or company, please enter the member id / folio number in the Dividend Bank details field.

ARUNJYOTI BIO VENTURES LIMITED

- (ii) After entering these details appropriately, click on “SUBMIT” tab.
- (iii) Shareholders holding shares in physical form will then directly reach the Company selection screen. However, shareholders holding shares in demat form will now reach ‘Password Creation’ menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- (iv) For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- (v) Click on the EVSN for the relevant Arunjyoti Bio Ventures Limited on which you choose to vote.
- (vi) On the voting page, you will see “RESOLUTION DESCRIPTION” and against the same the option “YES/NO” for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- (vii) Click on the “RESOLUTIONS FILE LINK” if you wish to view the entire Resolution details.
- (viii) After selecting the resolution, you have decided to vote on, click on “SUBMIT”. A confirmation box will be displayed. If you wish to confirm your vote, click on “OK”, else to change your vote, click on “CANCEL” and accordingly modify your vote.
- (ix) Once you “CONFIRM” your vote on the resolution, you will not be allowed to modify your vote.
- (x) You can also take a print of the votes cast by clicking on “Click here to print” option on the Voting page.
- (xi) If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- (xii) There is also an optional provision to upload BR/POA if any uploaded, which will be made available to scrutinizer for verification.
- (xiii) Additional Facility for Non – Individual Shareholders and Custodians –For Remote Voting only.
 - Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to www.evotingindia.com and register themselves in the “Corporates” module.

ARUNJYOTI BIO VENTURES LIMITED

- A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
- After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
- The list of accounts linked in the login will be mapped automatically & can be delink in case of any wrong mapping.
- It is Mandatory that, a scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
- Alternatively Non Individual shareholders are required mandatory to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz; cenport@gmail.com (designated email address by company) , if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL/MOBILE NO. ARE NOT REGISTERED WITH THE COMPANY/DEPOSITORIES.

1. For Physical shareholders- please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to Company/RTA email id.
2. For Demat shareholders -, Please update your email id & mobile no. with your respective Depository Participant (DP)
3. For Individual Demat shareholders – Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory while e-Voting & joining virtual meetings through Depository.

If you have any queries or issues regarding e-Voting from the CDSL e-Voting System, you can write an email to helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 21 09911

All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Sr. Manager, (CDSL) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call at toll free no. 18002109911

22. OTHER INSTRUCTIONS:

- (i) The voting rights of shareholders shall be in proportions to the shares held by them in the paid equity share capital of the Company as on the cut-off date i.e. 05.08.2026
 - (ii) The Scrutinizer shall after the conclusion of the Voting at the Annual General Meeting first count the votes cast at the meeting and thereafter unblock the votes cast through remote e-voting in the presence of at least two (2) witnesses not in the employment of the Company and make not later than three days of conclusion of the meeting a consolidated Scrutinizer's Report of the total votes cast in favour or against, if any, to the Chairman or person authorized by him.
 - (iii) Voting is provided to the members through e-voting and at the Annual General Meeting of the Company. A Member can opt for only one mode of voting i.e. either through e-voting or at the Annual General Meeting of the Company.
 - (iv) If a Member cast votes by both modes, then voting done through e-voting shall prevail.
 - (v) The results declared along with the Scrutinizer's Report shall be placed on the Company's website <https://www.abvl.co.in/investors.html> and on the website of CDSL and will be communicated to the BSE Limited.
23. Relevant Documents referred to in the accompanying Notice, as well as Annual Report is open for inspection at the Registered Office of the Company, during the office hours, on all working days up to the date of Annual General Meeting.

SEBI has notified vide Notification No. SEBI/LAD-NRO/GN/2018/24 that securities of the listed companies can be transferred only in dematerialized form. In view of the above and to avail various benefits of dematerialization, members are advised to dematerialize shares held by them in physical form.

**For and on behalf of the Board
Arunjyoti Bio Ventures Limited**

**Sd/-
Pabbathi Badari Narayana Murthy
Whole-time Director
(DIN: 01445523)**

**Place: Hyderabad
Date: 09.07.2026**

EXPLANATORY STATEMENT

[Pursuant to Section 102 of the Companies Act, 2013 and SEBI (LODR) Regulations, 2015]

ITEM NO. 3:

TO APPOINT M/S. VIVEK SURANA & ASSOCIATES., PRACTICING COMPANY SECRETARIES AS SECRETARIAL AUDITORS FOR A TERM OF UP TO 5 (FIVE) CONSECUTIVE YEARS.

M/s Manoj Parakh & Associates has tendered their resignation as Secretarial Auditors of the Company w.e.f. 09.07.2026. Pursuant to the amended provisions of Regulation 24A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR Regulations') vide SEBI Notification dated December 12, 2024 and provisions of Section 204 of the Companies Act, 2013 ('Act') and Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Audit Committee and the Board of Directors at their respective meetings held on 09.07.2026 have approved and recommended the appointment of M/s. Vivek Surana & Associates, Peer Reviewed Firm of Company Secretaries in Practice (Firm Registration Number: S2014TL278800) as Secretarial Auditors of the Company for a term of upto 5 (Five) consecutive years to hold office from Financial Year 2026-27 to Financial Year 2030-31 and issue Secretarial Audit Report for Financial Years ending 31st March 2027, 31st March 2028, 31st March 2029, 31st March 2030 and 31st March 2031.

- a. **Term of appointment:** Up to 5(Five) consecutive years from Financial Year 2026-27 to Financial Year 2030-31.
- b. **Proposed Fee:** In the range of Rs. 50,000/- per annum to Rs. 1,00,000/- per annum, plus applicable taxes and other out-of-pocket costs incurred in connection with the audit for Financial Year ending March 31, 2027 and for subsequent year(s) of their term, such fee as determined by the Board, on recommendation of Audit Committee subject to modification by the Board.

The proposed fee is based on knowledge, expertise, industry experience, time and efforts required to be put in by them, which is in line with the industry benchmark. The fees for services in the nature of certifications and other professional work will be in addition to the secretarial audit fee as above and will be determined by the Board in consultation with the Secretarial Auditors and as per the recommendations of the Audit Committee.

- c. **Basis of recommendations:** The recommendations are based on the fulfilment of the eligibility criteria & qualification prescribed under the Act

ARUNJYOTI BIO VENTURES LIMITED

& Rules made thereunder and SEBI LODR Regulations with regard to the secretarial audit, experience of the firm, capability, independent assessment, audit experience and also based on the evaluation of the quality of audit work done by them in the past.

- d. **Credentials:** M/s. Vivek Surana & Associates, is a Practicing Company Secretaries firm based in Hyderabad providing secretarial, filings and incorporations, foreign advisory services. The firm has existence of more than a decade in the above said services.

M/s. Vivek Surana & Associates, have given their consent to act as Secretarial Auditors of the Company and confirmed that their aforesaid appointment (if made) would be within the prescribed limits under the Act & Rules made thereunder and SEBI LODR Regulations. They have also confirmed that they are not disqualified to be appointed as Secretarial Auditors in terms of provisions of the Act & Rules made thereunder and SEBI LODR Regulations.

- e. **Any material changes in the fee payable to such auditor from that paid to the outgoing auditor along with the rationale for such change:** There is only a change in the Auditor. The proposed fees to be paid to the incoming auditor is same as the outgoing auditor.

The Board recommends the Ordinary Resolution as set out in Item No. 3 of this Notice for approval of the Members.

None of the Directors, Key Managerial Personnel (KMP), or their relatives have any financial or other interest in the proposed resolution.

ITEM NO. 4:

TO CHANGE THE NAME OF THE COMPANY AND CONSEQUENT ALTERATION OF ARTICLES OF ASSOCIATION AND MEMORANDUM OF ASSOCIATION

The Board of Directors vide circular resolution dated 17.06.2026 has made an application to the Registrar of Companies for ascertaining availability of the proposed new name "**Pasura Industries Limited**". Accordingly, the Company has obtained the name availability of "Pasura Industries Limited" from the Registrar of Companies vide its letter dated 07.07.2026.

Further, the Board of Directors in its meeting held on 09.07.2026 has approved for change in the name of the Company from **Arunjyoti Bio Ventures Limited**" to "**Pasura Industries Limited**".

Reason for name change:

The Company is proposing to change the name of the company to align the

ARUNJYOTI BIO VENTURES LIMITED

Company's corporate identity with that of the Group i.e., "PASURA" and to create a uniform brand presence. The proposed name change is purely for branding and business identification purposes and does not result in any Company's business activities or operations.

Memorandum of Association and Articles of Association of the Company is to be altered by substituting the old name with the new name as set out in the Notice for approval by the Shareholders of the Company. The proposed change of name will not affect any of the rights and obligations of the Company or of the shareholders/stakeholders of the Company.

All existing share certificates bearing the current name of the Company will, after the change of name, continue to be valid for all purposes.

Pursuant to Regulation 45(3) of SEBI (LODR), Regulations, 2015 a certificate certifying the compliance with the conditions specified in Reg. 45(1) of SEBI (LODR), Regulations, 2015 as provided by M/s. PKF Sridhar & Santhanam LLP, Chartered Accountant is annexed herewith.

As per the provisions of Sections 13 and 14 of the Companies Act, 2013, approval of the shareholders is required to be accorded for changing the name of the Company & consequent alteration in the Memorandum of Association and Articles of Association by way of passing a Special Resolution.

Your directors recommend the Resolution No.4 of the Notice for the approval of the Members as a Special Resolution.

None of the Directors or Key Managerial Personnel or any relative of any of the Directors/ Key Managerial Personnel of the Company are, in any way, concerned or interested, financially or otherwise, in the resolution.

ARUNJYOTI BIO VENTURES LIMITED

PKF SRIDHAR & SANTHANAM LLP

Chartered Accountants

To
The Board of Directors
Arunjyoti Bio Ventures Limited,
1-98/1/J5IC/6F/604-B, 6th Floor,
Jain Sadhguru Capital Park,
Beside Image Gardens, Madhapur,
Hyderabad, Shaikpet, Telangana,
India - 500081

Independent Auditor's Certificate on Compliance with Regulation 45(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in respect of proposed change of name of the Company.

1. In accordance with the terms of our engagement letter dated 18th June 2026.
2. We, PKF Sridhar & Santhanam LLP, Chartered Accountants, the Independent Auditors of Arunjyoti Bio Ventures Limited ("the Company"), are required to certify compliance under Regulation 45(1) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 with regard to proposed change of name of the Company from Arunjyoti Bio Ventures Limited to Pasura Industries Limited ("proposed name").

Management's Responsibility

3. The Board of Directors of Arunjyoti Bio Ventures Limited ("the Company") is responsible for ensuring compliance with the requirements of Regulation 45(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations") in relation to the proposed change of name of the Company from "Arunjyoti Bio Ventures Limited" to "Pasura Industries Limited" ("Proposed Name").
4. The Management is responsible for:
 - i. maintaining proper books of account, statutory records, resolutions, filings and other relevant documents supporting the activities carried on by the Company;
 - ii. determining and documenting the rationale for the proposed change of name, including whether the Proposed Name represents any new activity or new project undertaken or proposed to be undertaken by the Company;
 - iii. confirming that the Company has not commenced any new activity or new project represented by the Proposed Name during the relevant period;
 - iv. identifying the applicable requirements of Regulation 45(1) of the SEBI LODR Regulations and ensuring compliance with the same, including the requirement that a period of at least one year has elapsed from the last change in name of the Company;
 - v. preparing and providing to us all relevant information, explanations, management representations, records and documents necessary for the purpose of this certificate; and
 - vi. ensuring the completeness, accuracy and authenticity of the information furnished to us.

Auditor's Responsibility

5. Our responsibility is to examine the books of account, records and other relevant documents provided by the Management and issue a certificate on compliance with Regulation 45(1) of the SEBI LODR Regulations in respect of the proposed change of name of the Company.
6. We have conducted our examination in accordance with the Guidance Note on Reports or Certificates for Special Purposes issued by the Institute of Chartered Accountants of India (ICAI). This Guidance Note requires compliance with the ethical requirements of the Code of Ethics issued by ICAI.
7. We have complied with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information, and Other Assurance and Related Services Engagements.



Page 1 of 3

Office Unit No: 609, Jain Sadguru Images Capital Park, 6th Floor, Plot No: 1-98/4/1-2 28 & 29, Image Garden Road,

Madhapur Village, Serilingampally, Hyderabad - 500081, Telangana. Ph : 040 - 29323743 / 29332743

Head Office/Registered Office: KRD Gee Gee Crystal • No 91-92 7th Floor • Dr Radhakrishnan Salai • Mylapore • Chennai • 600004, India

Tel +91 44 28112985 • Fax +91 44 28112989 • Email sands@pkfindia.in • www.pkfindia.in

PKF SRIDHAR & SANTHANAM LLP is a registered limited liability partnership with LLPIN AAB-6552

REGISTRATION NO. WITH ICAI IS 903990/S/200018

ARUNJYOTI BIO VENTURES LIMITED

Summary of work performed

8. In performing our examination, we have carried out the following procedures:
 - a. Obtained and examined the relevant records, resolutions, statutory filings and other documents maintained by the Company in relation to the proposed change of name from Arunjyoti Bio Ventures Limited to Pasura Industries Limited.
 - b. Verified that a period of at least one year has elapsed from the date of the last change in name of the Company, in accordance with the requirements of Regulation 45(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
 - c. Obtained management representation and examined relevant records, including the Company's business activities, books of account, audited financial statements, Board/Committee records and other documents made available to us, to verify whether the proposed name represents any new activity or new project undertaken by the Company during the relevant period.
 - d. Based on the aforesaid examination, noted that the Company has not commenced any new activity or new project represented by the proposed name during the relevant period. Accordingly, the requirements relating to deriving at least fifty percent of total revenue from such activity or investing at least fifty percent of total assets in such activity/project, were considered not applicable.

Conclusion

9. Based on our examination, as stated above, and according to the information and explanations provided to us by the Management of the Company, we hereby certify that:
 - i. A period of at least one year has elapsed from the date of the last change in name of the Company.
 - ii. The Company has not commenced any new activity represented by the proposed name during the relevant period. Accordingly, the requirement of deriving at least fifty percent of the total revenue of the Company from such activity does not apply.
 - iii. The Company has not commenced any new activity/project represented by the proposed name during the relevant period. Accordingly, the requirement of investing at least fifty percent of the total assets of the Company in such activity/project does not apply.

Restrictions of use

10. This certificate is issued solely for submission to the Stock Exchange(s) in accordance with Regulation 45(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in connection with the proposed change of name of the Company.
11. This certificate should not be used for any other purpose or distributed to any other parties without our prior written consent. Accordingly, we do not accept or assume any liability or duty of care to any person other than the Company or for any purpose other than that for which it is issued

For PKF Sridhar & Santhanam LLP

Chartered Accountants

Firm's Registration No.0039905/S200018

Viswanadh VNSS Kuchi

Partner

Membership No.210789

UDIN: 26210789OIZIUQ9713

Date: 09-07-2026

Place: Hyderabad



ITEM NO.5

RATIFICATION OF THE LOAN GIVEN TO PASURA XPRESS LLP, A RELATED PARTY

It is informed that the Company has given a loan of Rs. 80.72 Lakhs in FY 2025-26 to a Pasura Xpress LLP, body corporate and a related party.

The consent and approval of the Shareholders is therefore, sought now in accordance with the provisions of Section 185 (2) (a) and (b) which is mentioned hereunder of the Companies Act, 2013 for the loan extended to Pasura Xpress LLP, a related party.

A company may advance any loan including any loan represented by a book debt, or give any guarantee or provide any security in connection with any loan taken by any person in whom any of the director of the company is interested, subject to the condition that—

(a) a special resolution is passed by the company in general meeting:

Provided that the explanatory statement to the notice for the relevant general meeting shall disclose the full particulars of the loans given, or guarantee given or security provided and the purpose for which the loan or guarantee or security is proposed to be utilised by the recipient of the loan or guarantee or security and any other relevant fact;

and

(b) the loans are utilised by the borrowing company for its principal business activities.

Mr. Pabbathi Badari Narayana Murthy and Mr. Pabbathi Dathvik, Whole-time Directors of the Company, are interested in the Borrower, Pasura Xpress LLP, by virtue of being its Designated Partners. Accordingly, pursuant to the provisions of Section 185 of the Companies Act, 2013, the approval of the members by way of a Special Resolution is required to enable the Company to grant a loan of up to ₹1,00,00,000 (Rupees One Crore Only) including the loan already advanced to the Borrower.

The proposed loan shall carry an interest rate of 10% (Ten Percent) per annum and shall be utilized by the Borrower solely for its principal business activities.

The Board of Directors recommends the passing of the above resolution as Special Resolution as set out in the item no. 5.

None of the other Directors /Key Managerial Personnel and their relatives except Mr. Pabbathi Badari Narayana Murthy and Mr. Pabbathi Dathvik are in any way interested or concerned financially or otherwise, in the Resolution set out in the notice.

ITEM NO.6

APPROVAL OF WAIVER OF RECOVERY OF EXCESS MANAGERIAL REMUNERATION PAID TO MR. PABBATHI BADARI NARAYANA MURTHY, WHOLE-TIME DIRECTOR FOR THE FINANCIAL YEAR 2025-26.

The shareholders vide Special Resolution passed at the Annual General Meeting held on 14.09.2024, approved payment of remuneration of Rs. 7,00,000/- per month to Mr. Pabbathi Badari Narayana Murthy, Whole-time Director of the Company for the period 01.07.2024 to 09.11.2025. Thereafter, the Shareholders in the Annual general Meeting held on 10.09.2025 revised payment of his remuneration to Rs. 5,00,000/- per month for the period 10.11.2025 to 09.11.2028.

Upon internal review, it was observed that total remuneration paid to Mr. Pabbathi Badari Narayana Murthy during the financial year 2025-26, aggregated to ₹85,71,432 resulting in an excess of ₹9,71,432 over and above the remuneration approved by the members ("Excess Remuneration"). The excess payment was inadvertent in nature and arose on account of a bona fide interpretation and implementation of the approved remuneration structure.

The Excess Remuneration arose because the remuneration approved by the members was treated and paid as a net amount to Mr. Pabbathi Badari Narayana Murthy, while the income-tax liability thereon was separately borne by the Company, though the same should have been added to Mr. Murthy's remuneration. Consequently, the aggregate remuneration, including the tax borne by the Company on behalf of the Whole-time Director, exceeded the amount approved by the members.

In terms of Section 197 of the Companies Act, 2013 and the applicable rules made thereunder, where remuneration has been paid in excess of the limits approved by the members, the Company is required either to recover the excess remuneration from the director concerned or obtain approval of the members by way of a Special Resolution for waiver of recovery of such excess remuneration.

ARUNJYOTI BIO VENTURES LIMITED

Accordingly, based on the recommendation of the Nomination and Remuneration Committee, Board of Directors in their meeting held on 09.07.2026 approved for waiver of recovery of the Excess Remuneration amounting to ₹9,71,432 paid to Mr. Pabbathi Badari Narayana Murthy during the financial year 2025-26 subject to the approval of the members by way of a Special Resolution.

It is also confirmed that as on the date of the notice, the company is not in default in repayment of any dues to any bank, public financial institution, non-convertible debenture holders or any other secured creditor. Accordingly, prior approval of such lenders or creditors is not required for obtaining the members' approval for the proposed Special Resolution.

The Board of Directors recommends the passing of the above resolution as Special Resolution as set out in the item no. 6.

None of the other Directors /Key Managerial Personnel and their relatives except Mr. Pabbathi Badari Narayana Murthy and Mr. Pabbathi Dathvik being his relative are in any way interested or concerned financially or otherwise, in the Resolution set out in the notice.

ITEM NO. 7:

APPROVAL OF WAIVER OF RECOVERY OF EXCESS MANAGERIAL REMUNERATION PAID TO MR. NADIMPALLI VISHAL, WHOLE-TIME DIRECTOR AND CFO FOR THE FINANCIAL YEAR 2025-26.

The shareholders vide Special Resolution passed at the Annual General Meeting held on 14.09.2024, approved payment of remuneration of Rs. 5,00,000/- per month to Mr. Nadimpalli Vishal for the period 10.11.2025 to 09.11.2028.

Upon internal review, it was observed that total remuneration paid to Mr. Nadimpalli Vishal during the financial year 2025-26, aggregated to ₹51,47,800/- resulting in an excess of ₹15,47,800/- over and above the remuneration approved by the members ("Excess Remuneration"). The excess payment was inadvertent in nature and arose on account of a bona fide interpretation and implementation of the approved remuneration structure.

The Excess Remuneration arose because the remuneration approved by the members was treated and paid as a net amount to Mr. Nadimpalli Vishal, while the income-tax liability thereon was separately borne by the Company, though the same should have been added to Mr. Vishal's remuneration.

ARUNJYOTI BIO VENTURES LIMITED

Consequently, the aggregate remuneration, including the tax borne by the Company on behalf of the Whole-time Director, exceeded the amount approved by the members.

In terms of Section 197 of the Companies Act, 2013 and the applicable rules made thereunder, where remuneration has been paid in excess of the limits approved by the members, the Company is required either to recover the excess remuneration from the director concerned or obtain approval of the members by way of a Special Resolution for waiver of recovery of such excess remuneration.

Accordingly, based on the recommendation of the Nomination and Remuneration Committee, Board of Directors in their meeting held on 09.07.2026 approved for waiver of recovery of the Excess Remuneration amounting to ₹15,47,800/- paid to Mr. Nadimpalli Vishal during the financial year 2025-26 subject to the approval of the members by way of a Special Resolution.

It is also confirmed that as on the date of the notice, the company is not in default in repayment of any dues to any bank, public financial institution, non-convertible debenture holders or any other secured creditor. Accordingly, prior approval of such lenders or creditors is not required for obtaining the members' approval for the proposed Special Resolution.

The Board of Directors recommends the passing of the above resolution as Special Resolution as set out in the item no. 7.

None of the other Directors /Key Managerial Personnel and their relatives except Mr. Nadimpalli Vishal is in any way interested or concerned financially or otherwise, in the Resolution set out in the notice.

ITEM NO. 8:

INCREASE IN THE REMUNERATION OF MR. PABBATHI BADARI NARAYANA MURTHY, WHOLE-TIME DIRECTOR OF THE COMPANY

At the Annual General Meeting held on 10.09.2025, Mr. Pabbathi Badari Narayana Murthy was reappointed as the Whole-Time Director of the Company with effect from 10.11.2025 for a period of three years at remuneration of Rs. 5,00,000/- per month.

Based on the recommendations of the Nomination and Remuneration Committee, and having considered the contribution of Mr. Pabbathi Badari

ARUNJYOTI BIO VENTURES LIMITED

Narayana Murthy in terms of leadership, strategy formulation and execution, financial planning, maintaining relations both with the board and external entities, the Board in its meeting held on 03.02.2026 has increased the remuneration to Rs. 8,00,000 per month w.e.f. 01.04.2026 for the remaining period of his tenure i.e., upto 09.11.2028.

Further, considering his continued responsibilities and contribution to the growth and operations of the Company, the Board of Directors in its meeting held on 09.07.2026 approved the additional component of remuneration by way of Leave travel allowance of Rs. 10,00,000 per annum for Mr. Pabbathi Badari Narayana Murthy and his family.

The Board of Directors recommends the passing of the above resolution as Special Resolution as set out in the item no. 8.

None of the other Directors /Key Managerial Personnel and their relatives except Mr. Pabbathi Badari Narayana Murthy and Mr. Pabbathi Dathvik being his relative are in any way interested or concerned financially or otherwise, in the Resolution set out in the notice.

ITEM NO. 9:

INCREASE IN THE REMUNERATION OF MR. NADIMPALLI VISHAL, WHOLE-TIME DIRECTOR AND CFO OF THE COMPANY

At the Annual General Meeting held on 10.09.2025, Mr. Nadimpalli Vishal was reappointed as the Whole-Time Director and CFO of the Company with effect from 10.11.2025 for a period of three years at remuneration of Rs. 3,00,000/- per month.

Based on the recommendations of the Nomination and Remuneration Committee, and having considered the contribution of Mr. Nadimpalli Vishal in terms of leadership, strategy formulation and execution, financial planning, maintaining relations both with the board and external entities, the Board in its meeting held on 03.02.2026 has increased the remuneration to Rs. 5,00,000 per month w.e.f. 01.04.2026 for the remaining period of his tenure i.e., upto 09.11.2028.

Further, considering his continued responsibilities and contribution to the growth and operations of the Company, the Board of Directors in its meeting held on 09.07.2026 approved the additional component of remuneration by way of Leave travel allowance of Rs. 10,00,000 per annum to Mr. Nadimpalli Vishal and his family.

ARUNJYOTI BIO VENTURES LIMITED

The Board of Directors recommends the passing of the above resolution as Special Resolution as set out in the item no. 9.

None of the other Directors /Key Managerial Personnel and their relatives except Mr. Nadimpalli Vishal are in any way interested or concerned financially or otherwise, in the Resolution set out in the notice.

ITEM NO. 10:

INCREASE IN THE REMUNERATION OF MR. PABBATHI DATHVIK, WHOLE-TIME DIRECTOR OF THE COMPANY

At the Annual General Meeting held on 10.09.2025, Mr. Pabbathi Dathvik was reappointed as the Whole-Time Director of the Company with effect from 10.11.2025 for a period of three years at remuneration of Rs. 3,00,000/- per month.

Based on the recommendations of the Nomination and Remuneration Committee, and having considered the contribution of Mr. Pabbathi Dathvik in terms of leadership, strategy formulation and execution, financial planning, maintaining relations both with the board and external entities, the Board in its meeting held on 03.02.2026 has increased the remuneration to Rs. 5,00,000 per month w.e.f. 01.04.2026 for the remaining period of his tenure i.e., upto 09.11.2028.

Further, considering his continued responsibilities and contribution to the growth and operations of the Company, the Board of Directors in its meeting held on 09.07.2026 approved the additional component of remuneration by way of Leave travel allowance of Rs. 10,00,000 per annum to Mr. Pabbathi Dathvik and his family.

The Board of Directors recommends the passing of the above resolution as a Special Resolution as set out in the item no. 10.

None of the other Directors /Key Managerial Personnel and their relatives except Mr. Pabbathi Dathvik and Mr. Pabbathi Badari Narayana Murthy being his relative are in any way interested or concerned financially or otherwise, in the Resolution set out in the notice.

Information in accordance with Schedule V of Companies Act, 2013 for Item Nos. 8, 9 and 10:

ARUNJYOTI BIO VENTURES LIMITED

I. GENERAL INFORMATION

1	Nature of Industry : Packaging of Drinking water
2	Date or expected date of commencement of commercial: Not Applicable as the Company is already in Operations.
3	In case of new companies, expected date of commencement of business activities as per project approved by financial institutions appearing in the prospects: Not Applicable
4	Financial performance based on given indications : The turnover of the Company for the financial year 2025-26 stood at ₹2,775.44 Lakhs, while the Company incurred a net loss of ₹453.61 Lakhs during the said period.
5	Foreign investments or collaborations, if any: Not Applicable

II. INFORMATION ABOUT THE APPOINTEE:

S. No	Particulars	Mr. Pabbathi Badari Narayana Murthy
1.	Background Details	Mr. Pabbathi Badari Narayana Murthy is the promoter and whole time director of the Company. He has an experience of 22 Years in the field of Retail Chain Stores, Import and Export of Good, Trading in Beverages and Building Materials
2.	Past Remuneration	Rs. 85.71 Lakhs for FY 2025-26
3.	Recognition or awards	Nil
4.	Job Profile and his suitability	Mr. Pabbathi Badari Narayana Murthy has an experience of 22 Years in the field of Retail Chain Stores, Import and Export of Goods, Trading in Beverages and Building Materials.

ARUNJYOTI BIO VENTURES LIMITED

5.	Remuneration proposed	As set out in the resolution for the item No.8 the remuneration to Mr. Pabbathi Badari Narayana Murthy has the approval of Board of Directors and is within the limits specified under Schedule V of Companies Act.
6.	Comparative remuneration profile with respect to industry, size of the company profile of the position and person (in case of expatriates the relevant details would be w.r.t. the country of his origin):	Taking into consideration the profile of Mr. Pabbathi Badari Narayana Murthy and the responsibilities shouldered by him, the aforesaid remuneration package is below the industry standards.
7.	Pecuniary relationship directly or indirectly with the Company, or relationship with the managerial personnel, if any	Besides the remuneration, he is holding 3,58,76,078 Equity Shares of the Company and he is the father of Mr. Pabbathi Dathvik.

II. INFORMATION ABOUT THE APPOINTEE:

S. No	Particulars	Mr. Nadimpalli Vishal
1.	Background Details	Mr. Nadimpalli Vishal is a post graduate diploma in business management and has working experience of more than 13 years in distribution, manufacturing, wholesale trade and e-commerce.
2.	Past Remuneration	Rs. 51.48 Lakhs for FY 2025-26
3.	Recognition or awards	Nil
4.	Job Profile and his suitability	Mr. Nadimpalli Vishal has work experience of more than 13 years in distribution, manufacturing, wholesale trade and e-commerce.
5.	Remuneration proposed	As set out in the resolution for the item No. 9 the remuneration to Mr. Nadimpalli Vishal has the approval of Board of Directors and is within the limits specified under Schedule V of Companies Act.

ARUNJYOTI BIO VENTURES LIMITED

6.	Comparative remuneration profile with respect to industry, size of the company profile of the position and person (in case of expatriates the relevant details would be w.r.t. the country of his origin):	Taking into consideration the profile of Mr. Nadimpalli Vishal and the responsibilities shouldered by him, the aforesaid remuneration package commensurate with the size of the company.
7.	Pecuniary relationship directly or indirectly with the Company, or relationship with the managerial personnel, if any	Nil

II. INFORMATION ABOUT THE APPOINTEE:

S. No	Particulars	Mr. Pabbathi Dathvik
1.	Background Details	Mr. Dathvik Pabbathi has completed his graduation in Banking and Insurance and has 7 years of experience in the field of Retail Chain Stores, Import and Export of Goods, Trading in Beverages and Building Materials
2.	Past Remuneration	Rs. 2,34,857 per month w.e.f 01.04.2026
3.	Recognition or awards	Nil
4.	Job Profile and his suitability	Mr. Pabbathi Dathvik has 7 years of experience in the field of Retail Chain Stores, Import and Export of Goods, Trading in Beverages and Building Materials.
5.	Remuneration proposed	As set out in the resolution for the item No. 10 the remuneration to Mr. Pabbathi Dathvik has the approval of Board of Directors and is within the limits specified under Schedule V of Companies Act.

ARUNJYOTI BIO VENTURES LIMITED

6.	Comparative remuneration profile with respect to industry, size of the company profile of the position and person (in case of expatriates the relevant details would be w.r.t. the country of his origin):	Taking into consideration the profile of Mr. Pabbathi Dathvik and the responsibilities shouldered by him, the aforesaid remuneration package commensurate with the size of the company.
7.	Pecuniary relationship directly or indirectly with the Company, or relationship with the managerial personnel, if any	Besides the remuneration, he is holding 4,30,04,890 Equity Shares of the Company and he is a son of Mr. Pabbathi Badari Narayana Murthy.

III. OTHER INFORMATION:

1.	Reasons for Loss or Inadequate Profits During the financial year under review, the Company incurred a loss due to a combination of operational and business factors that adversely impacted its financial performance. The principal reasons are summarized below: 1. Abnormal Inventory Consumption: During the year, the Company recorded abnormal inventory consumption, which significantly affected the cost of materials consumed and reduced the overall profitability of the Company. 2. Increase in Manufacturing and Operating Costs: The Company experienced higher production costs due to increased prices of raw materials, packaging materials, utilities, maintenance, and other manufacturing overheads, resulting in pressure on operating margins. 3. Under-utilization of Manufacturing Capacity: The manufacturing facilities did not operate at optimal capacity during certain periods of the year, leading to higher fixed costs per unit of production. 4. Increase in Employee and Administrative Expenses: The Company incurred higher employee benefit expenses and administrative costs to strengthen its operational capabilities and support future business growth. 5. Finance Costs and Depreciation: Finance costs on borrowings and depreciation on manufacturing assets continued to impact the profitability during the year. Despite the loss reported during the financial year, the management remains focused on improving operational efficiencies, strengthening internal controls, optimizing inventory management, enhancing capacity utilization,
----	--

ARUNJYOTI BIO VENTURES LIMITED

	reducing production costs, and expanding the customer base. The Company continues to pursue cost optimization initiatives and operational improvements with the objective of restoring profitability and creating long-term value for its stakeholders.
2.	Steps taken or proposed to be taken for improvement: Necessary efforts are being made to increase the revenue to explore various opportunities and to achieve a better growth.
3.	Expected increase in productivity and profit in measurable terms: The company is committed to build the business operations and it is believed that financial position of the company will increase considerably in the coming years.

**For and on behalf of the Board
Arunjyoti Bio Ventures Limited**

**Sd/-
Pabbathi Badari Narayana Murthy
Whole-time Director
(DIN: 01445523)**

**Place: Hyderabad
Date: 09.07.2026**

ARUNJYOTI BIO VENTURES LIMITED

As required under regulation 36 (3) of the SEBI (LODR), Regulations, 2015, brief particulars of the Directors seeking appointment/re-appointment are given as under:

Name of the Director	Mr. Nadimpalli Vishal
Designation	Whole-time Director
DIN	02745303
Date of Birth	14/11/1982
Age	43 years
Date of First Appointment on the Board	10.11.2022
Brief resume	He holds a Post Graduate Diploma in Business Management and possesses over 22 years of rich and diversified professional experience across distribution, manufacturing, wholesale trade, and e-commerce. Throughout his career, he has demonstrated strong leadership in business operations, supply chain management, strategic planning, and commercial functions. His extensive industry knowledge and operational expertise contribute significantly to the Company's growth, operational excellence, and long-term strategic objectives.
Qualifications and Experience/Expertise in specific functional area	Accounts, Finance, Operation and HR
Names of the listed entities in which the person is holding directorships or Board/ Committee memberships along with listed entities from which the person has resigned in past 3 years	Nil
Inter- se Relationships between Directors	Nil
Number of shares held in the Company	Nil

ARUNJYOTI BIO VENTURES LIMITED

DIRECTORS' REPORT

Dear Members,

Your Directors have pleasure in presenting the 40th Directors' Report and the Audited Statement of Accounts of the Company for the Financial Year ended 31.03.2026

1. FINANCIAL SUMMARY/HIGHLIGHTS:

The performance during the period ended 31st March, 2026 has been as under:

(Rs. in lakhs)

Particulars	2024-25	2025-26
Revenue from Operations	2,788.41	2,775.44
Other Income (Including Exceptional Items)	28.13	11.80
Total Income (Revenue + Other Income)	2,816.54	2,787.24
Total Expenses	2,287.18	2,487.07
Profit/(Loss) before Depreciation, Finance Costs, Exceptional items and Tax Expense (EBITDA approx.)	529.36	300.17
Less: Depreciation/ Amortisation/ Impairment	304.58	335.81
Profit/(Loss) before Finance Costs, Exceptional items and Tax Expense (EBIT)	224.79	-35.64
Less: Finance Costs	258.87	204.73
Profit/(Loss) before Exceptional items and Tax Expense	-34.09	-240.37
Add/(Less): Exceptional items	--	273.65
Profit/(Loss) before Tax Expense	-34.09	-514.02
Less: Tax Expense (Current & Deferred)	-6.47	-60.41
Profit / (Loss) for the year (1)	-27.62	-453.61
Other Comprehensive Income	Nil	Nil
Total Comprehensive Income	-27.62	-453.61
Balance of profit/(loss) for earlier years	-	-
Less: Transfer to Reserves	-	-
Less: Dividend paid on Equity Shares	-	-
Less: Dividend Distribution Tax	-	-
Balance carried forward	-	-
Earnings per Equity Share		
- Basic (₹)	(0.01)	(0.24)
- Diluted (₹)	(0.01)	(0.24)

2. REVIEW OF OPERATIONS:

During the year under review the Company has earned the total income of Rs. 2,787.24 Lakhs and incurred net loss of Rs. 453.61 Lakhs as compared to the total income of Rs. 2,816.54 Lakhs and net loss of Rs. 27.62 Lakhs in the previous financial year 2024-25.

3. BUSINESS UPDATE AND STATE OF COMPANY'S AFFAIRS:

The information on Company's affairs and related aspects is provided under Management Discussion and Analysis report, which has been prepared, inter-alia, in compliance with Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and forms part of the Annual Report.

4. CHANGE IN THE NATURE OF THE BUSINESS, IF ANY:

During the year under review, there were no changes in the nature of Business.

5. RESERVES

The Closing balance of reserves, including retained earnings, of the Company as at 31.03.2026 is Rs. 1008.00 Lakhs.

6. DIVIDEND :

During the year under review, the Board has not recommended or paid any dividend for the year 2025-26.

7. MATERIAL CHANGES & COMMITMENT AFFECTING THE FINANCIAL POSITION OF THE COMPANY:

There are no major material changes and commitments affecting the financial position of the Company after the end of the financial year and up to date of this report (09.07.2026).

8. REVISION OF FINANCIAL STATEMENTS:

During the year under review, there is no revision in the Financial Statements.

9. SHARE CAPITAL:

• **Authorized Share Capital**

During the year under review, there was no change in the authorized share capital and paid-up capital of the Company.

The Authorized Share Capital of the Company stands at Rs. 19,00,00,000 (Rupees Nineteen Crores only) divided into 19,00,00,000 (Nineteen Crores) equity shares of Re. 1/- (Rupee One) each.

- **Paid-up Share Capital**

The paid-up share capital of the Company is Rs. 18,63,81,000/- (Rupees Eighteen Crores Sixty-Three Lakhs Eighty-One Thousand Only) divided into 18,63,81,000 (Rupees Eighteen Crores Sixty-Three Lakhs Eighty-One Thousand Only) Equity Shares of Re. 1/- each.

10. UNPAID / UNCLAIMED DIVIDEND:

There is no unpaid or unclaimed dividend with the company till date.

11. INVESTOR EDUCATION AND PROTECTION FUND (IEPF):

During the year under review, the Company was not required to transfer any amount to Investor Education and Protection Fund (IEPF).

12. DIRECTORS OR KMP APPOINTED OR RESIGNED:

During the year under review, there was no change in the management of the Company. However, during the year, Mr. Pabbathi Badari Narayana Murthy, Mr. Dathvik Pabbathi and Mr. Nadimpalli Vishal were re-appointed as whole-time directors of the Company for a period of 3 years w.e.f. 10.11.2025.

13. COMPANY'S POLICY ON DIRECTORS' APPOINTMENT AND REMUNERATION

The Company has devised, inter alia, the following policies viz.:

- a) Policy for selection of Directors and determining Directors' independence; and
- b) Remuneration Policy for Directors, Key Managerial Personnel and other employees.

The Policy for selection of Directors and determining Directors' independence sets out the guiding principles for identifying persons who are qualified to become Directors and to determine the independence of Directors, while considering their appointment as independent directors of the Company.

The Policy also provides for the factors in evaluating the suitability of individual board members with diverse background and experience that are relevant for the Company's operations. The Policy is available on the Company's website and can be accessed at https://www.abvl.co.in/investors/policies/Board_Evaluation.pdf.

The Company's remuneration policy is directed towards rewarding performance, based on review of achievements. The Policy is available on the Company's website and can be accessed at

https://www.abvl.co.in/investors/policies/Nomination_Remuneration_Policies.pdf.

There has been no change in the above two policies, during the year under review.

14. DECLARATION BY INDEPENDENT DIRECTORS ON ANNUAL BASIS:

The Company has received declarations from Mr. Vijaya Rama Lakshmana Murthy Mylavarapu, Ms. Dhanalakshmi Guntaka, Mr. Srikar Ranga, Independent Directors of the Company to the effect that they are meeting the criteria of independence as provided in Sub-Section (6) of Section 149 of the Companies Act, 2013 and Regulation 25 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Independent Directors have also confirmed that they have complied with the Company's Code of Conduct.

During the year, Independent Directors of the Company had no pecuniary relationship or transactions with the Company, other than sitting fees, commission and reimbursement of expenses incurred by them for the purpose of attending meetings of the Board of Directors and Committee(s).

All the Independent Directors of your Company have been registered and are members of Independent Directors Databank maintained by the Indian Institute of Corporate Affairs (IICA).

All the Independent Director of the Company, has successfully passed/exempted from requirement of passing the Online Proficiency Self-Assessment Test conducted by the Indian Institute of Corporate Affairs in terms of the applicable provisions of the Companies Act 2013 and the relevant rules made thereunder, considering their extensive experience and expertise.

15. CONFIRMATION AND OPINION OF THE BOARD ON INDEPENDENT DIRECTORS

All the Independent Directors of the Company have given their respective declaration/ disclosures under Section 149(7) of the Act and Regulation 25(8) of the Listing Regulations and have confirmed that they fulfil the independence criteria as specified under section 149(6) of the Act and Regulation 16 of the Listing Regulations and have also confirmed that they are not aware of any circumstance or situation, which exist or may be reasonably anticipated, that could impair or impact their ability to discharge their duties with an objective independent judgment and without any external influence. Further, the Board, after taking these declarations/disclosures on record and acknowledging the

veracity of the same, concluded that the Independent Directors are persons of integrity and possess the relevant expertise and experience to qualify as Independent Directors of the Company and are Independent of the Management.

The Board opines that all the Independent Directors of the Company strictly adhere to corporate integrity, possesses requisite expertise, experience and qualifications to discharge the assigned duties and responsibilities as mandated by the Companies Act, 2013 and Listing Regulations diligently.

16. BOARD MEETINGS:

The Board of Directors duly met Five (5) times during the Financial Year from 1st April 2025 to 31st March 2026. The dates on which the meetings were held are 07.04.2025, 29.05.2025, 04.08.2025, 03.11.2025 and 03.02.2026 in respect of which proper notices were given and the proceedings were properly recorded and signed in the Minutes Book maintained for the purpose.

17. COMMITTEES:

The Company being a listed Company, has validly constituted various applicable and mandatory committees i.e. Audit Committee, Nomination and Remuneration Committee and Stakeholder Relationship Committee.

18. BOARD EVALUATION:

Nomination and Remuneration Committee has carried out an annual evaluation of its own performance, board committees, and individual directors pursuant to the provisions of the Act and SEBI Listing Regulations. The performance of the board was evaluated by the board after seeking inputs from all the directors on the basis of criteria such as the board composition and structure, effectiveness of board processes, information and functioning, etc. The performance of the committees was evaluated by the Nomination and Remuneration Committee after seeking inputs from the committee members on the basis of criteria such as the composition of committees, effectiveness of committee meetings, etc. The above criteria are based on the Guidance Note on Board Evaluation issued by the Securities and Exchange Board of India on January 5, 2017.

In a separate meeting of independent directors was conducted on 18.02.2026 to evaluate the performance of non-independent directors, the board as a whole and the Chairman of the Company, taking into account the views of executive directors and nonexecutive directors.

19. STATEMENT SHOWING THE NAMES OF THE TOP TEN EMPLOYEES IN TERMS OF REMUNERATION DRAWN AND THE NAME OF EVERY EMPLOYEE AS PER RULE 5(2) & (3) OF THE COMPANIES (APPOINTMENT & REMUNERATION) RULES, 2014:

A table containing the particulars in accordance with the provisions of Section 197(12) of the Act, read with Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is appended as **ANNEXURE - I** to this Report.

A statement showing the names of the top ten employees in terms of remuneration drawn and the name of every employee is annexed to this Annual report as **ANNEXURE - II**.

During the year, NONE of the employees (excluding Executive Directors) is drawing a remuneration of Rs.1,02,00,000/- and above per annum or Rs.8,50,000/- and above in aggregate per month, the limits specified under the Section 197(12) of the Companies Act, 2013 read with Rules 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

20. RATIO OF REMUNERATION TO EACH DIRECTOR:

Under section 197(12) of the Companies Act, 2013, and Rule 5(1) (2) & (3) of the Companies (Appointment & Remuneration) Rules, 2014, ratio of remuneration of Mr. Pabbathi Badari Narayana Murthy, Whole-time Director of the Company to the median remuneration of the employee is 18.35: 1 and Mr. Nadimpalli Vishal, Whole-time Director and CFO of the Company to the median remuneration of the employee is 11.02: 1.

21. DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to the requirement of Section 134(3) (C) and 134(5) of the Companies Act, 2013 and on the basis of explanation given by the executives of the Company and subject to disclosures in the Annual Accounts of the Company from time to time, we state as under:

- a) That in the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures;
- b) That the Directors have selected such accounting policies and applied them consistently and made judgment and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit or loss of the Company for that period;

- c) That the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- d) That the Directors have prepared the annual accounts on a going concern basis;
- e) That the Directors have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and are operating effectively; and
- f) That the Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

22. DETAILS OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS:

Your Company has well established procedures for internal control across its various locations, commensurate with its size and operations. The organization is adequately staffed with qualified and experienced personnel for implementing and monitoring the internal control environment. The internal audit function is adequately resourced commensurate with the operations of the Company and reports to the Audit Committee of the Board.

23. DETAILS IN RESPECT OF FRAUDS REPORTED BY AUDITORS UNDER SUB SECTION (12) OF SECTION 143 OTHER THAN THOSE WHICH ARE REPORTABLE TO THE CENTRAL GOVERNMENT:

During the year under review, the Auditors of the Company have not reported any frauds to the Board of Directors as prescribed under Section 143(12) of the Companies Act, 2013 and rules made thereunder.

24. CEO/ CFO CERTIFICATION:

The Whole-time Director and Chief Financial Officer Certification on the financial statements under Regulation 17 (8) of SEBI (Listing Obligations & Disclosure Requirements), Regulations, 2015 for the year 2025-26 is annexed in this Annual Report.

25. INFORMATION ABOUT THE FINANCIAL PERFORMANCE / FINANCIAL POSITION OF THE SUBSIDIARIES / ASSOCIATES/ JOINT VENTURES:

During the year under review, the Company does not have any subsidiaries, joint ventures or associate Companies.

26. NAMES OF COMPANIES, WHICH HAVE BECOME OR CEASED TO BE COMPANY'S SUBSIDIARIES, JOINT VENTURES OR ASSOCIATE COMPANIES DURING THE YEAR

During the financial year under review, no company has become or ceased to be a subsidiary, joint venture or associate of the Company.

27. DETAILS OF DEPOSITS NOT IN COMPLIANCE WITH THE REQUIREMENTS OF THE ACT:

Since the Company has not accepted any deposits during the Financial Year ended March 31, 2026, there has been no non-compliance with the requirements of the Act.

Pursuant to the Ministry of Corporate Affairs (MCA) notification dated 22nd January 2019 amending the Companies (Acceptance of Deposits) Rules, 2014, the Company is required to file with the Registrar of Companies (ROC) requisite returns in Form DPT-3 for outstanding receipt of money/loan by the Company, which is not considered as deposits.

28. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS:

During the year under review, the Company has granted a loan to Pasura Xpress LLP amounting to ₹80.72 lakhs. The Company has not provided any guarantees or made any investments that attract the provisions of Section 186 of the Companies Act, 2013

Sl.no	Name of the LLP	Amount (Rs. In Lakhs)	Transaction Type
1.	Pasura Xpress LLP	80.72	Granting of loan

However, The approval of the shareholders by way of ratification is proposed to be obtained at the ensuing Annual General Meeting. Further, the borrower, Pasura Xpress LLP is in the process of repaying the outstanding amount. Upon receipt of the said amount, Arunjyoti Bio Ventures Limited shall take necessary steps to file an application for compounding of the offence with the competent authority and regularize the matter in accordance with the applicable legal and regulatory requirements.

29. RELATED PARTY TRANSACTIONS:

Our Company has formulated a policy on related party transactions which is also available on Company's website at <https://www.abvl.co.in/policies.html>. This policy deals with the review and approval of related party transactions.

All related party transactions that were entered into during the financial

year were on arm's length basis and were in the ordinary course of business. There were no material significant related party transactions made by the Company with the Promoters, Directors, Key Managerial Personnel or the Senior Management which may have a potential conflict with the interest of the Company at large except purchase of land admeasuring 2 acres and 6 guntas along with a constructed warehouse admeasuring 22,023 square feet situated at Jangaon, Telangana, from related parties, in compliance with the applicable provisions of the Companies Act, 2013 and SEBI LODR Regulations.

Particulars of contracts or arrangements with related parties referred to in Section 188(1) of the Companies Act, 2013 in the prescribed Form AOC-2 is appended as ANNEXURE - IV which forms part of this Report.

All related party transactions were placed before the Audit Committee/Board for approval. Prior approval of the Audit Committee was obtained for the transactions which are foreseen and are in repetitive in nature. Members may refer to notes to the financial statements which sets out related party disclosures pursuant to IND AS-24.

30. DISCLOSURE OF PARTICULARS WITH RESPECT TO CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO:

The required information as per Sec.134 (3) (m) of the Companies Act 2013 is provided hereunder:

A. Conservation of Energy:

Your Company's operations are not energy intensive. Adequate measures have been taken to conserve energy wherever possible by using energy efficient computers and purchase of energy efficient equipment.

B. Technology Absorption:

1. Research and Development (R&D): NIL
2. Technology absorption, adoption and innovation: NIL

C. Foreign Exchange Earnings and Out Go:

Foreign Exchange Earnings : NIL

Foreign Exchange Outgo : NIL

31. CORPORATE GOVERNANCE AND SHAREHOLDERS INFORMATION:

The Company has implemented all of its major stipulations as applicable to the Company. As stipulated under Regulation 34 read with schedule V of SEBI (LODR) Regulations, 2015, a report on Corporate Governance duly audited is appended as Annexure VI for information of the

Members. A requisite certificate from the Secretarial Auditors of the Company confirming compliance with the conditions of Corporate Governance is attached to the Report on Corporate Governance.

32. CORPORATE SOCIAL RESPONSIBILITY (CSR, COMPOSITION OF CSR COMMITTEE AND CONTENTS OF CSR POLICY):

Since the Company does not have the net worth of Rs. 500 Crores or more, or turnover of Rs. 1000 Crores or more, or a net profit of Rs. 5 Crores or more during the financial year 2024-25, hence the section 135 of the Companies Act, 2013 relating to Corporate Social Responsibility is not applicable and the Company need not adopt any Corporate Social Responsibility Policy.

33. VIGIL MECHANISM/WHISTLE BLOWER POLICY:

In pursuant to the provisions of Section 177(9) & (10) of the Companies Act, 2013, a vigil Mechanism for Directors and employees to report genuine concerns has been established. It also provides for necessary safeguards for protection against victimization for whistle blowing in good faith.

Vigil Mechanism Policy has been established by the Company for directors and employees to report genuine concerns pursuant to the provisions of section 177(9) & (10) of the Companies Act, 2013. The same has been placed on the website of the Company.

34. SIGNIFICANT & MATERIAL ORDERS PASSED BY COURTS / REGULATORS/TRIBUNALS:

There are no significant and material orders passed by the regulators /courts that would impact the going concern status of the Company and its future operations.

35. STATUTORY AUDITORS AND STATUTORY AUDITORS REPORT:

Your Company's Statutory Auditors, M/s. Ravi & Co., Chartered Accountants have tendered their resignation w.e.f. 04.08.2025, therefore the Board in its meeting held on 04.08.2025 has approved the appointment of M/s. PKF Sridhar & Santhanam LLP, Chartered Accountants, Hyderabad, as the Statutory Auditors of the Company w.e.f. 04.08.2025 at a remuneration as fixed by the Board to fill the casual vacancy subject to approval of shareholders within 3 months from the date of recommendation/appointment and at the Annual General Meeting held on 10.09.2025 the shareholders has approved the appointment of M/s. PKF Sridhar & Santhanam LLP, Chartered Accountants for a period of 5 years.

M/s. PKF Sridhar & Santhanam LLP, Chartered Accountants, have issued the Auditors' Report for fiscal 2026 does not contain any qualification, reservation or adverse remark except the following:

ARUNJYOTI BIO VENTURES LIMITED

- a) The Company has granted loan of Rs. 80.72 Lakhs (Amount outstanding as on 31st March 2026 is Rs. 65.99 Lakhs) to LLP in which directors are interested, which is subject to approval by the company under Section 185 (2) and the company is proposing to place it before the ensuing AGM for members approval.
- b) During the year, managerial remuneration exceeded the remuneration approved by the shareholders by ₹25.19 lakhs due to the approval being granted on a net remuneration basis. The Company proposes to obtain shareholders' approval/ratification for the excess remuneration at the ensuing Annual General Meeting.
- c) No undisputed amounts payable in respect of Goods and Service Tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues were in arrears, as at 31 March 2026 for a period of more than six months from the date they became payable, except as below which are pending to be remitted on account of KYC issues and operational challenges.

Name of Statute	Nature of due	Amount in Rs	Period to which it relates	Due date	Date of payment	Remarks
The Employee State Insurance Act, 1948	Employee State Insurance	1,282	Apr-24	15-05-2024	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	3,662	May-24	15-06-2024	-	-
The Provident fund Act, 1952	Provident Fund	47,405	Jun-24	15-07-2024	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	5,080			-	-
The Provident fund Act, 1952	Provident Fund	51,479	Jul-24	15-08-2024	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	5,514			-	-
The Provident fund Act, 1952	Provident Fund	23,339	Aug-24	15-09-2024	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	559			-	-
The Provident fund Act, 1952	Provident Fund	66,941	Sep-24	15-10-2024	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	9,220			-	-
The Provident fund Act, 1952	Provident Fund	79,005	Oct-24	15-11-2024	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	12,144			-	-
The Provident fund Act, 1952	Provident Fund	82,442	Nov-24	15-12-2024	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	12,714			-	-
The Provident fund Act, 1952	Provident Fund	49,057	Dec-24	15-01-2025	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	9,562			-	-

ARUNJYOTI BIO VENTURES LIMITED

The Provident fund Act, 1952	Provident Fund	1,06,313	Jan-25	15-02-2025	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	18,479			-	-
The Provident fund Act, 1952	Provident Fund	1,09,225	Feb-25	15-03-2025	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	18,961			-	-
The Provident fund Act, 1952	Provident Fund	1,14,005	Mar-25	15-04-2025	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	20,229			-	-
The Provident fund Act, 1952	Provident Fund	1,23,028	Apr-25	15-05-2025	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	22,742				-
The Provident fund Act, 1952	Provident Fund	1,39,686	May-25	15-06-2025	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	25,151				-
The Provident fund Act, 1952	Provident Fund	1,49,491	Jun-25	15-07-2025	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	27,425				-
The Provident fund Act, 1952	Provident Fund	1,52,770	Jul-25	15-08-2025	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	27,722				-
The Provident fund Act, 1952	Provident Fund	1,56,590	Aug-25	15-09-2025	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	28,737			-	-

- d) Based on our audit procedures and as per the information and explanations given by the management, the Company has defaulted in repayment of loans or other borrowings or in payment of interest thereon to a lender as below:

Nature of borrowing including debt securities	Name of lender	Amount not paid on due date	Whether principal or interest	No. of days delay or unpaid	Remarks, if any
Term Loan	Axis Bank Ltd	15,35,431	Interest	1	Apr-25
Term Loan	Axis Bank Ltd	34,64,000	Principal	1	
Term Loan	Axis Bank Ltd	12,69,679	Interest	1	May-25
Term Loan	Axis Bank Ltd	27,70,000	Principal	1	
Term Loan	Axis Bank Ltd	11,05,176	Interest	1	Aug-25
Term Loan	Axis Bank Ltd	27,70,000	Principal	1	
Term Loan	Axis Bank Ltd	12,86,624	Interest	1	Sep-25
Term Loan	Axis Bank Ltd	34,64,000	Principal	1	
Term Loan	Axis Bank Ltd	10,65,638	Interest	1	Oct-25
Term Loan	Axis Bank Ltd	27,70,000	Principal	1	
Term Loan	Axis Bank Ltd	12,35,004	Interest	1	Nov-25
Term Loan	Axis Bank Ltd	34,64,000	Principal	1	
Term Loan	Axis Bank Ltd	12,43,610	Interest	1	Dec-25
Term Loan	Axis Bank Ltd	34,64,000	Principal	1	

ARUNJYOTI BIO VENTURES LIMITED

Term Loan	Axis Bank Ltd	3,49,403	Interest	1	Jan-26
Term Loan	Axis Bank Ltd	27,70,000	Principal	1	
Term Loan	Axis Bank Ltd	10,01,193	Interest	1	Feb-26
Term Loan	Axis Bank Ltd	34,64,000	Principal	1	
Term Loan	Axis Bank Ltd	10,88,550	Interest	1	Mar-26
Term Loan	Axis Bank Ltd	34,64,000	Principal	1	

Management Reply:

- a) The approval of the shareholders by way of ratification is proposed to be obtained at the ensuing Annual General Meeting. Further, the borrower, Pasura Xpress LLP is in the process of repaying the outstanding amount. Upon receipt of the said amount, Arunjyoti Bio Ventures Limited shall take necessary steps to file an application for compounding of the offence with the competent authority and regularize the matter in accordance with the applicable legal and regulatory requirements.
- b) In accordance with the provisions of Section 197 of the Companies Act, 2013, the Board in its meeting held on 09.07.2026 has approved the proposal for waiver of recovery of the excess remuneration aggregating to Rs. 25,19,232, comprising Rs. 9,71,432 paid to Mr. Pabbathi Badari Narayana Murthy, Whole-time Director and Rs. 15,47,800 paid to Mr. Nadimpalli Vishal, Whole-time Director and CFO. The necessary approval of the shareholders by way of a Special Resolution is proposed to be obtained at the ensuing Annual General Meeting.
- c) The delay in remittance of the outstanding statutory dues was primarily due to pending Know Your Customer (KYC) compliance requirements and certain operational challenges. The Company has initiated the necessary actions to complete the pending formalities and resolve the operational issues.
- d) The delay of one day in repayment of the principal and interest instalments was solely due to the timing of the bank's auto-debit process. The delay was operational in nature and was not attributable to any financial default by the Company.

The Auditors' Report is enclosed with the financial statements in this Annual Report. The Auditors have confirmed that they have subjected themselves to the peer review process of Institute of Chartered Accountants of India (ICAI) and hold valid certificate issued by the Peer Review Board of the ICAI.

36. SECRETARIAL AUDIT REPORT:

The Board has duly reviewed the Secretarial Audit Report for the year ended March 31, 2026 read with the Companies Act, 2013 on the Compliances according to the provisions of Section 204 of the Companies Act 2013, for conducting the Secretarial Audit for financial year ended March 31, 2026. The Secretarial Audit was carried out by M/s. Manoj Parakh & Associates, Company Secretaries for the financial year ended March 31, 2026. The Report given by the Secretarial Auditor is annexed herewith as ANNEXURE - III and forms integral part of this Report.

ARUNJYOTI BIO VENTURES LIMITED

M/s. Manoj Parakh & Associates, Company Secretaries, have issued the Secretarial Auditors' Report for fiscal 2026 and it does not contain any qualification, reservation or adverse remark except the following:

- Company has granted loan of Rs. 80.72 Lakhs (Amount outstanding as on 31st March 2026 is Rs. 65.99 Lakhs) to Pasura Xpress LLP, a related party in which directors are interested.

The said transaction falls within the ambit of Section 185(2) of the Companies Act, 2013 and was entered into without obtaining the requisite approval of the shareholders by way of a Special Resolution.

- We further report that the Company has paid remuneration in excess of the limits approved by the shareholders amounting to Rs. 9,71,432 to Mr. Pabbathi Badari Narayana Murthy, Whole-time Director and Rs. 15,47,800 to Mr. Nadimpalli Vishal, Whole-time Director and CFO aggregating to Rs. 25.19 Lakhs.
- No undisputed amounts payable in respect of Goods and Service Tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues were in arrears, as at 31 March 2026 for a period of more than six months from the date they became payable, except as below which are pending to be remitted on account of KYC issues and operational challenges.

Name of Statute	Nature of due	Amount in Rs	Period to which it relates	Due date	Date of payment	Remarks
The Employee State Insurance Act, 1948	Employee State Insurance	1,282	Apr-24	15-05-2024	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	3,662	May-24	15-06-2024		-
The Provident fund Act, 1952	Provident Fund	47,405	Jun-24	15-07-2024	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	5,080				-
The Provident fund Act, 1952	Provident Fund	51,479	Jul-24	15-08-2024	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	5,514				-
The Provident fund Act, 1952	Provident Fund	23,339	Aug-24	15-09-2024	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	559				-
The Provident fund Act, 1952	Provident Fund	66,941	Sep-24	15-10-2024	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	9,220				-
The Provident fund Act, 1952	Provident Fund	79,005	Oct-24	15-11-2024	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	12,144				-

ARUNJYOTI BIO VENTURES LIMITED

The Provident fund Act, 1952	Provident Fund	82,442	Nov-24	15-12-2024	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	12,714				-
The Provident fund Act, 1952	Provident Fund	49,057	Dec-24	15-01-2025	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	9,562				-
The Provident fund Act, 1952	Provident Fund	1,06,313	Jan-25	15-02-2025	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	18,479				-
The Provident fund Act, 1952	Provident Fund	1,09,225	Feb-25	15-03-2025	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	18,961				
The Provident fund Act, 1952	Provident Fund	1,14,005	Mar-25	15-04-2025	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	20,229				-
The Provident fund Act, 1952	Provident Fund	1,23,028	Apr-25	15-05-2025	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	22,742				-
The Provident fund Act, 1952	Provident Fund	1,39,686	May-25	15-06-2025	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	25,151				-
The Provident fund Act, 1952	Provident Fund	1,49,491	Jun-25	15-07-2025	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	27,425				-
The Provident fund Act, 1952	Provident Fund	1,52,770	Jul-25	15-08-2025	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	27,722				-
The Provident fund Act, 1952	Provident Fund	1,56,590	Aug-25	15-09-2025	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	28,737				-

ARUNJYOTI BIO VENTURES LIMITED

- Based on audit procedures and as per the information and explanations given by the management, the Company has defaulted in repayment of loans or other borrowings or in payment of interest thereon to a lender as below:

Nature of borrowing including debt securities	Name of lender	Amount not paid on due date	Whether principal or interest	No. of days delay or unpaid	Remarks, if any
Term Loan	Axis Bank Ltd	15,35,431	Interest	1	Apr-25
Term Loan	Axis Bank Ltd	34,64,000	Principal	1	
Term Loan	Axis Bank Ltd	12,69,679	Interest	1	May-25
Term Loan	Axis Bank Ltd	27,70,000	Principal	1	
Term Loan	Axis Bank Ltd	11,05,176	Interest	1	Aug-25
Term Loan	Axis Bank Ltd	27,70,000	Principal	1	
Term Loan	Axis Bank Ltd	12,86,624	Interest	1	Sep-25
Term Loan	Axis Bank Ltd	34,64,000	Principal	1	
Term Loan	Axis Bank Ltd	10,65,638	Interest	1	Oct-25
Term Loan	Axis Bank Ltd	27,70,000	Principal	1	
Term Loan	Axis Bank Ltd	12,35,004	Interest	1	Nov-25
Term Loan	Axis Bank Ltd	34,64,000	Principal	1	
Term Loan	Axis Bank Ltd	12,43,610	Interest	1	Dec-25
Term Loan	Axis Bank Ltd	34,64,000	Principal	1	
Term Loan	Axis Bank Ltd	3,49,403	Interest	1	Jan-26
Term Loan	Axis Bank Ltd	27,70,000	Principal	1	
Term Loan	Axis Bank Ltd	10,01,193	Interest	1	Feb-26
Term Loan	Axis Bank Ltd	34,64,000	Principal	1	
Term Loan	Axis Bank Ltd	10,88,550	Interest	1	Mar-26
Term Loan	Axis Bank Ltd	34,64,000	Principal	1	

Management Reply:

- The approval of the shareholders by way of ratification is proposed to be obtained at the ensuing Annual General Meeting. Further, the borrower, Pasura Xpress LLP is in the process of repaying the outstanding amount. Upon receipt of the said amount, Arunjyoti Bio Ventures Limited shall take necessary steps to file an application for compounding of the offence with the competent authority and regularize the matter in accordance with the applicable legal and regulatory requirements.
- In accordance with the provisions of Section 197 of the Companies Act, 2013, the Board in its meeting held on 09.07.2026 has approved the proposal for waiver of recovery of the excess remuneration aggregating to Rs. 25,19,232, comprising Rs. 9,71,432 paid to Mr. Pabbathi Badari Narayana Murthy, Whole-time Director and Rs. 15,47,800 paid to Mr. Nadimpalli Vishal, Whole-time Director and CFO. The necessary approval of the shareholders by way of a Special Resolution is proposed to be obtained at the ensuing Annual General Meeting.

- c) The delay in remittance of the outstanding statutory dues was primarily due to pending Know Your Customer (KYC) compliance requirements and certain operational challenges. The Company has initiated the necessary actions to complete the pending formalities and resolve the operational issues.
- d) The delay of one day in repayment of the principal and interest instalments was solely due to the timing of the bank's auto-debit process. The delay was operational in nature and was not attributable to any financial default by the Company.

37. INTERNAL AUDITORS:

M/s. K.S. Ramakrishna & Co., Chartered Accountants were re-appointed as Internal Auditors of the Company for the financial year 2025-26.

38. SECRETARIAL STANDARDS:

Your Company is in compliance with the applicable secretarial standards.

39. DECLARATION BY THE COMPANY:

The Company has issued a certificate to its Directors, confirming that it has not made any default under Section 164(2) of the Companies Act, 2013, as on March 31, 2026.

40. ANNUAL RETURN:

As required pursuant to Section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014, an annual return for FY 2025-26 is disclosed on the website www.abvl.co.in.

41. DISCLOSURE ABOUT COST AUDIT:

The provisions of Cost Audit and keeping mandatory cost records do not apply to your Company.

42. MANAGEMENT DISCUSSIONS AND ANALYSIS REPORT:

The Management Discussion and Analysis Report, pursuant to the SEBI (LODR) Regulation provides an overview of the affairs of the Company, its legal status and autonomy, business environment, mission & objectives, sectoral and operational performance, strengths, opportunities, constraints, strategy and risks and concerns, as well as human resource and internal control systems is appended as ANNEXURE - V for information of the Members.

43. FAMILIARIZATION PROGRAM FOR INDEPENDENT DIRECTORS:

Independent Directors are familiarized about the Company's operations

and businesses. Interaction with the Business heads and key executives of the Company is also facilitated. Detailed presentations on important policies of the Company are also made to the directors. Direct meetings with the Chairman are further facilitated to familiarize the incumbent Director about the Company/its businesses and the group practices.

44. INSURANCE:

The properties and assets of your Company are adequately insured.

45. NON-EXECUTIVE DIRECTORS' COMPENSATION AND DISCLOSURES:

None of the Independent / Non-Executive Directors has any pecuniary relationship or transactions with the Company which in the Judgment of the Board may affect the independence of the Directors.

46. CODE OF CONDUCT FOR THE PREVENTION OF INSIDER TRADING:

The Board of Directors has adopted the Insider Trading Policy in accordance with the requirements of the SEBI (Prohibition of Insider Trading) Regulation, 2018. The Insider Trading Policy of the Company lays down guidelines and procedures to be followed, and disclosures to be made while dealing with shares of the Company, as well as the consequences of violation. The policy has been formulated to regulate, monitor and ensure reporting of deals by employees and to maintain the highest ethical standards of dealing in Company securities. The Insider Trading Policy of the Company covering code of practices and procedures for fair disclosure of unpublished price sensitive information and code of conduct for the prevention of insider trading, is available on our website www.abvl.co.in.

47. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:

The Company has in place an Anti-Sexual Harassment Policy in line with the requirements of The Sexual Harassment of Women at workplace (Prevention, Prohibition and Redressal) Act, 2013. The following is the summary of sexual harassment complaints received and disposed during the calendar year.

- | | |
|---|-----|
| • No. of complaints received: | Nil |
| • No. of complaints disposed off: | Nil |
| • No. of cases pending for more than ninety days: | Nil |

48. INDUSTRY BASED DISCLOSURES AS MANDATED BY THE RESPECTIVE LAWS GOVERNING THE COMPANY:

The Company is not a NBFC, Housing Companies etc., and hence Industry based disclosures is not required.

49. FAILURE TO IMPLEMENT CORPORATE ACTIONS:

During the year under review, no corporate actions were done by the Company which were failed to be implemented.

50. DETAILS OF APPLICATION MADE OR PROCEEDING PENDING UNDER INSOLVENCY AND BANKRUPTCY CODE, 2016:

During the year under review, there were no applications made or proceedings pending in the name of the Company under Insolvency and Bankruptcy Code, 2016.

51. DETAILS OF DIFFERENCE BETWEEN VALUATION AMOUNT ON ONE TIME SETTLEMENT AND VALUATION WHILE AVAILING LOAN FROM BANKS AND FINANCIAL INSTITUTIONS:

During the year under review, there has been no one-time settlement of loans taken from banks and financial institutions.

52. COMPLIANCE OF THE PROVISIONS RELATING TO THE MATERNITY BENEFIT ACT 1961

The Company has duly complied with all provisions of the Maternity Benefit Act, 1961 and has extended all statutory benefits to eligible women employees during the year.

53. POLICIES:

The SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 mandated the formulation of certain policies for all listed companies. All the policies are available on our website (<https://www.abvl.co.in>). The policies are reviewed periodically by the Board and updated based on need and new compliance requirements.

54. RISK MANAGEMENT POLICY

The Company has developed and implemented a comprehensive Risk Management Policy for identifying, assessing and mitigating various risks that may affect its operations and overall performance. The Risk Management Policy is available on the Company's website at: www.abvl.co.in.

55. EVENT BASED DISCLOSURES:

During the year under review, the Company has not taken up any of the following activities except as mentioned:

1. Issue of sweat equity share: NA
2. Issue of shares with differential rights: NA
3. Issue of shares under employee's stock option scheme: NA
4. Disclosure on purchase by Company or giving of loans by it for purchase of its shares: NA
5. Buy back shares: NA
6. Disclosure about revision: NA
7. Preferential Allotment of Shares: NA

56. ACKNOWLEDGEMENTS:

Your Directors wish to place on record their appreciation of the contribution made by the employees at all levels, to the continued growth and prosperity of your Company. Your Directors also wish to place on record their appreciation of business constituents, banks and other financial institutions and shareholders of the Company for their continued support for the growth of the Company.

**For and on behalf of the Board
Arunjyoti Bio Ventures Limited**

**Place: Hyderabad
Date: 09.07.2026**

**Sd/-
Nadimpalli Vishal
Whole-time Director
& CFO
(DIN: 02745303)**

**Sd/-
Pabbathi Badari
Narayana Murthy
Whole-time Director
(DIN: 01445523)**

ANNEXURE - I

STATEMENT SHOWING THE NAMES OF TOP TEN EMPLOYEES PURSUANT TO SEC. 197 READ WITH RULE 5 (1) (2) and (3) OF THE COMPANIES (APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL) RULES, 2014

1. The ratio of remuneration to each director to the median remuneration of the employees of the company for the financial year.

Director Name	Remuneration (₹ Lakhs)	Median Employee Rem. (₹ Lakhs)	Ratio
Mr. Pabbathi Badari Narayana Murthy	85.71	4.67	18.35:1
Mr. Nadimpalli Vishal	51.48	4.67	11.02:1

2. The percentage increase in remuneration of each director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, in the financial year.

Name	Designation	Remuneration in (₹ in Lakhs)		Increase/ (Decrease) %
		FY 2024-25	FY 2025-26	
Mr. Pabbathi Badari Narayana Murthy	Whole Time Director	85.13	85.71	0.68%
Mr. Nadimpalli Vishal	Whole Time Director Cum Chief Financial Officer	36.63	51.48	40.54%
Ms. Swati Jain	Company Secretary	2.54	2.54	Nil

ARUNJYOTI BIO VENTURES LIMITED

3. The percentage increase in the median remuneration of employees in the financial year

(Amount in Rs.)

Particulars	Remuneration		Increase/ (Decrease)%
	FY 2025-26	FY 2024-25	
Median Remuneration of all the employees per Month*	4.67	3.97	17.63%

*Employees who have served for whole of the respective financial years have been considered.

4.

Particulars	Number
The number of employees on the rolls of the company as on March 31, 2026	168

ARUNJYOTI BIO VENTURES LIMITED

5. Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and details if there are any exceptional circumstances for increase in the managerial remuneration.

Particulars	Increase/ (Decrease) %
Average percentage increase in the remuneration of all Employees* (Other than Key Managerial Personnel)	9.00%
Average Percentage increase in the Remuneration of Key Managerial Personnel	12.67%

*Employees who have served for whole of the respective financial years have been considered.

6. **Affirmation that the remuneration is as per the remuneration policy of the company.**

The Company is in compliance with its remuneration policy.

**For and on behalf of the Board
Arunjyoti Bio Ventures Limited**

**Sd/-
Nadimpalli Vishal
Whole-time Director
& CFO
(DIN: 02745303)**

**Sd/-
Pabbathi Badari
Narayana Murthy
Whole-time Director
(DIN: 01445523)**

**Place: Hyderabad
Date: 09.07.2026**

ARUNJYOTI BIO VENTURES LIMITED

ANNEXURE - II

LIST OF TOP 10 EMPLOYEES

In terms of Remuneration drawn as per Rule 5(2) and (3) of the Companies (Appointment and Remuneration of Management personnel) Rules 2014:

S. No.	Name of the Employee	Designation	Remuneration Received (₹)	Nature of Employment	Qualification & Experience (Years)	Date of Joining	Age (Years)	Previous Employment	Equity Shareholding in Company (%)	Whether Relative of Director or Manager
1	CHINTA SURESH BABU	PLANT MANAGER	11,09,400	Permanent	M. Sc. Organic	11-05-2023	41	Bhavshiya Foods & Beverages Pvt. Ltd.	-	-
2	SHAIK ABDUL AZEEZ	PLANT IN-CHARGE	7,82,400	Permanent	DEGREE	01-06-2022	42	BALAJI MSRM LAMINATES PVT LTD	-	-
3	PONNURU PRASAD	WAREHOUSE MANAGER	6,02,400	Permanent	Degree	01-06-2022	65	MSRM INTERNATIONAL TRADING PVT LTD	-	-
4	YERRAMSETTI BALASUBRAHMANYAM	ASSISTANT ACCOUNTS MANAGER	6,00,400	Permanent	Degree (B. Com)	01-06-2022	43	MSRM INTERNATIONAL TRADING PVT LTD	-	-
5	THOTA SURESU BABU	SENIOR OPERATIONS MANAGER	5,42,400	Permanent	BA (Economics)	01-02-2023	47	Yas to Neely Foundation	-	-
6	VADLA LAVAJAH CHARY	ASSISTANT ACCOUNTS MANAGER	4,74,400	Permanent	MBA	15-05-2024	42	Sahuwala Aluminium Pvt Ltd	-	-
7	TALARI SIVUDU	ASSISTANT H R MANAGER	4,73,400	Permanent	MBA	23-05-2024	32	Ghanta Foods Pvt Ltd	-	-
8	PALVA SRINIVASA REDDY	LEGAL & ADMIN MANAGER	4,70,400	Permanent	Degree	01-06-2022	53	MSRM INTERNATIONAL TRADING PVT LTD	-	-
9	GANGIRALA MAHESH	LINE EXECUTIVE	4,26,840	Permanent	DEGREE (BSC)	15-02-2023	38	JDM Fruit Products Pvt Ltd	-	-
10	BELLAM HANUMANTH	Asst Manager Production	4,27,305	Permanent	DME	09-11-2024	47	Pearl Beverages Limited (Peps)	-	-

**FORM MR-3
SECRETARIAL AUDIT REPORT**

(Pursuant to section 204(1) of the Companies Act, 2013 and
Rule 9 of the Companies (Appointment and Remuneration of Managerial
Personnel) Rules, 2014

FOR THE FINANCIAL YEAR ENDED 31st MARCH, 2026

To,
The Members
Arunjyoti Bio Ventures Limited

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Arunjyoti Bio Ventures Limited (hereinafter called "the Company"). Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's Books, Papers, Minutes Books, Forms and Returns filed and other Records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the company has, during the financial year commencing from 1st April, 2025 and ended 31st March, 2026 complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made herein after:

1. We have examined the books, papers, minutes books, forms and returns filed and other records maintained by the Company for the financial year ended on 31st of March, 2026 according to the provisions of:
 - (i) The Companies Act, 2013 (the Act) and the rules made there under;
 - (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made there under;
 - (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;
 - (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment (FDI), Overseas Direct Investment and External Commercial Borrowings;

ARUNJYOTI BIO VENTURES LIMITED

2. Compliance status in respect of the provisions of the following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI ACT') is furnished hereunder for the financial year 2025-26:
- (i) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - (ii) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Amended Regulations 2018; **The Company has framed code of conduct for regulating & reporting trading by insiders and for fair disclosure and displayed the same on the Company's website i.e. www.abvl.co.in.**
 - (iii) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; **Not Applicable as the Company has not issued any securities during the year under review.**
 - (iv) The Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021; **Not Applicable as the Company has not issued any Employee Stock Options during the year under review.**
 - (v) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008/ The Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021; **Not Applicable as the Company has not issued any debt securities during the year under review.**
 - (vi) The Securities and Exchange Board of India (Registrars to an issue and Share Transfer Agents) Regulations, 1993, regarding the Companies Act and dealing with client; **Not Applicable as the Company is not registered as Registrar to an Issue and Share Transfer Agent during the year under review. However, the company has Venture Capital and Corporate Investments Private Limited as its Share Transfer Agent.**
 - (vii) Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021; **Not Applicable as the company has not delisted/ proposed to delist its equity shares during the year under review.**
 - (viii) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; **Not Applicable as the Company has not bought back/ proposed to buy-back any of its securities during the year under review**

(i) Other applicable laws include the following:

- The Code on Wages, 2019
- The Code on Social Security, 2020
- Income Tax Act, 1961
- Indian Stamp Act, 1899
- Shops and Establishments Act, 1948
- Central Goods and Services Tax Act, 2017
- State Goods and Services Tax Act, 2017

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India.
- (ii) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 were complied with to the extent applicable.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above including the following:

- a) During the year the Company has conducted 5 meetings of the Board of Directors, 5 meetings of the Audit committee, 1 Meetings of Stakeholder Relationship Committee, 3 meetings of Nomination and Remuneration Committee and 1 meeting of Independent Directors.
- b) As per the information and explanations provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we report that
 - (i) the provisions of the Foreign Exchange Management Act, 1999 and the Rules and Regulations made there under to the extent of:
 - External Commercial Borrowings were not attracted to the Company under the financial year under report;
 - Foreign Direct Investment (FDI) was not attracted to the company under the financial year under report;
 - Overseas Direct Investment by Residents in Joint Venture/Wholly Owned Subsidiary abroad was not attracted to the company under the financial year under report.

ARUNJYOTI BIO VENTURES LIMITED

- (ii) As per the information and explanations provided by the company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, we report that the Company has not made any

GDRs/ADRs or any Commercial Instrument under the financial year under report.

We further report that:

- The Company has reappointed internal auditors namely M/s. K.S. Ramakrishna & Co.,
 - The website of the Company contains policies as specified by SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and the provisions of Companies Act, 2013.
 - The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. There is no change in the composition of the Board of Directors of the Company.
 - Adequate notice of board meeting is given to all the directors along with agenda at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and meaningful participation at the meeting.
 - As per the minutes of the meeting duly recorded and signed by the Chairman, the decisions of the Board were unanimous and no dissenting views have been recorded.
 - We, further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.
 - The Compliance by the Company of applicable financial laws like Direct and Indirect Tax laws has not been reviewed thoroughly in this audit since the same has been subject to review by statutory financial audit and other designated professionals.
 - We further report that during the audit period except the following the company has no events/actions having a major bearing on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines etc.
1. Resignation of M/s. V Ravi & Co., Chartered Accountants, Statutory Auditors of the Company with effect from 04.08.2025.
 2. Appointment of M/s. PKF Sridhar & Santhanam LLP, Chartered

ARUNJYOTI BIO VENTURES LIMITED

Accountants as Statutory Auditors of the Company to fill the casual vacancy for a term of 5 years w.e.f. 04.08.2025.

3. Re-appointment of

- a. Mr. Pabbathi Badari Narayana Murthy as a whole-time director of the Company for a period of 3 years w.e.f. 10.11.2025.
 - b. Mr. Dathvik Pabbathi as a whole-time director of the Company for a period of 3 years w.e.f., 10.11.2025.
 - c. Mr. Nadimpalli Vishal as a whole-time director of the Company for a period of 3 years w.e.f., 10.11.2025.
- We further report that the Company has granted a loan of Rs. 80.72 Lakhs (Amount outstanding as on 31st March 2026 is Rs. 65.99 Lakhs) to an LLP in which directors are interested. The said transaction falls within the ambit of Section 185(2) of the Companies Act, 2013 and was entered into without obtaining the prior approval of the shareholders by way of a Special Resolution.
 - We further report that the Company has paid remuneration in excess of the limits approved by the shareholders amounting to Rs. 9,71,432 to Mr. Pabbathi Badari Narayana Murthy, Whole-time Director and Rs. 15,47,800 to Mr. Nadimpalli Vishal, Whole-time Director and CFO aggregating to Rs. 25.19 Lakhs.
 - No undisputed amounts payable in respect of Goods and Service Tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues were in arrears, as at 31 March 2026 for a period of more than six months from the date they became payable, except as below which are pending to be remitted on account of KYC issues and operational challenges.

ARUNJYOTI BIO VENTURES LIMITED

Name of Statute	Nature of due	Amount in Rs	Period to which it relates	Due date	Date of payment	Remarks
The Employee State Insurance Act, 1948	Employee State Insurance	1,282	Apr-24	15-05-2024	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	3,662	May-24	15-06-2024		-
The Provident fund Act, 1952	Provident Fund	47,405	Jun-24	15-07-2024	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	5,080				-
The Provident fund Act, 1952	Provident Fund	51,479			-	-
The Employee State Insurance Act, 1948	Employee State Insurance	5,514	Jul-24	15-08-2024		-
The Provident fund Act, 1952	Provident Fund	23,339			-	-
The Employee State Insurance Act, 1948	Employee State Insurance	559				-
The Provident fund Act, 1952	Provident Fund	66,941	Sep-24	15-10-2024	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	9,220				-
The Provident fund Act, 1952	Provident Fund	79,005				-
The Employee State Insurance Act, 1948	Employee State Insurance	12,144	Oct-24	15-11-2024		-
The Provident fund Act, 1952	Provident Fund	82,442			-	-
The Employee State Insurance Act, 1948	Employee State Insurance	12,714				-
The Provident fund Act, 1952	Provident Fund	49,057	Dec-24	15-01-2025	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	9,562				-
The Provident fund Act, 1952	Provident Fund	1,06,313			-	-
The Employee State Insurance Act, 1948	Employee State Insurance	18,479	Jan-25	15-02-2025		-
The Provident fund Act, 1952	Provident Fund	1,09,225			-	-
The Employee State Insurance Act, 1948	Employee State Insurance	18,961				-
The Provident fund Act, 1952	Provident Fund	1,14,005	Mar-25	15-04-2025	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	20,229				-

ARUNJYOTI BIO VENTURES LIMITED

The Provident fund Act, 1952	Provident Fund	1,23,028	Apr-25	15-05-2025	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	22,742				-
The Provident fund Act, 1952	Provident Fund	1,39,686	May-25	15-06-2025	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	25,151				-
The Provident fund Act, 1952	Provident Fund	1,49,491	Jun-25	15-07-2025	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	27,425				-
The Provident fund Act, 1952	Provident Fund	1,52,770	Jul-25	15-08-2025	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	27,722				-
The Provident fund Act, 1952	Provident Fund	1,56,590	Aug-25	15-09-2025	-	-
The Employee State Insurance Act, 1948	Employee State Insurance	28,737				-

ARUNJYOTI BIO VENTURES LIMITED

- Based on our audit procedures and as per the information and explanations given by the management, the Company has defaulted in repayment of loans or other borrowings or in payment of interest thereon to a lender as below:

Nature of borrowing including debt securities	Name of lender	Amount not paid on due date	Whether principal or interest	No. of days delay or unpaid	Remarks, if any
Term Loan	Axis Bank Ltd	15,35,431	Interest	1	Apr-25
Term Loan	Axis Bank Ltd	34,64,000	Principal	1	
Term Loan	Axis Bank Ltd	12,69,679	Interest	1	May-25
Term Loan	Axis Bank Ltd	27,70,000	Principal	1	
Term Loan	Axis Bank Ltd	11,05,176	Interest	1	Aug-25
Term Loan	Axis Bank Ltd	27,70,000	Principal	1	
Term Loan	Axis Bank Ltd	12,86,624	Interest	1	Sep-25
Term Loan	Axis Bank Ltd	34,64,000	Principal	1	
Term Loan	Axis Bank Ltd	10,65,638	Interest	1	Oct-25
Term Loan	Axis Bank Ltd	27,70,000	Principal	1	
Term Loan	Axis Bank Ltd	12,35,004	Interest	1	Nov-25
Term Loan	Axis Bank Ltd	34,64,000	Principal	1	
Term Loan	Axis Bank Ltd	12,43,610	Interest	1	Dec-25
Term Loan	Axis Bank Ltd	34,64,000	Principal	1	
Term Loan	Axis Bank Ltd	3,49,403	Interest	1	Jan-26
Term Loan	Axis Bank Ltd	27,70,000	Principal	1	
Term Loan	Axis Bank Ltd	10,01,193	Interest	1	Feb-26
Term Loan	Axis Bank Ltd	34,64,000	Principal	1	
Term Loan	Axis Bank Ltd	10,88,550	Interest	1	Mar-26
Term Loan	Axis Bank Ltd	34,64,000	Principal	1	

For Manoj Parakh & Associates

Sd/-

Manoj Parakh

Proprietor

M. No: F8572, CP No: 8957

UDIN: F008572H000782664

Peer Review Cer. No.: 3439/2023

Place: Vishakhapatnam

Date: 08.07.2026

ARUNJYOTI BIO VENTURES LIMITED

Annexure A

To
The Members of
Arunjyoti Bio Ventures Limited

Our report of even date is to be read along with this letter.

1. Maintenance of secretarial record is the responsibility of the management of the company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have relied on the reports given by the concerned professionals in verifying the correctness and appropriateness of financial records and books of accounts of the company.
4. Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The secretarial Audit report is neither an assurance as to future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the company.

For Manoj Parakh & Associates

Sd/-

**Manoj Parakh
Proprietor**

M. No: F8572, CP No: 8957

UDIN: F008572H000782664

Peer Review Cer. No.: 3439/2023

Place: Vishakhapatnam

Date: 08.07.2026

ARUNJYOTI BIO VENTURES LIMITED

ANNEXURE - IV

Form No. AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

This form pertains to the disclosure of particulars of contracts/arrangements entered into between the Company with related parties referred to in Sub-Section (1) of Section 188 of the Companies Act, 2013 including arm's length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at arm's length basis: NotApplicable
2. Details of material contracts or arrangement or transactions at arm's length basis:

S. No	Name of Related Party and Nature of Relationship	Nature of Contract / Arrangement / Transaction	Duration of Contract / Arrangement / Transaction	Salient Terms of the Contract / Arrangement / Transaction including Value, if any	Date of Approval by the Board
a)	Mr. Pabbathi Dathvik – Whole-Time Director	Purchase of Land & Constructed Godown	During FY 2025-26	Purchase consideration aggregating to ₹222.74 Lakhs (Comprising of advance amount of ₹158.20 Lakhs paid in the year 2024-25 and the balance amount of ₹64.54 Lakhs paid in the current financial year), which was undertaken on an arm's length basis and approved by the Board.	11-12-2024
b)	Mr. Pabbathi Dathvik – Whole-Time Director	Rent	During FY 2025-26	Rent paid during FY 2025-26 in the ordinary course of business and on an arm's length basis. Aggregate transaction value: ₹6.00 Lakhs.	27-01-2024
c)	Mrs. Pabbathi Siva Ratna Mahalakshmi Prasanna	Purchase of Land & Constructed Godown	During FY 2025-26	Purchase consideration aggregating to ₹222.74 Lakhs (Comprising of advance amount of ₹150 Lakhs paid in the year 2024-25 and the balance amount of ₹72.74 Lakhs paid in the current financial year), which was undertaken on an arm's length basis and approved by the Board.	11-12-2024
d)	Mrs. P. S. R. M. Prasanna	Rent	During FY 2025-26	Rent paid during FY 2025-26 in the ordinary course of business and on an arm's length basis. Aggregate transaction value: ₹6.00 Lakhs.	27-01-2025

ARUNJYOTI BIO VENTURES LIMITED

3. Details of contracts or arrangements or transactions not in the ordinary course of business

S. No	Particulars	Details
a)	Name(s) of the related party & nature of relationship	None
b)	Nature of contracts/arrangements/transaction	Nil
c)	Duration of the contracts/arrangements/transaction	Nil
d)	Salient terms of the contracts or arrangements or transaction including the value, if any	None
e)	Justification of entering into such contracts or arrangements or transactions	None
f)	Date of approval by the Board	Not Applicable
g)	Amount paid as advances, if any	Nil
h)	Date on which the special resolution was passed in General Meeting as required under first proviso to Section 188	Not Applicable

All related party transactions that were entered during the financial year were on arms-length basis and are according to the policy of related party transactions adopted by the Company.

**For and on behalf of the Board
Arunjyoti Bio Ventures Limited**

**Sd/-
Nadimpalli Vishal
Whole-time Director
& CFO
(DIN: 02745303)**

**Sd/-
Pabbathi Badari
Narayana Murthy
Whole-time Director
(DIN: 01445523)**

**Place: Hyderabad
Date: 09.07.2026**

MANAGEMENT DISCUSSION AND ANALYSIS REPORT**INDUSTRY STRUCTURE, DEVELOPMENTS AND PERFORMANCE:**

Arunjyoti Bio Ventures Limited (ABVL) is a BSE-listed beverage co-packing and packaging company engaged in providing end-to-end manufacturing, processing, filling and packaging solutions for the beverage industry. The Company caters to reputed consumer brands in the packaged drinking water and fruit-based beverage segments.

The Indian beverage industry continues to experience growth driven by rising consumer demand for packaged beverages, increasing health consciousness, urbanization and growing preference for quality-assured products. The contract manufacturing and co-packing segment has emerged as a key enabler for leading beverage brands to expand their market presence efficiently.

The Company operates two modern manufacturing facilities located at Kallem, Jangaon, Telangana and Annadevarapeta, Kovvur, Andhra Pradesh. Both facilities are FSSAI licensed and BIS compliant. The Company operates high-capacity production lines comprising water bottling lines capable of producing 150 bottles per minute and juice packaging lines with a capacity of 180 containers per minute.

During the year, the Company continued to undertake beverage processing and co-packing operations for leading brands, including non-carbonated water and juice products for Tata Consumer Products Limited. The Company also commissioned a new Jelly Pouch Production Line with a capacity of 160 containers per minute at its Jangaon facility, enhancing its production capabilities and strengthening its position in the beverage packaging industry.

The Company reported total income of Rs. 2,787.24 lakhs during FY 2025-26 as compared to Rs. 2,816.54 lakhs during FY 2024-25. Profitability during the year was impacted by higher operating costs, employee expenses and exceptional items recognized during the year.

Opportunities and Threats:**Opportunities**

- Growing demand for packaged drinking water, fruit juices and ready-to-consume beverages.

ARUNJYOTI BIO VENTURES LIMITED

- Increasing outsourcing of manufacturing and packaging activities by leading FMCG and beverage companies.
- Expansion of production capacities and product diversification.
- Rising consumer preference for hygienically packed beverages.
- Long-term growth prospects in the Indian food and beverage sector.

Threats

- Intense competition in the contract manufacturing and beverage packaging industry.
- Fluctuations in raw material and packaging material costs.
- Regulatory and compliance requirements relating to food safety and quality standards.
- Dependence on key customers and contract manufacturing arrangements.
- Economic uncertainties and inflationary pressures affecting operating margins.

SEGMENT-WISE OR PRODUCT-WISE PERFORMANCE:

During the year under review, the Company achieved a total income of Rs. 2,787.24 lakhs and incurred a net loss of Rs. 453.61 lakhs as compared to a total income of Rs. 2,816.54 lakhs and incurred a net loss of Rs. 27.62 lakhs in the previous financial year.

The Company does not have any geographical segment.

OUTLOOK:

The outlook for the Indian beverage industry remains positive, supported by increasing consumer demand, expanding distribution networks and growing preference for branded packaged beverages. The Company is focused on strengthening customer relationships, improving operational efficiencies, enhancing capacity utilization and expanding its product offerings.

The newly commissioned Jelly Pouch Production Line and existing high-capacity beverage packaging infrastructure are expected to support future growth. Management remains committed to improving profitability and generating long-term value for stakeholders.

RISKS AND CONCERNS:

The Company is exposed to various business risks including customer concentration risk, raw material price fluctuations, operational risks, regulatory compliance risks and liquidity risks. Changes in consumer preferences, inflationary pressures, supply chain disruptions and competitive market conditions may impact business performance.

The Company continuously monitors these risks and adopts suitable risk mitigation measures through operational controls, compliance mechanisms and periodic management reviews.

INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY:

The company's internal control/supervisory system is established to ensure that the board and management are able to achieve their business objectives in a prudent manner, safeguarding the interest of company's shareholders and other stakeholders whilst minimizing the key risk such as fraud, misleading financial statements, breach of legal and contractual obligations, unauthorized business activities.

The Company has adequate internal financial controls commensurate with the size and nature of its business. Internal control systems are periodically reviewed to ensure effective monitoring of operations, safeguarding of assets, accuracy of financial reporting and compliance with applicable laws and regulations.

DISCUSSION ON FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE:

Financial and operational performance forms part of the Annual Report and is presented elsewhere in the report.

MATERIAL DEVELOPMENTS IN HUMAN RESOURCES / INDUSTRIAL RELATIONS FRONT, INCLUDING NUMBER OF PEOPLE EMPLOYED:

There are no material developments in the Human Resources area. The Industrial relations have been considered to be satisfactory. The Company constantly reviews the manpower requirements and effective steps are being taken to meet the requirements.

The Company follows a strategy of attracting and retaining the best talent and keeping employees engaged, motivated and innovative. The Company continues to have cordial relations with its employees and provides personnel development opportunities for all-round exposure to them.

ARUNJYOTI BIO VENTURES LIMITED

The number of employees on the rolls of the Company as on March 31, 2026 was 168.

Details of significant changes (i.e. change of 25% or more as compared to the immediately previous financial year) in key financial ratios, along with detailed explanations therefore, including:

Particulars	As at 31.03.2026	As at 31.03.2025	Change%
Debtor's Turnover Ratio (Revenue from Operations ÷ Avg. Trade Receivables)	7.11	8.33	-15%
Inventory Turnover Ratio (Revenue from Operations ÷ Avg. Inventory)	21.67	10.35	109%
Interest Coverage Ratio ((PBT + Finance Cost) ÷ Finance Cost)	1.51	0.87	74%
Current Ratio (Current Assets ÷ Current Liabilities)	0.43	1.36	-69%
Debt-Equity Ratio (Total Debt ÷ Equity)	0.76	0.77	-2%
Operating Profit Margin (%) ((PBT + Finance Cost) ÷ Revenue × 100)	-11.14%	8.06%	-238%
Net Profit Margin (%) (Net Profit ÷ Revenue × 100)	-16.34%	-0.99%	1550%

- Inventory Turnover Ratio decreased due to absence of stock-in-trade purchases during the year and reduction in inventory levels.
- Interest Coverage Ratio declined significantly owing to losses incurred during the year and lower operating profitability.
- Current Ratio decreased mainly due to reduction in current assets and increase in current liabilities.
- Operating Profit Margin and Net Profit Margin declined due to increased employee costs, higher operating expenses and exceptional items recognized during the year.

ARUNJYOTI BIO VENTURES LIMITED

Details of any change in return on net worth as compared to the immediately previous financial year along with a detailed explanation thereof:

The Return on Net Worth (RONW) decreased from (1.61%) in FY 2024-25 to (14.64%) in FY 2025-26. The decline was primarily attributable to the higher net loss of Rs. 453.61 lakhs incurred during the year as compared to a net loss of Rs. 27.62 lakhs in the previous year. The increase in operating expenses, employee benefit costs and exceptional items adversely impacted the profitability and return on shareholders' funds.

Disclosure of Accounting Treatment:

The Company has complied with all the requirements of Accounting Standards/Indian Accounting Standards applicable to the Company and during the year the Company has not changed any accounting policies.

NOTE:

Readers are advised to kindly note that the above discussion contains statements about risks, concerns, opportunities, etc., which are valid only at the time of making the statements. A variety of factors known/unknown, expected or otherwise, may influence the financial results. We do not expect these statements to be updated or revised to take care of any changes in the underlying presumptions.

Readers may therefore appreciate the context in which these statements are made before making use of the same.

**For and on behalf of the Board
Arunjyoti Bio Ventures Limited**

**Sd/-
Nadimpalli Vishal
Whole-time Director
& CFO
(DIN: 02745303)**

**Sd/-
Pabbathi Badari
Narayana Murthy
Whole-time Director
(DIN: 01445523)**

**Place: Hyderabad
Date: 09.07.2026**

CORPORATE GOVERNANCE REPORT

In accordance with Regulation 34 (3) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the report containing the details of Corporate Governance systems and processes at Arunjyoti Bio Ventures Limited as follows:

1. COMPANY'S PHILOSOPHY ON CORPORATE GOVERNANCE:

In addition to the requirements of the Companies Act, 2013 ("the Act") and the Rules framed there under, which are mandatory for every such company to comply with, the Securities and Exchange Board of India ("SEBI") has introduced a Code of Corporate Governance for a Listed Company, which is implemented through the Listing Regulations.

The Company sincerely believe that corporate governance is a collection of procedures and practices designed to make sure that a company's operations are managed in a way that guarantees responsibility, openness, and justice in all of its dealings in the broadest sense and satisfies the expectations and goals of the stakeholders and the general public. The system of policies and procedures known as "corporate governance" is what the company uses to guarantee moral behaviour that aligns with the interests of all of its stakeholders. Professionals in corporate governance must continuously improve their knowledge, skills, and talents in order to adjust systems and procedures that support the most ethical and successful management of the company and its resources.

In the Company the Board of Directors, Senior Management, Employees, and other members of the organization are all given different roles and levels of responsibility within the company's corporate governance structure. In order to live up to the expectations of shareholders, the company considers good corporate governance to be an ongoing process and works to enhance its procedures.

A. BOARD DIVERSITY:

With a view to achieving a sustainable and balanced development, the Company is looking forward to increase diversity at the Board level as an essential element in supporting the attainment of its strategic objectives and its sustainable development. In designing the Board's composition, Board diversity has been considered from a number of aspects, including but not limited to gender, age, cultural and educational background, ethnicity, professional experience, skills, knowledge and

length of service. The Board has adopted the Board Diversity Policy which sets out the approach to diversity of the Board of Directors. The Board Diversity Policy is available on our website, <https://www.abvl.co.in/policies.html>.

B. DATE OF REPORT

The information provided in the Report on Corporate Governance for the purpose of unanimity is as on 31st March, 2026. The Report is updated as on the date of the report wherever applicable.

2. BOARD OF DIRECTORS

A. COMPOSITION AND CATEGORY OF DIRECTORS

The Company has a well experienced and a well-informed Board with an optimum combination of 6 (Six) Directors comprising of 3 (Three) Non-Executive Directors [all being Independent Directors] and 3 (Three) Executive Directors as on March 31, 2026. The composition of the Board is in conformity with Regulation 17 of the Listing Regulations read with Section 149 of the Act.

B. ATTENDANCE OF EACH DIRECTOR AT THE MEETING OF THE BOARD OF DIRECTORS AND THE LAST ANNUAL GENERAL MEETING:

The Board of Directors is provided access to all the Company-related information, including but not limited to, information mentioned under Regulation 17 read with Part A of Schedule II to the Listing Regulations. Further as mandated by SEBI all the Directors have confirmed that they do not serve as an independent director in more than seven listed companies or where they are whole-time directors in any listed company, they do not serve as independent director in more than three listed companies.

The Company also adheres to the provisions of the Companies Act, 2013 read with the Rules framed thereunder, Secretarial Standards and Listing Regulations with respect to convening and holding the Meetings of the Board of Directors and its Committees.

The names and categories of the Directors on the Board, their attendance at Board meeting during the year and at last Annual General Meeting, as also the number of Directorships and Committee memberships held by them in other companies as on date are shown in following Table.

ARUNJYOTI BIO VENTURES LIMITED

C. NO. OF MEETINGS OF THE BOARD OF DIRECTORS HELD AND DATES ON WHICH HELD: 07.04.2025, 29.05.2025, 04.08.2025, 03.11.2025 and 03.02.2026.

Name of the Director	Category	Attendance at the AGM held on 10.09.2025	Attendance in Board Meetings		No. of Directorships in other companies (Name of the listed company to be mentioned)		No. of committee positions held in other public companies	
			Held	Present	Chairman	Director	Chairman	member
Mr. Pabbathi Badari Narayana Murthy	Promoter and Whole-time Director	Yes	5	5	-	-	-	-
Mr. Dathvik Pabbathi	Promoter and Whole-time Director	Yes	5	5	-	-	-	-
Mr. Nadimpalli Vishal	Whole-time Director and CFO	Yes	5	5	-	-	-	-
Mrs. Dhanalakshmi Guntaka	Non-Executive - Independent Director	Yes	5	5	-	4	3	5
Mr. Srikar Ranga	Non-Executive - Independent Director	Yes	5	5	-	-	-	-
Mr. Vijaya Rama Lakshmana Murthy	Non-Executive - Independent Director	Yes	5	5	-	-	-	-

ARUNJYOTI BIO VENTURES LIMITED

D. THE NAME OF OTHER LISTED ENTITIES WHERE DIRECTORS OF THE COMPANY ARE DIRECTORS AND THE CATEGORY OF DIRECTORSHIP

Name of Director	Other Listed Entities in which concern Director is Director	Category of Directorship
Mr. Pabbathi Badari Narayana Murthy	--	--
Mr. Dathvik Pabbathi	--	--
Mr. Nadimpalli Vishal	--	--
Mrs. Dhanalakshmi Guntaka	B. N. Rathi Securities Limited Sigachi Industries Limited	Independent Director Independent Director
Mr. Srikar Ranga	--	--
Mr. Vijaya Rama Lakshmana Murthy Mylavarapu	--	--

E. DISCLOSURE OF RELATIONSHIPS BETWEEN DIRECTORS INTER-SE:

Mr. Dathvik Pabbathi, Whole-time Director is the son of Mr. Pabbathi Badari Narayana Murthy, Whole-time Director. Other Directors do not have any inter se relation with each other.

F. NUMBER OF SHARES AND CONVERTIBLE INSTRUMENTS HELD BY NON-EXECUTIVEDIRECTORS:

None of the Non-Executive Directors is holding any Equity Shares or Convertible Instruments.

G. FAMILIARIZATION PROGRAM FOR INDEPENDENT DIRECTORS:

The Board members are provided with necessary documents, reports, internal policies and site visits to enable them to familiarize with the Company's operations, its procedures and practices. Periodic presentations are made at the Board and Board Committee Meetings, on business and performance updates of the Company business, strategy and risks involved. Detailed presentations on the Company's business were made at the meetings of the Directors held during the year.

During the financial year 2025-26 there has been no change in the Independent directors of the Company. The details of familiarization programmes imparted to independent directors is available on our company website at <https://www.abvl.co.in/policies.html>.

H. A CHART OR A MATRIX SETTING OUT THE SKILLS/ EXPERTISE/COMPETENCE OF THE BOARD OF DIRECTORS:

Sl. No	Skills / Expertise / Competence of the Board of Directors are required in the context of business of the Company	Names of the Directors who have such skills / expertise / competence
1	Strategy & Business	Mr. Pabbathi Badari Narayana Murthy and Mr. Dathvik Pabbathi
2.	Industry Expertise	Mr. Srikar Ranga
3	Market Expertise &Marketing	Mr. Srikar Ranga and Mrs. Dhanalakshmi Guntaka
4	Technology Perspective	Mr. Dathvik Pabbathi and Mr. Nadimpalli Vishal
5	Finance & Accounting	Mrs. Dhanalakshmi Guntaka, Mr. Srikar Ranga and Mr. Vijaya Rama Lakshmana Murthy Mylavarapu
6	Research & Development	Mr. Srikar Ranga and Mrs. Dhanalakshmi Guntaka
7	Legal and General Management	Mr. Pabbathi Badari Narayana Murthy and Mr. Dathvik Pabbathi

I. DECLARATION BY INDEPENDENT DIRECTORS:

All the Independent Directors have confirmed that they meet the criteria of independence as mentioned under Regulation 16(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements), 2015 read with Section 149(6) of the Companies Act, 2013.

J. DECLARATION BY BOARD:

The Board has confirmed that in its opinion, the independent directors fulfill the conditions specified in these regulations and are independent of the management.

K. RESIGNATION OF INDEPENDENT DIRECTOR

During the Financial Year 2025-26, there was no resignation of Independent Director in the Company.

3. COMMITTEES OF THE BOARD:

The Company has Four Board-level Committees - Audit Committee, Nomination & Remuneration Committee, Stakeholder Relationship Committee.

All decisions pertaining to the constitution of Committees, appointment of members and fixing of terms of service for Committee members are taken by the Board of Directors. Details on the role and composition of these Committees, including the number of meetings held during the financial year and the related attendance are provided in this report below:

1. **AUDIT COMMITTEE:** Audit Committee constituted in terms of Section 177 of Companies Act, 2013 read with Regulation 18 of SEBI (LODR) Regulations, 2015

A. BRIEF DESCRIPTION OF TERMS OF REFERENCE:

Overview of the Company's financial reporting process and disclosure of its financial information to ensure that the financial statements reflect a true and fair position and that sufficient and credible information is disclosed.

- i. Oversight of the listed entity's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;
- ii. Recommending the appointment, remuneration and terms of appointment of auditors of the listed entity;
- iii. Approval of payment to statutory auditors for any other services rendered by the statutory auditors;
- iv. Reviewing, with the management, the annual financial statements and Auditor's Report before submission to the Board for approval with particular reference to:
 - (a) Matters required to be included in the directors' responsibility statement to be included in the board's report in terms of clause (c) of sub-section (3) of Section 134 of the Act;
 - (b) Changes, if any, in accounting policies and practices and reasons for the same;
 - (c) Major accounting entries involving estimates based on the exercise of judgment by management;
 - (d) Significant adjustments made in the financial statements arising out of audit findings;
 - (e) Compliance with listing and other legal requirements relating to financial statements;
 - (f) Disclosure of any related party transactions;
 - (g) Modified opinion(s) in the draft audit report;

ARUNJYOTI BIO VENTURES LIMITED

- v. Reviewing, with the management, the quarterly financial statements before submission to the board for approval;
- vi. Reviewing, with the management, the statement of uses / application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document / prospectus / notice and the report submitted by the monitoring agency monitoring the utilization of proceeds of [public issue or rights issue or preferential issue or qualified institutional placement], and making appropriate recommendations to the board to take up steps in this matter;
- vii. Review and monitoring the auditor's independence and performance and effectiveness of audit process;
- viii. Approval or any subsequent modification of transactions of the listed entity with related parties;
- ix. Scrutiny of inter-corporate loans and investments;
- x. Valuation of undertakings or assets of the listed entity wherever it is necessary;
- xi. Evaluation of internal financial controls and risk management systems;
- xii. Reviewing, with the management, performance of statutory and internal auditors, adequacy of internal control systems;
- xiii. Reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure, coverage and frequency of internal audit;
- xiv. Discussion with internal auditors of any significant findings and follow up there on;
- xv. Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board;
- xvi. Discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;
- xvii. To look into the reasons for substantial defaults in the payment to the depositors, debenture-holders, shareholders (in case of non-payment of declared dividend) and creditors,
- xviii. To review the functioning of the whistle blower mechanism;

ARUNJYOTI BIO VENTURES LIMITED

- xix. Approval of appointment of Chief Financial Officer after assessing the qualifications, experience and background, etc. of the candidate
- xx. Carrying out any other function as is mentioned in the terms of reference of the audit committee.
- xxi. Reviewing the utilization of loans and/ or advances from/investment by the holding company in the subsidiary exceeding rupees 100 crore or 10% of the asset size of the subsidiary, whichever is lower including existing loans / advances / investments existing as on the date of coming into force of this provision.
- xxii. Consider and comment on rationale, the cost-benefits and the impact of schemes involving merger, demerger, amalgamation etc., on the listed entity and its shareholders.
- xxiii. Carrying out any other function as may be referred to the Committee by the Board.
- xxiv. Authority to review / investigate into any matter covered by Section 177 of the Companies Act, 2013 and matters specified in Part C of Schedule II of the Listing Regulations.

B. COMPOSITION, MEETINGS & ATTENDANCE

There were Five (5) Audit Committee Meetings held during the year on 07.04.2025, 29.05.2025, 04.08.2025, 03.11.2025 and 03.02.2026.

Name	Designation	Designation	Number of meetings during the year 2025-26	
			Held	Present
Ms. Dhanalakshmi Guntaka	Chairperson	Non-Executive Independent Director	5	5
Mr. Srikar Ranga	Member	Non-Executive Independent Director	5	5
Mr. Vijaya Rama Lakshmana Murthy	Member	Non-Executive Independent Director	5	5

Previous Annual General Meeting of the Company was held on 10.09.2025, Ms. Dhanalakshmi Guntaka, Chairperson of the Audit Committee for that period, attended previous AGM.

2. NOMINATION AND REMUNERATION COMMITTEE:

The Nomination and Remuneration Committee ('NRC') functions in accordance with Section 178 of the Act, Regulation 19 of the Listing Regulations and its Charter adopted by the Board. The terms of reference of the NRC includes:

A. BRIEF DESCRIPTION OF TERMS OF REFERENCE

- i. Formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the board of directors a policy relating to, the remuneration of the directors, key managerial personnel and other employees;
- ii. For every appointment of an independent director, the Nomination and Remuneration Committee shall evaluate the balance of skills, knowledge and experience on the Board and on the basis of such evaluation, prepare a description of the role and capabilities required of an independent director. The person recommended to the Board for appointment as an independent director shall have the capabilities identified in such description.

For the purpose of identifying suitable candidates, the Committee may:

- a. use the services of an external agencies, if required;
- b. consider candidates from a wide range of backgrounds, having due regard to diversity; and
- c. consider the time commitments of the candidates.
- iii. Formulation of criteria for evaluation of performance of Independent Directors and the Board of Directors.
- iv. Devising a policy on diversity of board of directors;
- v. Identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down, and recommend to the board of directors their appointment and removal.
- vi. Whether to extend or continue the term of appointment of the independent director, on the basis of the report of performance evaluation of independent directors.
- vii. Recommend to the board, all remuneration, in whatever form, payable to senior management.

ARUNJYOTI BIO VENTURES LIMITED

C. COMPOSITION OF THE NOMINATION AND REMUNERATION COMMITTEE, MEETINGS & ATTENDANCE

There were Three (3) Nomination and Remuneration Committee Meeting held during the financial year i.e., on 04.08.2025, 03.02.2026 and 18.02.2026

Name	Designation	Designation	Number of meetings during the year 2025-26	
			Held	Present
Mr. Vijaya Rama Lakshmana Murthy Mylavarapu	Chairperson	Non-Executive Independent Director	3	3
Mr. Srikar Ranga	Member	Non-Executive Independent Director	3	3
Ms. Dhanalakshmi Guntaka	Member	Non-Executive Independent Director	3	3

C. PERFORMANCE EVALUATION CRITERIA FOR INDEPENDENT DIRECTORS:

The performance evaluation of independent directors shall be done by the entire Board of Directors, excluding the director being evaluated. On the basis of the report of performance evaluation, it shall be determined whether to extend or continue the term of appointment of the independent director.

D. REMUNERATION POLICY:

The objectives of the remuneration policy are to motivate Directors to excel in their performance, recognize their contribution and retain talent in the organization and reward merit. The remuneration levels are governed by industry pattern, qualifications and experience of the Directors, responsibilities shouldered and individual performance.

POLICY FOR SELECTION OF DIRECTORS AND DETERMINING DIRECTORS' INDEPENDENCE:

1. Scope:

This policy sets out the guiding principles for the Nomination & Remuneration Committee for identifying persons who are qualified to

become Directors and to determine the independence of Directors, in case of their appointment as independent Directors of the Company.

2. Terms and References:

- 2.1 “Director” means a director appointed to the Board of a Company.
- 2.2 “Nomination and Remuneration Committee means the committee constituted in accordance with the provisions of Section 178 of the Companies Act, 2013 and reg. 19 of SEBI (Listing Obligation and Disclosure Requirement), Regulations, 2015.
- 2.3 “Independent Director” means a director referred to in sub-section (6) of Section 149 of the Companies Act, 2013 and Regulation 16(1)(b) of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015.

3. Policy:

- 3.1.1 The Nomination and Remuneration Committee, and the Board, shall review on annual basis, appropriate skills, knowledge and experience required of the Board as a whole and its individual members. The objective is to have a board with diverse background and experience that are relevant for the Company's operations.
- 3.1.2 In evaluating the suitability of individual Board member the Nomination and Remuneration Committee may take into account factors, such as:
- General understanding of the Company's business dynamics, global business and social perspective;
 - Educational and professional background
 - Standing in the profession;
 - Personal and professional ethics, integrity and values;
 - Willingness to devote sufficient time and energy in carrying out their duties and responsibilities effectively.
- 3.1.3 The proposed appointee shall also fulfil the following requirements:
- shall possess a Director Identification Number;
 - shall not be disqualified under the companies Act, 2013;

ARUNJYOTI BIO VENTURES LIMITED

- shall Endeavour to attend all Board Meeting and wherever he is appointed as a Committee member, the committee meeting;
 - shall abide by the code of conduct established by the company for Directors and senior management personnel;
 - shall disclose his concern or interest in any Company or companies or bodies corporate, firms, or other association of individuals including his shareholding at the first meeting of the Board in every financial year and thereafter whenever there is a change in the disclosures already made;
 - Such other requirements as any prescribed, from time to time, under the Companies Act, 2013, Regulation 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other relevant laws.
- 3.1.4 The Nomination & Remuneration Committee shall evaluate each individual with the objective of having a group that best enables the success of the Company's business.

3.2 Criteria of Independence.

- 3.2.1 The Nomination & Remuneration Committee shall assess the independence of Directors at time of appointment/ re-appointment and the Board shall assess the same annually. The Board shall re-assess determinations of independence when any new interest or relationships are disclosed by a Director.
- 3.2.2 The criteria of independence shall be in accordance with the guidelines as laid down in Companies Act, 2013 and Regulation 16 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

An independent Director in relation to a Company, means a director other than a managing Director or a whole-time Director or a nominee Director

- a. who, in the opinion of the Board, is a person of integrity and possesses relevant expertise and experience;
- b. (i) who is or was not a promoter of the Company or its holding, subsidiary or associate Company or member of the promoter group of the listed entity;
- (ii) who is not related to promoters or Directors of the Company its holding, subsidiary or associate Company

ARUNJYOTI BIO VENTURES LIMITED

- c. who, apart from receiving director's remuneration, has or had no material pecuniary relationship with the Company, its holding, subsidiary or associate Company, or their promoters, or Director, during the three immediately preceding financial year or during the current financial year;
- d. none of whose relative
- (A) is holding securities of or interest in the listed entity, its holding, subsidiary or associate company during the three immediately preceding financial years or during the current financial year of face value in excess of fifty lakh rupees or two percent of the paid-up capital of the listed entity, its holding, subsidiary or associate company, respectively, or such higher sum as may be specified;
- (B) is indebted to the listed entity, its holding, subsidiary or associate company or their promoters or directors, in excess of such amount as may be specified during the three immediately preceding financial years or during the current financial year;
- (C) has given a guarantee or provided any security in connection with the indebtedness of any third person to the listed entity, its holding, subsidiary or associate company or their promoters or directors, for such amount as may be specified during the three immediately preceding financial years or during the current financial year; or
- (D) has any other pecuniary transaction or relationship with the listed entity, its holding, subsidiary or associate company amounting to two percent or more of its gross turnover or total income:

Provided that the pecuniary relationship or transaction with the listed entity, its holding, subsidiary or associate company or their promoters, or directors in relation to points (A) to (D) above shall not exceed two percent of its gross turnover or total income or fifty lakh rupees or such higher amount as may be specified from time to time, whichever is lower.

- e. who, neither himself nor any of his relative-
- (i) Holds or has held the position of a key managerial personnel or is or has been employee of the or associate Company or any company belonging to the promoter group of the listed entity in any of the three finance years immediately preceding the finance year in which he is proposed to be appointed;

ARUNJYOTI BIO VENTURES LIMITED

Provided that in case of a relative, who is an employee other than key managerial personnel, the restriction under this clause shall not apply for his / her employment

- (ii) Is or has been an employee or proprietor or a partner, in any of the three financial year immediately preceding the financial year in which he is proposed to be appointed of-
- (A) a firm of auditors or Company secretaries in practice or cost auditors of the Company or its holding, subsidiary or associate Company; or
- (B) any legal or a consulting firm that has or had any transaction with the Company, its holding subsidiary or associate Company amounting to ten per cent or more of the gross turnover of more of the gross turnover of such firm;
- (iii) holds together with his relatives two per cent or more of the total voting power of the Company;

Or

- (iv) is a chief Executive or Director, by whatever name called, of any non-profit organization that receives twenty-five per cent or more of its receipt from the Company any of its promoters, Directors or its holding subsidiary or associate Company or that holds two per cent or more of the total voting power of the Company; or
 - (v) is a material supplier, service provider or customer or a lesser or lessee of the Company.
- f. who is not less than 21 years of age

- g. Who is not a non-independent Director of another company on the Board of which any non-independent director of the listed entity is an independent director.

3.2.3 The independent Director shall abide by the “code for independent Directors “as specified in Schedule IV to the Companies Act, 2013.

3.3 Other Directorships/ Committee Memberships

- 3.3.1 The Board members are expected to have adequate time and expertise and experience to contribute to effective Board performance. Accordingly, members should voluntarily limit their directorships in other listed public limited companies in such a way that it does not interfere with their role as director of the Company. The NR Committee shall take into account the nature of and the time

involved in a director's service on other Boards, in evaluating the suitability of the individual Director and making its recommendations to the Board.

- 3.3.2 A Director shall not serve as director in more than 20 companies of which not more than 10 shall be public limited companies.
- 3.3.3 A Director shall not serve as an independent Director in more than 7 listed companies and not more than 3 listed companies in case he is serving as a whole-time Director in any listed Company.
- 3.3.4 A Director shall not be a member in more than 10 committees or act as chairman of more than 5 committee across all companies in which he holds directorships.

For the purpose of considering the limit of the committee, Audit committee and stakeholder's relationship committee of all public limited companies, whether listed or not, shall be included and all other companies including private limited companies, foreign companies and companies under section 8 of the companies Act, 2013 shall be excluded.

Remuneration policy for Directors, key managerial personnel and other employees:

The objectives of the remuneration policy are to motivate Directors to excel in their performance, recognize their contribution and retain talent in the organization and reward merit. The remuneration levels are governed by industry pattern, qualifications and experience of the Directors, responsibilities shouldered and individual performance.

Remuneration policy for Directors, key managerial personnel and other employees

1. Scope:

- 1.1 This policy sets out the guiding principles for the Nomination and Remuneration committee for recommending to the Board the remuneration of the directors, key managerial personnel and other employees of the Company.

2. Terms and Reference:

- 2.1 "Director" means a Director appointed to the Board of the Company.
- 2.2 "key managerial personnel" means

ARUNJYOTI BIO VENTURES LIMITED

- (i) The Chief Executive Officer or the managing Director or the manager;
- (ii) The Company Secretary;
- (iii) The Whole-time Director;
- (iv) The Chief Financial Officer; and
- (v) Such other office as may be prescribed under the Companies Act, 2013

2.3 “Nomination and Remuneration committee” means the committee constituted by Board in accordance with the provisions of Section 178 of the companies Act, 2013, clause 49 of the Equity Listing Agreement and Regulation 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3. Policy:

3.1 Remuneration to Executive Director and key managerial personnel

3.1.1 The Board on the recommendation of the Nomination and Remuneration (NR)

3.1.2 The Board on the recommendation of the NR committee shall also review and approve the remuneration payable to the key managerial personnel of the Company.

3.1.3 The remuneration structure to the Executive Director and key managerial personnel shall include the following components:

- (i) Basic pay
- (ii) Perquisites and Allowances
- (iii) Stock Options
- (iv) Commission (Applicable in case of Executive Directors)
- (v) Retrial benefits
- (vi) Annual performance Bonus

3.1.4 The Annual plan and Objectives for Executive committee shall be reviewed by the Nomination and Remuneration committee and Annual performance bonus will be approved by the committee based on the achievement against the Annual plan and Objectives.

3.2 Remuneration to Non – Executive Directors

3.2.1 The Board, on the recommendation of the Nomination and Remuneration Committee, shall review and approve the remuneration payable to the Non – Executive Directors of the Company within the overall limits approved by the shareholders as per the provisions of the Companies Act.

3.2.2 Non – Executive Directors shall be entitled to sitting fees attending the meetings of the Board and the Committees thereof. The Non-Executive Directors shall also be entitled to profit related commission in addition to the sitting fees.

3.3. Remuneration to other employees

3.3.1. Employees shall be assigned grades according to their qualifications and work experience, competencies as well as their roles and responsibilities in the organization. Individual remuneration shall be determined within the appropriate grade and shall be based on various factors such as job profile skill sets, seniority, experience and prevailing remuneration levels for equivalent jobs.

PERFORMANCE EVALUATION OF BOARD, COMMITTEES AND DIRECTORS

Pursuant to provisions of Regulation 17(10) of the SEBI Listing Regulations and the provisions of the Act, an annual Board effectiveness evaluation was conducted for FY 2025-26 on 18.02.2026, involving the following:

- i. Evaluation of IDs, in their absence, by the entire Board was undertaken, based on their performance and fulfilment of the independence criteria prescribed under the Act and SEBI Listing Regulations; and
- ii. Evaluation of the Board of Directors, its Committees and individual Directors, including the role of the Board Chairman. An IDs' meeting, in accordance with the provisions of Section 149(8) read with Schedule IV of the Act and Regulation 25(3) and 25(4) of the SEBI Listing Regulations, was convened on 18.02.2026, mainly to review the performance of Independent Directors and the Chairman & Managing Director as also the Board as a whole.
- i) Board: Composition, responsibilities, stakeholder value and responsibility, Board development, diversity, governance, leadership, directions, strategic input, etc.

ARUNJYOTI BIO VENTURES LIMITED

- ii) Executive Directors: Skill, knowledge, performance, compliances, ethical standards, risk mitigation, sustainability, strategy formulation and execution, financial planning & performance, managing human relations, appropriate succession plan, external relations including CSR, community involvement and image building, etc.
- iii) Independent Directors: Participation, managing relationship, ethics and integrity, Objectivity, brining independent judgement, time devotion, protecting interest of minority shareholders, domain knowledge contribution, etc.
- iv) Chairman: Managing relationships, commitment, leadership effectiveness, promotion of training and development of directors etc.
- v) Committees: Terms of reference, participation of members, responsibility delegated, functions and duties, objectives alignment with company strategy, composition of committee, committee meetings and procedures, management relations.

Disclosures as prescribed under SEBI circular dated 10th May 2018 are given below:

Observations of Board evaluation carried out for the year	No observations.
Previous year's observations and actions taken	Since no observations were received, no actions were taken.
Proposed actions based on current year observations	Since no observations were received, no actions were taken.

C. MECHANISM FOR EVALUATION OF THE BOARD

Evaluation of all Board members is performed on an annual basis. The evaluation is performed by the Board/Nomination and Remuneration Committee and Independent Directors with specific focus on the performance and effective functioning of the Board and Individual Directors.

In line with Securities and Exchange Board of India Circular No. SEBI/HO/ CFD/ CMD/ CIR/ P/ 2017/ 004, dated January 5, 2017 and the Companies Amendment Act, 2017 the Company adopted the recommended criteria by Securities and Exchange Board of India.

The Directors were given six Forms for evaluation of the following:

- (i) Evaluation of Board;
- (ii) Evaluation of Committees of the Board;
- (iii) Evaluation of Independent Directors;
- (iv) Evaluation of Chairperson;
- (v) Evaluation of Non-Executive and Non-Independent Directors; and
- (vi) Evaluation of Managing Director/Whole time Director.

The Directors were requested to give following ratings for each criteria:

- 1. Could do more to meet expectations;
- 2. Meets expectations; and
- 3. Exceeds expectations.

Based on the evaluation done by the Independent Directors, Chairman of the Independent Director meeting has compiled the data and made a report and informed the rankings of each Director in the Board Meeting and also informed that the performance of Directors is satisfactory and they are recommended for continuation as Directors of the Company.

E. PERFORMANCE EVALUATION CRITERIA FOR INDEPENDENT DIRECTORS:

The performance evaluation criteria for Independent Directors are already mentioned under the head “Board Evaluation” in Directors’ Report.

3. STAKEHOLDERS RELATIONSHIP COMMITTEE:

Stakeholders Relationship Committee constituted in terms of Section 178(5) of Companies Act, 2013 read with Regulation 20 of SEBI (LODR) Regulations, 2015

A. BRIEF DESCRIPTION OF TERMS OF REFERENCE: The Committee’s role includes:

Terms of reference of the committee comprise of various matters provided under Regulation 20 of the Listing Regulations and section 178 of the Companies Act, 2013 which inter-alia include:

ARUNJYOTI BIO VENTURES LIMITED

- i. Resolving the grievances of the security holders of the Company including complaints related to transfer/ transmission of shares, non-receipt of annual report, non-receipt of declared dividends, issue of new/duplicate certificates, general meetings etc;
- ii. Review of measures taken for effective exercise of voting rights by shareholders;
- iii. Review of adherence to the service standards adopted by the Company in respect of various services being rendered by the Registrar & Share Transfer Agent;
- iv. Review of the various measures and initiatives taken by the Company for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/annual reports/statutory notices by the shareholders of the company;
- v. Such other matter as may be specified by the Board from time to time.
- vi. Authority to review / investigate into any matter covered by Section 178 of the Companies Act, 2013 and matters specified in Part D of Schedule II of the Listing Regulations.
- vi. Authority to review / investigate into any matter covered by Section 178 of the Companies Act, 2013 and matters specified in Part D of Schedule II of the Listing Regulations.

B. COMPOSITION OF THE COMMITTEE, MEETINGS AND ATTENDANCE DURING THE YEAR

During the Financial Year April 2025 to March 2026, one (1) Stakeholders Relationship Committee Meeting was held on 18.02.2026.

Name	Designation	Designation	Number of meetings during the year 2025-26	
			Held	Present
Ms. Dhanalakshmi Guntaka	Chairperson	Non-Executive Independent Director	1	1
Mr. Dathvik Pabbathi	Member	Executive Director	1	1
Mr. Vijaya Rama Lakshmana Murthy Mylavarapu	Member	Non-Executive Independent Director	1	1

ARUNJYOTI BIO VENTURES LIMITED

C. DETAILS OF COMPLAINTS/REQUESTS RECEIVED, RESOLVED AND PENDING DURING THE YEAR 2025-26

INVESTOR COMPLAINTS	
Particulars	Year ended 31.03.2026
Pending at the beginning of the year	0
Received during the year	0
Disposed of during the year	0
Remaining unresolved at the end of the year	0

D. NAME AND DESIGNATION OF COMPLIANCE OFFICER

Ms. Swati Jain, Company Secretary of the Company is the Compliance Officer of the Company.

4. PARTICULARS OF SENIOR MANAGEMENT INCLUDING THE CHANGES THEREIN SINCE THE CLOSE OF THE PREVIOUS FINANCIAL YEAR:

Sl. no	Name of the Senior Management	Designation	Appointment/ Resignation	Date of appointment /Date of Resignation (if any)
1.	Ms. Swati Jain	Company Secretary and Compliance Officer	Appointment	19/09/2020
2.	Mr. Chinta Suresh Babu	Plant Manager	Appointment	11/05/2023
3.	Mr. Shaik Abdul Azeez	Plant In-Charge	Appointment	01/06/2022

5. REMUNERATION OF DIRECTORS**a) PECUNIARY RELATIONSHIP OR TRANSACTIONS OF THE NON-EXECUTIVE DIRECTORS VIS-À-VIS THE LISTED COMPANY:**

None of the Non-Executive Directors have any pecuniary relationship or transaction with the company other than the Directors sitting fees and commission, if any.

b) WEB LINK FOR CRITERIA OF MAKING PAYMENTS TO NON-EXECUTIVE DIRECTORS:

The web-link for Familiarization Program for Independent Directors is <https://www.abvl.co.in/policies.html>.

c) DETAILS OF REMUNERATION

Name of the Director	Remuneration (Rs)	Sitting Fee (Rs)	Total (Rs)	No. of Equity Shares held
Mrs. Dhanalakshmi Guntaka	–	1,05,000	1,05,000	Nil
Mr. Srikar Ranga	–	1,05,000	1,05,000	Nil
Mr. Vijaya Rama Lakshmana Murthy Mylavarapu	–	1,05,000	1,05,000	Nil
Mr. Pabbathi Badari Narayana Murthy	85,71,432	–	85,71,432	3,58,76,078 Equity Shares
Mr. Dathvik Pabbathi	–	–	Nil	4,30,04,890 Equity Shares
Mr. Nadimpalli Vishal	51,47,800	–	51,47,800	Nil

- c. Except for the remuneration details mentioned above, there are no other pecuniary relationship or transactions of the non-executive directors vis-à-vis the listed entity in terms of salary, benefits, bonuses, stock options, pension, fixed component and performance linked incentives.

6. GENERAL BODY MEETINGS**a. LOCATION, DATE AND TIME OF LAST THREE AGMS AND SPECIAL RESOLUTIONS THERE AT AS UNDER:**

Financial Year	Date	Time	Venue	Special Resolution Passed
2024-25	AGM 10.09.2025	11:00 AM	through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM")	Yes
2023-24	AGM 14.09.2024	11:00 AM	through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM")	Yes
2022-23	AGM 29.09.2023	11:00 AM	through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM")	No
2023-24	EGM 17.06.2023	03:00 P.M.	through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM")	Yes
2023-24	EGM 27.11.2023	11:00 A.M.	through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM")	Yes
2024-25	EGM 06.01.2025	11:00 A.M.	through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM")	Yes

B. PASSING OF RESOLUTIONS BY POSTAL BALLOT

There were no resolutions passed by the Company through Postal Ballot during the Financial Year 2025-26 and no special resolution is proposed to be conducted through postal ballot.

7. MEANS OF COMMUNICATION:

The Company promptly discloses information on material corporate developments and other events as required under the Listing Regulations. Such timely disclosures indicate the good corporate governance practices of the Company. For this purpose, it provides multiple channels of communications through dissemination of information on the online portal of the Stock Exchange, Annual Reports and by placing relevant information on its website.

- i. Publication of financial results: Quarterly, half-yearly and annual financial results of the Company are published in leading English and

ARUNJYOTI BIO VENTURES LIMITED

Telugu language newspaper, viz., all India editions of Financial Express and Nava Telangana in English and Telugu language, Hyderabad edition.

- ii. Website and News Releases: In compliance with Regulation 46 of the Listing Regulations, a separate dedicated section under 'Investors' i.e. 'Disclosure under Regulation 46 of SEBI (LODR) Regulations' on the Company's website gives information on various announcements made by the Company, Annual Reports, financial results along with the applicable policies of the Company.

The Company's official news releases and presentations made to the institutional investors and analysts are also available on the Company's website: Not Applicable

- iii. Stock Exchange: The Company has a Policy for determination of Materiality of Events/Information for the purpose of making disclosure to the Stock Exchange. The Company makes timely disclosures of necessary information to BSE Limited (BSE), where shares of the Company are listed, in terms of the Listing Regulations and other applicable rules and regulations issued by the SEBI. The Policy for determination of Materiality of Events/Information is available on the Company's website at <https://www.abvl.co.in/policies.html>.
- v. Exclusive email ID for investors: The Company has a designated email id i.e. cenport@gmail.com exclusively for investor services, and the same is prominently displayed on the Company's website.
- vi. BSE Listing Centre: BSE Listing are web-based application designed by BSE, respectively, for corporates to make submissions. All periodical compliance filings, inter alia, shareholding pattern, corporate announcements, amongst others, are filed electronically in accordance with the Listing Regulations. Further, in compliance with the provisions of the Listing Regulations, all the disclosures made to the Stock Exchange are in a format that allows users to find relevant information easily through a searching tool.

8. GENERAL SHAREHOLDERS INFORMATION:

Company Registration Details	The Company is registered in the State of Telangana, India. The Corporate Identity Number (CIN) allotted to the Company by the Ministry of Corporate Affairs (MCA) is L01400TG1986PLC062463.
Date	12.08.2026
Time	11.00 a.m.
Venue of AGM	Through video conference
Financial Year	2025-26
Dividend payment date	Nil
Name and address of each stock exchange(s) at which the Company's securities are listed	BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai 400023
Confirmation of Payment of annual listing fees to stock exchanges	Paid to BSE Limited
Stock Code	BSE: 530881
Suspension of Trading	All the Equity Shares of the Company are traded on BSE.
Registrars to an issue and share transfer agents	Venture Capital and Corporate Investments Private Limited Address: "AURUM", 4th & 5th Floors, Plot no. 57, Jayabheri Enclave Phase II, Gachibowli, Hyderabad-500032, Telangana Ph No. 040-23818475 / 040-35164940 Email: info@vccipl.com Website: https://www.vccipl.com/
Tentative Schedule for considering Financial Results:	
For the Quarter ending June, 2026	09.07.2026
For the Quarter ending September, 2026	October/ November, 2026

ARUNJYOTI BIO VENTURES LIMITED

For the Quarter ending December,2026	January/ February, 2027
For the Quarter/year ending March, 2027	April/ May, 2027
commodity price risk or foreign exchange risk and hedging activities	NIL Charges for Monitoring Foreign Investment Limit
ISIN Number for NSDL & CDSL	INE485K01022
Branch Offices /Plant Locations	Unit 1: Sy No.36-40-B 36-39-B 36-34-B 17-G-3 36-45-B 36-33-B 36-48-B, And 36-44-B, 36-47-B, Lingalaghanpur Mandal, Kallem, Kallem, Jangaon, Telangana, 506201 Unit 2: 160/1, Annadevarapeta, Tallapudi Mandal, Annadevarapeta, East Godavari, Andhra Pradesh, 534341
Address for correspondence:	#1-98/1/JSIC/6F/604-B6th Floor, Jain Sadhguru Capital Park, Beside Image Gardens, Madhapur, Shaikpet Hyderabad - 500081, Telangana Website: https://www.abvl.co.in/index.html
Investor Correspondence / Query on Annual Report, etc.	Swati Jain Company Secretary and Compliance Officer #1-98/1/JSIC/6F/604-B6th Floor, Jain Sadhguru Capital Park, Beside Image Gardens, Madhapur, Shaikpet Hyderabad - 500081, Telangana Ph. 040-40114874 Website: https://www.abvl.co.in/index.html

ARUNJYOTI BIO VENTURES LIMITED

SHARE TRANSFER SYSTEM:

As mandated by SEBI, securities of the Company can be transferred/ traded only in dematerialised form. Shareholders holding shares in physical form are advised to avail the facility of dematerialisation.

DISTRIBUTION OF SHAREHOLDING AS ON 31.03.2026

Distribution Schedule - Standalone As on 31-03-2026				
Category (Amount)	No. of Shareholders	% of Total	No. of Shares	% to Total
Upto - 500	4988	86.57	2743089	1.47
501 - 1000	275	4.77	2108384	1.13
1001 - 2000	156	2.71	2288171	1.23
2001 - 3000	87	1.51	2164350	1.16
3001 - 4000	45	0.78	1653534	0.89
4001 - 5000	41	0.71	1909125	1.02
5001 - 10000	60	1.04	4454555	2.39
10001 and above	110	1.91	169059792	90.71
Total	5762	100	186381000	100

DEMATERIALISATION & LIQUIDITY OF SHARES:

Trading in Company's shares is permitted only in dematerialized form for all investors. The ISIN allotted to the Company's scrip is **INE485K01022**. Investors are therefore advised to open a demat account with a Depository participant of their choice to trade in dematerialized form.

Particulars	No. of Shares	% Share Capital
CSDL	13,48,17,972	72.33
NDSL	5,09,21,028	27.32
Physical	6,42,000	0.34
TOTAL	18,63,81,000	100.00

OUTSTANDING GLOBAL DEPOSITORY RECEIPTS OR AMERICAN DEPOSITORY RECEIPTS OR WARRANTS OR ANY CONVERTIBLE INSTRUMENTS, CONVERSION DATE AND LIKELY IMPACT ON EQUITY:

The Company has not issued these types of securities.

LIST OF ALL CREDIT RATINGS OBTAINED BY THE ENTITY ALONG WITH ANY REVISIONS THERETO DURING THE RELEVANT FINANCIAL YEAR, FOR ALL DEBT INSTRUMENTS OF SUCH ENTITY OR ANY FIXED DEPOSIT PROGRAMME OR ANY SCHEME OR PROPOSAL OF THE LISTED ENTITY INVOLVING MOBILIZATION OF FUNDS, WHETHER IN INDIA OR ABROAD:

The Company has not issued any debt instruments and did not have any fixed deposit programme or any scheme or proposal involving mobilization of funds in India or abroad during the financial year ended 31st March 2026.

9. OTHER DISCLOSURES**A. MATERIALLY SIGNIFICANT RELATED PARTY TRANSACTIONS:**

During the year under review, the Company had not entered in to any materially significant transaction with any related party except purchase of land admeasuring 2 acres and 6 guntas along with a constructed warehouse admeasuring 22,023 square feet situated at Jangaon, Telangana, from related parties.

All the related party transactions during the year are in the ordinary course of business and on arm's length basis.

The policy on related party transactions is available in the Company's website <https://www.abvl.co.in/policies.html>.

B. DETAILS OF NON-COMPLIANCE BY THE LISTED ENTITY, PENALTIES, STRICTURES IMPOSED ON THE LISTED ENTITY BY STOCK EXCHANGE(S) OR THE BOARD OR ANY STATUTORY AUTHORITY, ON ANY MATTER RELATED TO CAPITAL MARKETS, DURING THE LAST THREE YEARS:

Sl. No	Exchange	FY	Reg.no	Details of Violation	Penalty Details	Complied/not
1.	BSE	2023-24	Reg 33	Delay in filing of Financial Results for the quarter and half year ended September, 2022	Rs.5,900/- (incl. GST)	Complied
2.	BSE	2024-25	Reg 14	Delay in payment of Annual Listing fees	Rs. 7,670/- (Interest)	Complied
3.	BSE	2024-25	Reg 31	Non-Submission of shareholding pattern	Rs. 18,000/- (incl. GST)	Complied

C. VIGIL MECHANISM/ WHISTLE BLOWER POLICY:

The Company has adopted a Whistle Blower Policy and has established the necessary vigil mechanism as defined in Regulation 22 of SEBI (LODR) Regulations 2015 and in terms of Section 177 of the Companies Act, 2013.

With a view to adopt the highest ethical standards in the course of business, the Company has a whistle blower policy in place for reporting the instances of conduct which are not in conformity with the policy. Directors, employees, vendors or any person having dealings with the Company may report non-compliance to the Chairman of the Audit Committee, who reviews the report. Confidentiality is maintained of such reporting and it is ensured that the whistle blowers are not subjected to any discrimination. No person has been denied access to the Chairman of the Audit Committee.

D. COMPLIANCE WITH THE MANDATORY REQUIREMENTS AND ADOPTION OF THE NON-MANDATORY REQUIREMENTS OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

The Company has complied with the mandatory requirements of SEBI (LODR) Regulations, 2015 and is in the process of implementation of non– mandatory requirements.

(E) WEB LINK WHERE POLICY FOR DETERMINING ‘MATERIAL’ SUBSIDIARIES IS DISCLOSED;

The Company does not have any subsidiary as defined under Listing Regulations.

(F) WEB LINK WHERE POLICY ON DEALING WITH RELATED PARTY TRANSACTIONS;

In line with the requirements of the Companies Act, 2013 and Listing Regulations, your Company has formulated a Policy on Related Party Transactions which is also available on Company's Website <https://www.abvl.co.in/policies.html>. The Policy intends to ensure that proper reporting, approval and disclosure processes are in place for all transactions between the Company and Related Parties.

All Related Party Transactions are placed before the Audit Committee for review and approval. Prior omnibus approval is obtained for Related Party Transactions on yearly basis for transactions which are of repetitive nature and / or entered in the Ordinary Course of Business and are at Arm's Length. All Related Party Transactions are subjected to independent review by the statutory auditor to establish compliance with the requirements of Related Party Transactions under the Companies Act, 2013 and Listing Regulations.

All Related Party Transactions entered during the year were in Ordinary Course of the Business and on Arm's Length basis.

During the year under review, the Company obtained the prior approval of the shareholders for the purchase of land admeasuring 2 acres and 6 guntas along with a constructed warehouse admeasuring 22,023 square feet situated at Jangaon, Telangana, from related parties, in compliance with the applicable provisions of the Companies Act, 2013 and SEBI LODR Regulations.

Accordingly, the disclosure of Related Party Transactions as required under Section 134(3) (h) of the Companies Act, 2013 in Form AOC-2 annexed as Annexure IV.

(G) DISCLOSURE OF COMMODITY PRICE RISKS AND COMMODITY HEDGING ACTIVITIES:

The company does not have any significant exposure to commodity price risk and hedging activities

(H) DETAILS OF UTILIZATION OF FUNDS RAISED THOROUGH PREFERENTIAL ALLOTMENT OR QUALIFIED INSTITUTIONS PLACEMENT.

The Company has not raised any amounts through preferential allotment or through Qualified Institutional placements.

(I) CERTIFICATE FROM PRACTICING COMPANY SECRETARY

The Company has obtained certificate from M/s. Manoj Parakh, Practicing Company Secretaries that none of the Directors on the Board of the Company are debarred or disqualified from being appointed or continuing as Directors of Companies by the Board/Ministry of Corporate Affairs or any such authority.

(J) RECOMMENDATIONS OF COMMITTEES

The Board has accepted and acted upon all the recommendations by the Audit & Nomination and Remuneration Committees.

(K) TOTAL FEES FOR ALL SERVICES PAID BY THE COMPANY, ON A CONSOLIDATED BASIS, TO THE STATUTORY AUDITOR.

The fees paid by the Company to its statutory Auditors (on a consolidated basis) is Rs. 9.50 Lakhs per annum.

(L) DISCLOSURE IN RELATION TO THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013.

The following is the summary of sexual harassment complaints received and disposed during the calendar year.

- No. of complaints received during the financial year: Nil
- No. of complaints disposed off during the financial year: Nil
- No. of complaints pending at the end of the financial year: Nil

(M) DISCLOSURE BY LISTED ENTITY AND ITS SUBSIDIARIES OF 'LOANS AND ADVANCES IN THE NATURE OF LOANS TO FIRMS/COMPANIES IN WHICH DIRECTORS ARE INTERESTED BY NAME AND AMOUNT

During the year, the listed company has not advanced any loan to firm/ companies in which directors are interested except the following:

Sl.no	Name of the LLP	Amount (Rs. In Lakhs)	Transaction Type
1.	Pasura Xpress LLP	80.72	Granting of loan

ARUNJYOTI BIO VENTURES LIMITED

(N) DETAILS OF MATERIAL SUBSIDIARIES OF THE LISTED ENTITY; INCLUDING THE DATE AND PLACE OF INCORPORATION AND THE NAME AND DATE OF APPOINTMENT OF THE STATUTORY AUDITORS OF SUCH SUBSIDIARIES

The Company does not have any material subsidiaries.

10. NON-COMPLIANCE OF ANY REQUIREMENT OF CORPORATE GOVERNANCE REPORT.

During the year, the company has complied with the requirement of Corporate Governance Report of sub-para (2) to (10) of Schedule-V of the Securities Exchange Board of India (LODR) Regulations, 2015.

11. ADOPTION OF DISCRETIONARY REQUIREMENTS AS SPECIFIED IN PART E OF SCHEDULE II of SEBI (LODR) REGULATIONS, 2015.

The company has adopted discretionary requirements to the extent of Internal Auditors reporting to the Audit Committee.

12. DISCLOSURE OF COMPLIANCE WITH CORPORATE GOVERNANCE REQUIREMENTS SPECIFIED IN REGULATIONS 17 TO 27 AND CLAUSES (b) TO (i) OF SUB-REGULATION (2) OF REGULATION 46 ARE AS FOLLOWS:

Regulation	Particulars	Compliance Status
17	Board of Directors	Yes
18	Audit Committee	Yes
19	Nomination and Remuneration Committee	Yes
20	Stakeholders Relationship Committee	Yes
21	Risk Management Committee	NA
22	Whistle Blower Mechanism/ Vigil Mechanism	Yes
23	Related Party Transactions	Yes
24	Corporate Governance requirements with respect to subsidiary of Listed company	NA
25	Obligations with respect to Independent Directors	Yes
26	Obligations with respect to Directors and Senior Management	Yes
27	Other Corporate Governance Requirements	Yes
46(2)(b)to(i)	Website	Yes

13. a) CODE OF CONDUCT

The Company has formulated and implemented a Code of Conduct for Board Members and Senior Management of the Company. Requisite annual affirmations of compliance with the respective Codes have been made by the Directors and Senior Management of the Company.

b) DECLARATION ON CODE OF CONDUCT FOR THE YEAR 2025-26.

This is to confirm that the Board has laid down a code of conduct for all Board members and senior management personnel of the Company. The code of Conduct has also been posted on the website of the Company. It is further confirmed that all Directors and senior management personnel of the Company have affirmed compliance with the Code of Conduct of the Company for the Financial Year ended on March 31, 2026 as envisaged in Regulation 26(3) of the SEBI (Listing obligations and disclosure requirements) Regulations, 2015.

14. CEO/ CFO Certification

The Managing Director and CEO/ CFO certification of the financial statements as specified in Regulation 17(8) read with Part B of Schedule II of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for the Financial Year 2025-26 is provided elsewhere in this Annual Report.

15. DISCLOSURE OF CERTAIN TYPES OF AGREEMENTS BINDING LISTED ENTITIES: NIL**16. DISCLOSURE OF ACCOUNTING TREATMENT:**

The Company has complied with the appropriate accounting policies and has ensured that they have been applied consistently. There have been no deviations from the treatment prescribed in the Accounting Standards notified under Section 133 of the Companies Act, 2013.

**For and on behalf of the Board
Arunjyoti Bio Ventures Limited**

**Sd/-
Nadimpalli Vishal
Whole-time Director
& CFO
(DIN: 02745303)**

**Sd/-
Pabbathi Badari
Narayana Murthy
Whole-time Director
(DIN: 01445523)**

**Place: Hyderabad
Date: 09.07.2026**

ARUNJYOTI BIO VENTURES LIMITED

CERTIFICATE ON CORPORATE GOVERNANCE

TO THE MEMBERS OF
ARUNJYOTI BIO VENTURES LIMITED

We have examined the compliance of the conditions of Corporate Governance by Arunjyoti Bio Ventures Limited ('the Company') for the year ended on March 31, 2026, as stipulated under Regulations 17 to 27, clauses (b) to (i) of sub-regulation (2) of Regulation 46 and para-C, D & E of Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations').

The compliance of the conditions of Corporate Governance is the responsibility of the Management. Our examination was limited to the review of procedures and implementation thereof, as adopted by the Company for ensuring compliance with conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us, and the representations made by the Directors and the management and considering the relaxations granted by the Ministry of Corporate Affairs and Securities and Exchange Board of India, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the SEBI Listing Regulations for the year ended on March 31, 2026.

We further state that such compliance is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the Management has conducted the affairs of the Company.

For Manoj Parakh & Associates

Sd/-

**Manoj Parakh
Proprietor**

M. No: F8572, CP No: 8957

UDIN: F008572H000782862

Peer Review Cer. No.: 3439/2023

Place: Vishakhapatnam

Date: 08.07.2026

ARUNJYOTI BIO VENTURES LIMITED

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

(Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To,
The Members of
Arunjyoti Bio Ventures Limited
Hyderabad

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of Arunjyoti Bio Ventures Limited having CIN L01400TG1986PLC062463 and having registered office at Door No.1-98/1/JSIC/6F/604-B, 6th Floor, Jain Sadhguru Capital Park, Beside Image Gardens, Madhapur, Hyderabad, Shaikpet, Telangana, India, 500081 (hereinafter referred to as 'the Company'), produced before us by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to us by the Company & its officers, We hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on 31st March, 2026 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs, or any such other Statutory Authority.

Sr. No	Name of Director	DIN	Date of Appointment in Company
1.	Mr. Pabbathi Badari Narayana Murthy	01445523	10/11/2022
2.	Mr. Srikar Ranga	02965183	10/11/2022
3.	Mrs. Vijaya Rama Lakshamana Murthy Mylavaram	07788466	10/11/2022
4.	Mr. Nadimpalli Vishal	02745303	10/11/2022
5.	Mrs. Dhanalakshmi Guntaka	09363100	10/11/2022
6.	Mr. Dathvik Pabbathi	09629913	10/11/2022

ARUNJYOTI BIO VENTURES LIMITED

Ensuring the eligibility of for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For Manoj Parakh & Associates

Sd/-

**Manoj Parakh
Proprietor**

M. No: F8572, CP No: 8957

UDIN: F008572H000782763

Peer Review Cer. No.: 3439/2023

Place: Vishakhapatnam

Date: 08.07.2026

ARUNJYOTI BIO VENTURES LIMITED

WHOLE-TIME DIRECTOR AND CFO CERTIFICATION IN RESPECT OF FINANCIAL STATEMENTS AND CASH FLOW STATEMENT

Pursuant to Regulation 17 (8) of SEBI (Listing Obligations & Disclosure Requirements), Regulations, 2015 For the Financial Year ended 31st March, 2026

We have reviewed the Financial Statements and the Cash Flow Statement for the year ended 31st March 2026 and we hereby certify and confirm to the best of our knowledge and belief the following:

- a. The Financial Statements and Cash Flow statement do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading.
- b. The Financial Statements and the Cash Flow Statement together present a true and fair view of the affairs of the Company and are in compliance with existing accounting standards, applicable laws and regulations.
- c. There are no transactions entered in to by the Company during the year ended 31st March 2026 which are fraudulent, illegal or violative of Company's Code of Conduct.
- d. We accept responsibility for establishing and maintaining internal controls for Financial Reporting and we have evaluated the effectiveness of these internal control systems of the Company pertaining to financial reporting. Deficiencies noted, if any, are discussed with the Auditors and Audit Committee, as appropriate, and suitable actions are taken to rectify the same.
- e. There have been no significant changes in the above-mentioned internal controls over financial reporting during the relevant period.
- f. That there have been no significant changes in the accounting policies during the relevant period.
- g. We have not noticed any significant fraud particularly those involving the, management or an employee having a significant role in the Company's internal control system over Financial Reporting.

**For and on behalf of the Board
Arunjyoti Bio Ventures Limited**

**Sd/-
Nadimpalli Vishal
Whole-time Director
& CFO
(DIN: 02745303)**

**Sd/-
Pabbathi Badari
Narayana Murthy
Whole-time Director
(DIN: 01445523)**

**Place: Hyderabad
Date: 13.05.2026**

ARUNJYOTI BIO VENTURES LIMITED

Declaration on Code of Conduct as required by Schedule V of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

I, Pabbathi Badari Narayana Murthy, Whole-time Director of the Company hereby declare that all the members of Board of Directors and Senior Management Personnel have affirmed compliance with Code of Conduct, as applicable to them, in respect of the financial year 2025-26.

**For and on behalf of the Board
Arunjyoti Bio Ventures Limited**

Sd/-

**Pabbathi Badari Narayana Murthy
Whole-time Director
(DIN: 01445523)**

Place: Hyderabad

Date: 09.07.2026

INDEPENDENT AUDITORS' REPORT

To the Members of Arunjyoti Bio Ventures Limited

Report on the Audit of the Financial Statements**Opinion**

We have audited the financial statements of Arunjyoti Bio Ventures Limited ("the Company"), which comprise the balance sheet as at 31 March 2026, and the statement of Profit and Loss (including other comprehensive income), statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of material accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ('the Act') in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended (Ind AS), and other accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2026, loss and other comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the financial statements.

Emphasis of Matter

- a. We draw attention to Note 40 to the financial statements, which describes the adjustments made by the Company relating to the correction of deferred tax computation on temporary differences arising from depreciation and the recognition of previously unavailed tax benefit on unabsorbed depreciation. As stated in the said note, the comparative figures have been restated in accordance with Ind AS 8 Accounting Policies, Changes in Accounting Estimates and Errors.

- b. We draw attention to Note 28(b) to the financial statements regarding the write-off of certain balances amounting to Rs. 273.65 lakhs recognised during the year based on board approval.

Our opinion is not modified in respect of these matters.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. This matter was addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on this matter.

We have determined the matter described below to be the key audit matter to be communicated in our report.

Sr. No.	Key audit matters	How our audit addressed the key audit matter
1.	Revenue recognition: Revenue from operations is a key performance indicator of the Company and represents a significant component of the Statement of Profit and Loss. The Company generates its revenue from providing bottling services under a contractual arrangement with its principal customer. The revenue arrangement contains pricing mechanisms comprising minimum guaranteed charges and volume-based conversion charges determined using slab-wise pricing structures linked to production volumes. Accordingly, the amount of revenue recognized depends upon the accurate determination of quantities processed and application of the relevant contractual pricing terms. The accounting policies provide additional information on how company accounts for its revenue in compliance with Ind AS 115.	Our audit procedures included the following: • Obtained an understanding of and evaluated the design and implementation of key controls over revenue recognition, including controls relating to capture of production volumes, application of contractual pricing terms and billing. • Reviewed the contractual arrangement with the customer to understand the pricing mechanism, including minimum guaranteed charges, conversion rates and volume-based pricing slabs. • Tested, on a sample basis, quantities processed during the year by agreeing them to underlying production records and other supporting documentation. • Tested the application of contractual pricing terms, including slab rates and minimum guaranteed charges, and agreed revenue invoices to supporting records. • Performed substantive analytical procedures by comparing revenue with production volumes and prior-period trends and investigated significant variances identified. • Performed cut-off testing around the year end to assess whether revenue had been recognized in the appropriate accounting period. • Evaluated the adequacy of the disclosures relating to revenue recognition in the financial statements.

Information Other than the Financial Statements and Auditors' Report Thereon

The Company's Management and Board of Directors are responsible for the preparation of the other information. The other information comprises the information included in the Directors' report but does not include the financial statements and our auditors' report thereon. The Directors' report is expected to be made available to us after the date of this auditor's report.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. When we read the Directors' report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance.

Responsibilities of the Management and Those Charged with Governance for Financial Statements

The Company's management and Board of Directors are responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the state of affairs, loss, and other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and

using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than from one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to the financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material

uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern; and

- Evaluate the overall presentation, structure, and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Matter

The financial statements of the company as at and for the year ended March 31, 2025, have been audited by V Ravi & Co, Chartered Accountants, whose report dated May 29, 2025 expressed an unmodified opinion on those financial statements. As explained in Note 40 to the financial statements, the comparative financial information for the year ended March 31, 2025 has been restated pursuant to the requirements of Ind AS 8, Accounting Policies, Changes in Accounting Estimates and Errors. We have audited the adjustments made to restate the comparative financial information and, in our opinion, such adjustments are appropriate and have been properly applied. However, we were not engaged to audit, review or apply any procedures to the financial statements of the Company for the year ended March 31, 2025 other than with respect to such adjustments. Accordingly, we, PKF Sridhar & Santhanam LLP, Chartered Accountants do not express any opinion on the figures and disclosures reported in the financial statements as at and for the

year ended March 31, 2025.

Our opinion on the financial statements and our report on Other Legal and Regulatory Requirements below is not modified in respect of this matter.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditors' Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143(3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit.
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books except for the matter stated in the paragraph 2h(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014.
 - (c) The Balance Sheet, the Statement of Profit and Loss including other comprehensive income, Statement of Changes in Equity and the statement of cash flows dealt with by this Report are in agreement with the books of account.
 - (d) In our opinion, the aforesaid financial statements comply with the (Ind AS) specified under Section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS").
 - (e) On the basis of the written representations received from the directors as on 31 March 2026 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2026 from being appointed as a director in terms of Section 164 (2) of the Act.
 - (f) The matters relating to the maintenance of accounts and other matters connected therewith are as stated in the paragraph 2(b) above on reporting under Section 143(3)(b) of the Act and paragraph 2(h)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014.
 - (g) With respect to the adequacy of the internal financial controls with reference to the financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".

- (h) With respect to the other matters to be included in the Auditors' Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations on its financial position on financial statements.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company during the year ended 31 March 2026.
 - iv. (a) The management has represented that, to the best of its knowledge and belief, other than as disclosed in Note no. 43(e) in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries
(b) The management has represented, that, to the best of its knowledge and belief, as disclosed in Note no. 43(f) in the notes to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries and
(c) Based on such audit procedures that were considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (a) and (b) contain any material misstatement.
 - v. The Company has not paid/declared any dividend during the financial year. Accordingly, reporting on compliance with the provisions of Section 123 of the Act is not applicable.

ARUNJYOTI BIO VENTURES LIMITED

- vi. As stated in Note 44 to the financial statement and relying on representations/explanations from the company, and based on our examination which included test checks, the Company has, for FY 2025-26, used accounting software for maintaining its books of accounts, which has a feature of recording audit trail (edit log) facility being enabled except for the ones explained below. Further, during the course of our audit we did not come across any instance of audit trail feature being tampered with:
- a. In case of application used for maintaining books of accounts which has a feature of recording audit trail (edit log) not being enabled at database level.

Additionally, other than the periods where audit trail was not enabled in the current year and prior years, The audit trail has been preserved by the company as per the statutory requirements for record retention.

3. With respect to the matter to be included in the Auditors' Report under section 197(16):

The Company has paid managerial remuneration in excess of the remuneration approved by the shareholders by Rs. 25.19 lakhs during the year. The excess remuneration arose on account of the remuneration approval being expressed on a net-of-tax basis. The Company proposes to seek shareholders' ratification/approval of the aforesaid excess remuneration at the ensuing Annual General Meeting. The Ministry of Corporate Affairs has not prescribed any other details under Section 197(16) of the Act which are required to be reported upon by us.

For PKF Sridhar & Santhanam LLP
Chartered Accountants
Firm's Registration No.003990S/S200018

Sd/-
Viswanadh VNSS Kuchi
Partner
Membership No. 210789
UDIN: 26210789WZOIJC9313

Place of Signature: Hyderabad
Date: 13th May 2026

Annexure A

Referred to in paragraph 1 on 'Report on Other Legal and Regulatory Requirements' of our report of even date to the members of Arunjyoti Bio Ventures Limited ("the Company") on the financial statements as of and for the year ended 31 March 2026.

In terms of the information and explanations sought by us and given by the company and the books of account and records examined by us in the normal course of audit and to the best of our knowledge and belief, we state that

- (i) (a) In respect of the company's fixed assets:
 - The Company has maintained proper records showing full particulars, including quantitative details, situation of its Property, Plant and Equipment, as required under the applicable provisions.
 - The Company has maintained proper records showing full particulars of intangible assets.
- (b) The Company has a regular programme of physical verification of its Property, Plant and Equipment and Investment Property by which all Property, Plant and Equipment and Investment Property are verified every year, in our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the programme, Property, Plant and Equipment and Investment Property were physically verified by the management during the financial year. In our opinion, and according to the information and explanations given to us, no material discrepancies were noticed on such verification.
- (c) Based on the examination of the conveyance deeds provided to us, we report that, the title deeds, comprising all the immovable properties disclosed in the financial statements are held in the name of the Company and are Hypothecated to Axis bank as at Balance Sheet date,
- (d) The Company has not revalued its Property, Plant and Equipment during the year and hence this clause is not applicable to the Company.
- (e) No proceedings have been initiated or are pending against the Company for holding any benami property under the Benami Transactions (Prohibitions) Act, 1988 and rules made thereunder.
- (ii)
 - (a) The inventory has been physically verified by the management at reasonable intervals during the year. In our opinion, the frequency of

ARUNJYOTI BIO VENTURES LIMITED

such verification is reasonable and the coverage and procedure of such verification by the management is appropriate. The discrepancies noticed on verification between the physical stocks and the book records are not 10% or more in the aggregate for each class of inventory.

- (b) The Company has not been sanctioned working capital limits exceeding Rs. 500 Lakhs, in aggregate, from banks or financial institutions on the basis of security of current assets. Accordingly, the requirements relating to submission of quarterly returns or statements to such banks or financial institutions and their reconciliation with the books of account are not applicable.

(iii)

- (a) The Company has not provided any loan or guarantee or security to Companies, Firms, Limited Liability Partnerships or any other parties except for the below:

Particulars	Loans (Rs. in lakhs)
Aggregate amount granted / provided during the year	
- Subsidiaries	-
- Joint Ventures	-
- Associates	-
- Others	80.72
Balance outstanding as at balance sheet date	
- Subsidiaries	-
- Joint Ventures	-
- Associates	-
- Others	65.99

There are no investments, guarantees or securities given by the Company. In respect of loan reported in (a) above, the terms and conditions are not prejudicial to the Company's interest.

- (c) In respect of loan reported in (a) above, the loan is repayable on demand. Accordingly, no schedule of repayment of principal and interest has been stipulated.
- (d) In respect of loan reported in (a) above, as there is no demand been made by the Company, we conclude that there are no amounts overdue for more than ninety days as at the balance sheet date.

ARUNJYOTI BIO VENTURES LIMITED

- (e) In respect of loan reported in (a) above, did not fell due during the year and accordingly, the question of renewal, extension or grant of fresh loan does not arise.
- (f) In respect of loan reported in (a) above, which is repayable on demand. The details are as follows:

Particulars	Related parties
Aggregate amount of loans/ advances nature of loans	
- Repayable on demand (A)	80.72
- Agreement does not specify any terms or period of repayment (B)	-
Total (A+B)	80.72
Percentage of loans/ advances in nature of loans to the total loans	100%

- (iv) According to the information and explanations given to us and based on our examination of the records of the Company, The Company has granted loan of Rs. 80.72 Lakhs (Amount outstanding as on 31st March 2026 is Rs. 65.99 Lakhs) to LLP in which directors are interested, which is subject to approval by the company under Section 185 (2) and the company is proposing to place it before the ensuing AGM for members approval.
- (v) The Company has not accepted any deposits or amounts which are deemed to be deposits within the meaning of the Act and the directives issued by the Reserve Bank of India and the provisions of sections 73 to 76 or any other relevant provisions of the Act and the rules framed thereunder. Accordingly, paragraph 3(v) of the Order is not applicable to the Company.
- (vi) The Central Government has not prescribed the maintenance of cost records under sub-section (1) of section 148 of the Act for the services of the Company. Accordingly, the requirements under clause 3(vi) of the Companies (Auditor's Report) Order, 2020 are not applicable.
- (vii)
- (a)
- i) The Company is generally regular in depositing with the appropriate authorities undisputed statutory dues including Goods and Services

ARUNJYOTI BIO VENTURES LIMITED

Tax, Income-tax, Sales tax, Service tax, Duty of Customs, Duty of Excise, Value Added Tax, Cess and other statutory dues applicable to it. However, there were slight delay in 6 instances for tax deduction at source, 4 instances for professional tax, 1 instance for provident fund, 6 instances for goods and services tax.

- ii) No undisputed amounts payable in respect of Goods and Service Tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues were in arrears, as at 31 March 2026 for a period of more than six months from the date they became payable, except as below which are pending to be remitted on account of KYC issues and operational challenges.

Name of Statute	Nature of due	Amount in Rs	Period to which it relates	Due date	Date of payment	Remarks
The Employee State Insurance Act, 1948	Employee State Insurance	1,282	Apr-24	15-05-2024		
The Employee State Insurance Act, 1948	Employee State Insurance	3,662	May-24	15-06-2024		
The Provident fund Act, 1952	Provident Fund	47,405	Jun-24	15-07-2024	-	
The Employee State Insurance Act, 1948	Employee State Insurance	5,080				
The Provident fund Act, 1952	Provident Fund	51,479	Jul-24	15-08-2024	-	
The Employee State Insurance Act, 1948	Employee State Insurance	5,514				
The Provident fund Act, 1952	Provident Fund	23,339	Aug-24	15-09-2024	-	
The Employee State Insurance Act, 1948	Employee State Insurance	559				
The Provident fund Act, 1952	Provident Fund	66,941	Sep-24	15-10-2024	-	
The Employee State Insurance Act, 1948	Employee State Insurance	9,220				
The Provident fund Act, 1952	Provident Fund	79,005	Oct-24	15-11-2024		
The Employee State Insurance Act, 1948	Employee State Insurance	12,144				
The Provident fund Act, 1952	Provident Fund	82,442	Nov-24	15-12-2024	-	
The Employee State Insurance Act, 1948	Employee State Insurance	12,714				
The Provident fund Act, 1952	Provident Fund	49,057	Dec-24	15-01-2025	-	
The Employee State Insurance Act, 1948	Employee State Insurance	9,562				
The Provident fund Act, 1952	Provident Fund	1,06,313	Jan-25	15-02-2025	-	
The Employee State Insurance Act, 1948	Employee State Insurance	18,479				
The Provident fund Act, 1952	Provident Fund	1,09,225	Feb-25	15-03-2025	-	
The Employee State Insurance Act, 1948	Employee State Insurance	18,961				

ARUNJYOTI BIO VENTURES LIMITED

The Provident fund Act, 1952	Provident Fund	1,14,005	Mar-25	15-04-2025	-	
The Employee State Insurance Act, 1948	Employee State Insurance	20,229				
The Provident fund Act, 1952	Provident Fund	1,23,028	Apr-25	15-05-2025	-	
The Employee State Insurance Act, 1948	Employee State Insurance	22,742				
The Provident fund Act, 1952	Provident Fund	1,39,686	May-25	15-06-2025	-	
The Employee State Insurance Act, 1948	Employee State Insurance	25,151				
The Provident fund Act, 1952	Provident Fund	1,49,491	Jun-25	15-07-2025	-	
The Employee State Insurance Act, 1948	Employee State Insurance	27,425				
The Provident fund Act, 1952	Provident Fund	1,52,770	Jul-25	15-08-2025	-	
The Employee State Insurance Act, 1948	Employee State Insurance	27,722				
The Provident fund Act, 1952	Provident Fund	1,56,590	Aug-25	15-09-2025	-	
The Employee State Insurance Act, 1948	Employee State Insurance	28,737				

- (b) There are no statutory dues referred to in sub-clause (a) as at 31 March 2026, which have not been deposited with the appropriate authorities on account of any dispute.
- (viii) No amount has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961. Accordingly, paragraph 3(viii) of the order is not applicable to the Company.
- (ix)
- (a) Based on our audit procedures and as per the information and explanations given by the management, the Company has defaulted in repayment of loans or other borrowings or in payment of interest thereon to a lender as below:

ARUNJYOTI BIO VENTURES LIMITED

Nature of borrowing including debt securities	Name of lender	Amount not paid on due date	Whether principal or interest	No. of days delay or unpaid	Remarks, if any
Term Loan	Axis Bank Ltd	15,35,431	Interest	1	Apr-25
Term Loan	Axis Bank Ltd	34,64,000	Principal	1	
Term Loan	Axis Bank Ltd	12,69,679	Interest	1	May-25
Term Loan	Axis Bank Ltd	27,70,000	Principal	1	
Term Loan	Axis Bank Ltd	11,05,176	Interest	1	Aug-25
Term Loan	Axis Bank Ltd	27,70,000	Principal	1	
Term Loan	Axis Bank Ltd	12,86,624	Interest	1	Sep-25
Term Loan	Axis Bank Ltd	34,64,000	Principal	1	
Term Loan	Axis Bank Ltd	10,65,638	Interest	1	Oct-25
Term Loan	Axis Bank Ltd	27,70,000	Principal	1	
Term Loan	Axis Bank Ltd	12,35,004	Interest	1	Nov-25
Term Loan	Axis Bank Ltd	34,64,000	Principal	1	
Term Loan	Axis Bank Ltd	12,43,610	Interest	1	Dec-25
Term Loan	Axis Bank Ltd	34,64,000	Principal	1	
Term Loan	Axis Bank Ltd	3,49,403	Interest	1	Jan-26
Term Loan	Axis Bank Ltd	27,70,000	Principal	1	
Term Loan	Axis Bank Ltd	10,01,193	Interest	1	Feb-26
Term Loan	Axis Bank Ltd	34,64,000	Principal	1	
Term Loan	Axis Bank Ltd	10,88,550	Interest	1	Mar-26
Term Loan	Axis Bank Ltd	34,64,000	Principal	1	

- (b) The Company is not a declared willful defaulter by any bank or financial institution or government or government authority.
- (c) Term loans were applied for the purpose for which the loans were obtained.
- (d) Based on the information and explanation given to us and based on an overall examination of the financial statements of the Company, funds raised on short term basis have, prima facie, not been used during the year for long-term purposes by the Company
- (e) The Company does not have any subsidiaries, joint ventures, or associate companies. Accordingly, the question of taking any funds from any entity or person on account of or to meet the obligations of such subsidiaries, joint ventures, or associate companies does not arise and hence paragraph 3(ix)(e) of the Order is not applicable to the Company.
- (f) The Company does not have any subsidiaries, joint ventures, or associate companies. Accordingly, the Company has not raised any loans during the year on the pledge of securities held in any such entities, and therefore paragraph 3(ix)(f) of the Order is not applicable to the Company.

(x)

- (a) The Company did not raise money by way of initial public offer or further public offer (including debt instruments) during the year and hence the question of whether money raised were applied for the purposes for which those are raised does not arise. Accordingly, paragraph 3(x) (a) of the Order is not applicable to the Company.
- (b) The Company has not made any preferential allotment or private placement of shares or convertible debentures (fully, partially or optionally convertible) during the year and hence the question of whether the requirements of section 42 and section 62 of the Companies Act, 2013 have been complied with and the funds raised have been used for the purposes for which the funds were raised does not arise. Accordingly, paragraph 3(x)(b) of the Order is not applicable to the Company.

(xi)

- (a) We report that no material fraud by the Company or on the Company has been noticed or reported during the year.
 - (b) No report under sub-section (12) of section 143 of the Companies Act has been filed by secretarial auditor or by us in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government for the period covered by our audit.
 - (c) As represented to us by the management there are no whistle blower complaints that were received during the year by the Company.
- (xii) The Company is not a Nidhi company in accordance with Nidhi Rules 2014. Accordingly, paragraph 3(xii)(a) to (c) of the Order is not applicable.

- (xiii) The transactions entered into with the related parties during the year are in compliance with Section 177 and Section 188 of the Act where applicable and the details of the related parties have been disclosed in the financial statements as required by the applicable accounting standards.

(xiv)

- (a) The Company has an internal audit system commensurate with the size and nature of its business.

ARUNJYOTI BIO VENTURES LIMITED

- (b) We have considered the reports of the Internal Auditors issued till date for the period under audit.
- (xv) During the year the Company has not entered into any non-cash transactions with its directors or persons connected with its directors and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.
- (xvi)
 - (a) The Company is not required to be registered under Section 45-IA of Reserve Bank of India Act, 1934 (2 of 1934).
 - (b) The Company has not conducted any Non-Banking Financial or Housing Finance activities without a valid Certificate of Registration (CoR) from the Reserve Bank of India as per the Reserve Bank of India Act, 1934. Accordingly, paragraph 3(xvi)(b) of the Order is not applicable to the Company.
 - (c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India and hence the questions of fulfilling criteria of a CIC, and in case the Company is an exempted or unregistered CIC, whether it continues to fulfill such criteria, do not arise. Accordingly, paragraph 3(xvi)(c) of the Order is not applicable to the Company.
 - (d) None of the group companies are Core Investment Company (CIC) and hence the question of number of CICs which are part of the Group does not arise. Accordingly, paragraph 3(xvi)(d) of the Order is not applicable to the Company.
- (xvii) The Company has incurred cash losses amounting to Rs. 124.36 lakhs during the financial year. The Company had not incurred cash losses in the immediately preceding financial year.
- (xviii) There has been resignation of the statutory auditors during the year due to preoccupation. We have taken into consideration the information and explanations provided to us in this regard and noted that no issues, objections or concerns were raised by the outgoing auditors.
- (xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material

uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.

Also refer to the Other Information paragraph of our main audit report which explains that the other information comprising the information included in the Directors' report is expected to be made available to us after the date of this auditors' report.

(xx)

- (a) According to the information and explanations given to us and based on the records of the Company examined by us, the provisions of Section 135 of the Companies Act, 2013 relating to Corporate Social Responsibility are not applicable to the Company. Accordingly, reporting under Clause 3(xx) of the Order is not applicable to the Company.

For PKF Sridhar & Santhanam LLP
Chartered Accountants
Firm's Registration No.003990S/S200018

Sd/-
Viswanadh VNSS Kuchi
Partner
Membership No. 210789
UDIN: 26210789WZOIJC9313

Place of Signature: Hyderabad
Date: 13th May 2026

Annexure B

Referred to in paragraph 2(g) on 'Report on Other Legal and Regulatory Requirements' of our report of even date

Report on the Internal Financial Controls with reference to the aforesaid financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013

We have audited the internal financial controls with reference to financial statements of Arunjyoti Bio Ventures Limited as of 31 March 2026 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal control with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the "Guidance Note"). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013 (hereinafter referred to as "the Act").

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial

statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

Meaning of Internal Financial Controls with reference to financial statements

A Company's internal financial control with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial control with reference to financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with reference to financial statements

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial control with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to financial statements and such internal financial controls were operating effectively as at 31 March 2026, based on the internal control with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note.

For PKF Sridhar & Santhanam LLP
Chartered Accountants
Firm's Registration No.003990S/S200018

Sd/-
Viswanadh VNSS Kuchi
Partner
Membership No. 210789
UDIN: 26210789WZOIJC9313

Place of Signature: Hyderabad
Date: 13th May 2026

ARUNJYOTI BIO VENTURES LIMITED

Balance Sheet as at March 31, 2026

(All amounts in lakhs of Indian Rupees except share data and where otherwise stated)

Particulars	Note No.	As at 31 March 2026	As at 31 March 2025 (As restated)
ASSETS			
Non Current Assets			
(a) Property, Plant and Equipment	3(a)	4,240.31	4,291.95
(b) Investment Property	3(b)	271.45	-
(b) Intangible assets	4	1.36	3.21
(c) Right of use assets	3(c)	46.18	54.58
(d) Financial Assets			
i) Other financial assets	5	187.83	149.57
(e) Deferred tax assets (Refer Note 40)	6	97.45	37.05
(f) Other non-current assets		-	-
Total Non - Current Assets		4,844.58	4,536.36
Current Assets			
(a) Inventories	7	10.53	245.57
(b) Financial Assets			
(i) Trade Receivables	8	383.73	396.51
(ii) Cash and Cash Equivalents	9	12.67	59.22
(iii) Loans	10	65.99	0.27
(iv) Other Financial Assets	11	0.90	0.37
(c) Current Tax Assets (Net)	12	62.22	51.41
(d) Other current assets	13	35.67	849.05
Total Current Assets		571.71	1602.4
TOTAL ASSETS		5,416.29	6,138.76
EQUITY AND LIABILITIES			
Equity			
(a) Equity Share capital	14	1,863.81	1,863.81
(b) Other Equity	15	1,008.00	1,461.61
Total Equity		2,871.81	3,325.42
LIABILITIES			
Non-current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	16(a)	1,150.05	1,579.66
(ii) Lease Liabilities	17(a)	45.01	52.03
(b) Provisions	18(a)	9.89	-
Total Non - Current Liabilities		1,204.95	1,631.69
Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	16(b)	1,025.07	982.25
(ii) Lease Liabilities	17(b)	7.03	7.03
(iii) Trade payables			
(a) Total outstanding dues of Micro and Small Enterprises	19	4.23	0.71
(b) Total outstanding dues other than Micro and Small Enterprises	19	175.37	140.62
(vi) Other financial liabilities	20	81.35	40.40
(b) Other Current Liabilities	21	46.44	10.64
(c) Provisions	18(b)	0.04	-
Total Current Liabilities		1,339.53	1,181.65
TOTAL EQUITY AND LIABILITIES		5,416.29	6,138.76
The accompanying notes are an integral part of the financial statements			
Summary of Material accounting policies			
	1 & 2		

As per our Report of even date attached
for PKF Sridhar & Santhanam LLP
Chartered Accountants
Firm Registration Number: 003990S/S200018

for and on behalf of the Board of Directors of
Arunjyoti Bio Ventures Limited
CIN: L01400TG1986PLC062463

Sd/-
Viswanadh VNSS Kuchi
Partner
Membership No.: 210789

Sd/-
Pabbathi Badari Narayana Murthy
Wholetime Director
DIN:01445523

Sd/-
Vishal Nadimpalli
Wholetime Director Cum CFO
DIN:02745303

Place: Hyderabad
Date: 13th May 2026

Sd/-
Swati Jain
Company Secretary
Membership No.:A58986

ARUNJYOTI BIO VENTURES LIMITED

Statement of Profit and Loss for the Year ended March 31, 2026

(All amounts in lakhs of Indian Rupees except share data and where otherwise stated)

Particulars	Note No.	For the Year ended 31 March 2026	For the Year ended 31 March 2025 (As Restated)
Income			
I Revenue from Operations	22	2,775.44	2,788.41
II Other income	23	11.80	28.13
III Total Income (I+II)		2,787.24	2,816.54
IV Expenses			
Purchase of Stock in Trade	24	-	376.91
Changes in inventories of finished goods, stock-in-trade and work-in progress	25	-	134.72
Employee benefits expense	26	1,123.49	893.12
Finance costs	27	204.73	258.87
Depreciation and amortisation expense	3	335.81	304.58
Other expenses	28(a)	1,363.58	882.43
V Total Expenses		3,027.61	2,850.63
VI Profit / (Loss) before exceptional items and tax (IV-V)		(240.37)	(34.09)
VII Exceptional item	28(b)	(273.65)	-
VIII Profit / (Loss) before tax (VI+VII)		(514.02)	(34.09)
IX Tax expense:			
(1) Current tax		-	-
(2) Prior period tax		-	-
(3) Deferred tax	30	(60.41)	(6.47)
X Profit / (Loss) for the year (VIII-IX)		(453.61)	(27.62)
XI Other Comprehensive Income			
a) (i) Items that will not be reclassified to profit or loss		-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss		-	-
b) (i) Items that will be reclassified to profit or loss		-	-
(ii) Income tax relating to items that will be reclassified to profit or loss		-	-
XII Total Comprehensive Income for the year (X+XI)		(453.61)	(27.62)
XIII Earning per equity share (face value per equity share Rs 1 each)	31		
(1) Basic (Rs.)		(0.24)	(0.01)
(2) Diluted (Rs.)		(0.24)	(0.01)

See accompanying notes referred to above form an integral part of Financial Statements
Summary of Material accounting policies 1 & 2

As per our Report of even date attached
for PKF Sridhar & Santhanam LLP
Chartered Accountants
Firm Registration Number: 003990S/S200018

for and on behalf of the Board of Directors of
Arunjyoti Bio Ventures Limited
CIN: L01400TG1986PLC062463

Sd/-
Viswanadh VNSS Kuchi
Partner
Membership No.: 210789

Sd/-
Pabbathi Badari Narayana Murthy
Wholetime Director
DIN:01445523

Sd/-
Vishal Nadimpalli
Wholetime Director Cum CFO
DIN:02745303

Place: Hyderabad
Date: 13th May 2026

Sd/-
Swati Jain
Company Secretary
Membership No.:A58986

ARUNJYOTI BIO VENTURES LIMITED

Cash flow statement for the Year ended March 31, 2026

(All amounts in lakhs of Indian Rupees except share data and where otherwise stated)

Particulars	For the Year ended 31 March 2026	For the Year ended 31 March 2025
A. Cash flows from operating activities		
Profit/(Loss) before taxation	(514.02)	(34.09)
Adjustments for:		
Depreciation and amortisation	335.81	304.58
Bad debts written off (Refer Note 28 (b))	170.93	-
Advances to vendors written off (Refer Note 28 (b))	102.72	-
Adjustment for abnormal inventory consumption arising from operational bottlenecks(Refer Note 28 (c))	241.18	-
(Profit) / Loss on sale of Property , Plant and Equipment	11.93	-
Interest expenses	204.73	258.87
Interest income	(11.80)	(28.13)
Income from Investment Property	(61.08)	-
Operating cash flows before working capital changes	480.40	501.23
Changes in Working Capital:		
(Increase)/decrease in trade receivables	(158.15)	(123.39)
(Increase)/decrease in inventories	(6.14)	47.44
(Decrease)/ increase in trade payables	38.27	(206.82)
(Increase)/decrease in loans	(65.72)	(0.27)
(Increase)/decrease in other financial assets	(0.53)	(0.37)
(Increase)/decrease in non-current financial assets	(38.26)	(26.35)
(Increase)/decrease in other non-current assets	-	-
(Increase)/decrease in other current assets	710.66	(6.74)
(Decrease)/increase in provisions	9.93	-
(Decrease)/increase in other financial liabilities	40.95	12.50
(Decrease)/increase in other current liabilities	35.80	(3.92)
Cash generated/(used) in operations	1,047.21	193.31
Income taxes paid/ TDS (net)	(10.81)	(31.46)
Net cash generated/(used) in operating activities (A)	1,036.40	161.85
B. Cash flows from investing activities		
Payment for Purchase of property plant equipment (Including Capital advance & Work in Progress)	(291.04)	(604.03)
Payment for Purchase of investment property	(276.32)	-
Proceeds from sale of Property , Plant and Equipment	10.08	-
Income from Investment Property	61.08	-
Interest income received	11.80	28.13
Net cash provided by/ (used in) investing activities (B)	(484.40)	(575.90)
C. Cash flows from financing activities		
Proceeds from Issue of share capital (net of expenses)	-	3,243.44
Proceeds from/(Repayment of) non-current borrowings	(429.61)	(2,664.46)
Proceeds from/(Repayment of) current borrowings	42.82	151.00
Interest paid	(199.76)	(253.30)
Payment of lease liabilities	(12.00)	(12.00)
Net cash provided by/(used in) financing activities (C)	(598.55)	464.68
Net increase/ (decrease) in cash and cash equivalents during the year (A+B+C)	(46.55)	50.63
Cash and cash equivalents at the beginning of the year	59.22	8.59
Add/(less): exchange (loss)/gain on cash and cash equivalents		
Cash and cash equivalents at the end of the year (Refer Note 9)	12.67	59.22

As per our Report of even date attached
for PKF Sridhar & Santhanam LLP
Chartered Accountants
Firm Registration Number: 003990S/S200018

for and on behalf of the Board of Directors of
Arunjyoti Bio Ventures Limited
CIN: L01400TG1986PLC062463

Sd/-
Viswanadh VNSS Kuchi
Partner
Membership No.: 210789

Sd/-
Pabbathi Badari Narayana Murthy
Wholetime Director
DIN:01445523

Sd/-
Vishal Nadimpalli
Wholetime Director Cum CFO
DIN:02745303

Place: Hyderabad
Date: 13th May 2026

Sd/-
Swati Jain
Company Secretary
Membership No.:A58986

ARUNJYOTI BIO VENTURES LIMITED

Statement of changes in equity for the year ended 31 March, 2026 (All amounts in lakhs of Indian Rupees except share data and where otherwise stated)

A. Equity Share Capital	Amount
Balance as at 1st April 2024	207.09
Changes in equity share capital due to prior period errors	-
Restated balance as at 1st April 2024	207.09
Changes in equity share capital during the year	1,656.72
Balance as at 1st April 2025	1,863.81
Changes in equity share capital due to prior period errors	-
Restated balance as at 1st April 2025	1,863.81
Changes in equity share capital during the year	-
Balance as at 31st March 2026	1,863.81

Particulars	Reserves and Surplus			Total equity
	Securities premium	Retained earnings	Capital Reserve	
Balance as at 1 April 2024	-	(53.77)	23.34	(30.43)
Changes in accounting policy or prior period errors (Refer Note 40)	-	(67.06)	-	(67.06)
Restated Balance as at April 1st, 2024	-	(120.83)	23.34	(97.49)
Additions during the year	1,656.72	-	-	1,656.72
Profit/(Loss) for the year	-	(27.62)	-	(27.62)
Other comprehensive income- Remeasurement of defined benefit obligations	-	-	-	-
Total comprehensive income for the year	-	(27.62)	-	(27.62)
Expenses related to rights issue	-	(70.00)	-	(70.00)
Balance as at 31st March 2025	1,656.72	(218.45)	23.34	1,461.61
Balance as at 1 April 2025	1,656.72	(218.45)	23.34	1,461.61
Changes in accounting policy or prior period errors	-	-	-	-
Restated Balance as at April 1st, 2025	1,656.72	(218.45)	23.34	1,461.61
Profit/(Loss) for the year	-	(453.61)	-	(453.61)
Additions during the year	-	-	-	-
Other comprehensive income- Remeasurement of defined benefit obligations	-	-	-	-
Total comprehensive income for the year	-	(453.61)	-	(453.61)
Balance as at 31st March 2026	1,656.72	(672.06)	23.34	1,008.00

Nature and purpose of reserves:

Securities premium is used to record the premium on issue of shares. The reserve is utilised in accordance with the provisions of Section 52 of the Companies Act, 2013

Capital Reserve - Reserve of capital nature taken to this head under the erstwhile GAAP

Retained Earnings -This reserve represents undistributed accumulated earnings of the company as on balance sheet date.

As per our Report of even date attached
for PKF Sridhar & Santhanam LLP
Chartered Accountants
Firm Registration Number: 003990S/S200018

for and on behalf of the Board of Directors of
Arunjyoti Bio Ventures Limited
CIN: L01400TG1986PLC062463

Sd/-
Viswanadh VNSS Kuchi
Partner
Membership No.: 210789

Sd/-
Pabbathi Badari Narayana Murthy
Wholetime Director
DIN:01445523

Sd/-
Vishal Nadimpalli
Wholetime Director Cum CFO
DIN:02745303

Place: Hyderabad
Date: 13th May 2026

Sd/-
Swati Jain
Company Secretary
Membership No.:A58986

Notes to the Financial Statements for the year ended 31st March 2026**1. General Information**

ArunJyoti Bio Ventures Limited is engaged in providing co-packing services and operates with the objective of strengthening its co-packing operations by delivering consistent quality, improving operational efficiency, and optimizing resources while supporting the brand standards and requirements of its partner.

The Company is a Public Limited Company incorporated and domiciled in India and has its registered office at Plot No. 6th Floor-604B, Jain Sadhguru Capital Park, Beside Image Gardens, Madhapur, Shaikpet, Hyderabad – 500081, Telangana.

The financial statements for the year ended March 31, 2026 were approved by the Board of Directors and authorised for issue on 13th May 2026.

2. Basis of Preparation

The financial statements of the Company have been prepared in accordance with Indian Accounting Standards ("Ind AS") issued under Section 133 of the Companies Act, 2013 and notified by the Ministry of Corporate Affairs under the Companies (Indian Accounting Standards) Rules, 2015 (as amended), under the historical cost convention on accrual basis except for certain items which are measured at fair values.

The accounting policies as set out below have been applied consistently except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use.

All assets and liabilities have been classified as current or non-current as per the company's normal operating cycle and other criteria set out in Division II of the Schedule III to the Companies Act 2013. Based on the nature of products and services and the time between the acquisition of assets for processing and their realization in cash and cash equivalent, the Company has ascertained its operating cycle as 12 months for the purpose of current and non-current classification of assets and liabilities.

The financial statements have been prepared on a going concern basis, which assumes that the Company will continue to operate in the foreseeable future and will be able to realise its assets and discharge its liabilities in the normal course of business.

In assessing the appropriateness of the going concern assumption, management has evaluated the Company's financial position, cash flows, liquidity position and forecasted results. This assessment has, inter alia, considered the Company's continuing long-term contractual business arrangement with its principal customer, its positive net worth, and planned capacity expansion initiatives aimed at enhancing operational efficiency and supporting future growth.

Based on this assessment, management believes that the Company has adequate resources to continue its operations for the foreseeable future, and accordingly, the going concern basis of accounting remains appropriate.

2.1 Statement of Compliance with Ind AS

The Financial Statements comprising Balance Sheet, Statement of Profit and Loss, Statement of Changes in Equity, Statement of Cash Flow together with notes for the year ended March 31, 2026, have been prepared in accordance with Ind AS issued under Section 133 of the Companies Act, 2013.

2.2

(i) Recent Accounting Pronouncements

During the year, the Ministry of Corporate Affairs (MCA) has notified certain amendments to existing Indian Accounting Standards (Ind AS), applicable for annual reporting periods beginning on or after April 1, 2025. The Company has evaluated the applicability of such amendments and noted that they do not have any material impact on the financial statements of the Company.

Accordingly, the following amendments are not applicable / do not have any significant impact on the financial statements of the Company:

Ind AS 21 – The Effects of Changes in Foreign Exchange Rates

In May 2025, the Ministry of Corporate Affairs (MCA) notified amendments to Ind AS 21 – The Effects of Changes in Foreign Exchange Rates, applicable for annual periods beginning on or after April 1, 2025. The amendment introduces a new framework for assessing whether a currency is exchangeable into another currency and provides guidance when exchangeability is lacking.

The Company has reviewed the amendment and, based on its evaluation, has determined that the same is not applicable to its financial statements.

Ind AS 1 – Presentation of Financial Statements

The amendment relates to classification of liabilities as current or non-current and non-current liabilities with covenants. In the context of classifying a liability as current, it removes the requirement of existence of a right to defer settlement for at least 12 months after the reporting date and instead requires that the said right should exist on the reporting date and have substance. The amendment also introduces guidance on classification of liabilities with covenants.

Based on the Company's assessment, the Company has no impact of these amendments in its classification criteria of current and non-current liabilities.

Ind AS 7 – Statement of Cash Flows and Ind AS 107 – Financial Instruments: Disclosures

The amendment in Ind AS 7 requires to inform users of financial statements of the existence of supplier finance arrangements and explain the nature of the arrangements, the carrying amount of liabilities and the range of payment due dates. Ind AS 107 has been amended to add supplier finance arrangements as a factor that may cause concentration of liquidity risk.

The Company has reviewed the amendment and, based on its evaluation, has determined that the same is not applicable to its financial statements.

Ind AS 12 – International Tax Reform – Pillar Two Model Rules

The Company has reviewed the amendment and, based on its evaluation, has determined that the same is not applicable to its financial statements.

(ii) New Standards/Amendments notified but not yet effective:

Ministry of Corporate Affairs ("MCA") notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. During the year ended March 31, 2026, MCA has not notified any other new standards or amendments to the existing standards applicable to the Company.

2.3 Functional and Presentation Currency

Items included in financial statements of the Company are measured using the currency of the primary economic environment in which the

Company operates ("the functional currency"). Indian rupee is the functional currency of the Company.

The Financial Statements are presented in Indian Rupees which is company's presentation currency. All financial information presented in Indian Rupees has been rounded to the nearest Lakhs with two decimals except where otherwise indicated.

3. Summary of material accounting policies

3.1 Property, Plant and Equipment:

a. Recognition and Measurement

Property, Plant and Equipment are stated at cost less accumulated depreciation and accumulated impairment loss based on cost model. Cost comprises the purchase price and any attributable cost of bringing the asset to its working condition for its intended use. Such cost includes the cost of replacing part of the plant and equipment and borrowing costs for long-term construction projects if the recognition criteria are met. Cost also includes non-refundable taxes and duties, freight and other direct or allocated expenses during construction period, net of any income earned.

Subsequent costs

Subsequent expenditure related to an item of Property, Plant and Equipments are added to its book value only if it increases the future benefits from the existing asset beyond its previously assessed standard of performance. When significant parts of plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives. All other repair and maintenance costs are recognised in Statement of Profit and Loss as incurred.

Derecognition

An item of Property, Plant and Equipment is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. The cost and related accumulated depreciation are eliminated from the financial statements upon sale or retirement of the asset and the resultant gains or losses are recognized in the Statement of Profit and Loss.

Advances paid towards the acquisition of Property, Plant and Equipment outstanding at each Balance Sheet date is classified as capital

ARUNJYOTI BIO VENTURES LIMITED

advances under other non-current assets and the cost of assets not ready to use before such date are disclosed under 'Capital work-in-progress'.

b. Depreciation:

Depreciation on property, plant and equipment is calculated on a straight-line basis using the rates arrived at based on the useful lives estimated by the management based on technical assessment. The management believes that depreciation rates currently used fairly reflect its estimate of the useful lives of property, plant and equipment.

Useful lives of property, plant and equipment are as follows:

Particulars	Useful life
Factory Building	30 years
Plant & Machinery	5 to 15 years
Furniture & Fittings	10 years
Motor Vehicles	8 years
Electrical Equipment	10 to 15 years
IT Equipment	3 years

3.2 Intangible Assets

Intangible assets that are acquired by the company, which have finite useful lives are measured at cost less accumulated amortization and accumulated impairment losses. Cost includes expenditure that is directly attributable to the acquisition of the intangible asset.

Amortization of intangible asset with finite useful lives

Amortization is recognized in the statement of profit and loss on a straight line basis over the estimated useful lives of intangible assets from the date that they are available to use based on the estimates made by the management w.r.t the useful life and residual value.

Estimated useful life:

- a) Software is amortised over 3 years

Amortization methods, useful lives and residual values are reviewed at each reporting date and adjusted prospectively, if appropriate.

3.3 Investment property

a. Recognition and Measurement

Investment property is property (land or building or part of a building) held to earn rental income and/or for capital appreciation and not for use in production, supply of goods or services, administrative purposes, or sale in the ordinary course of business.

Investment property is stated at cost less accumulated depreciation and accumulated impairment losses, in accordance with the cost model prescribed under Ind AS 40.

Cost comprises:

- purchase price
- directly attributable expenditure (such as legal fees, property transfer taxes, brokerage, and registration charges)
- any other costs directly attributable to bringing the asset to the condition necessary for its intended use

Borrowing costs directly attributable to acquisition or construction of investment property are capitalised in accordance with Ind AS 23. Any income earned during the construction period is adjusted against the cost of the asset.

Subsequent Costs

Subsequent expenditure related to investment property is added to its carrying amount only when it is probable that future economic benefits associated with the item will flow to the Company and the cost can be measured reliably.

All other repairs and maintenance costs are recognised in the Statement of Profit and Loss as incurred.

Derecognition

An item of investment property is derecognised upon disposal or when no future economic benefits are expected from its use or disposal.

The difference between the net disposal proceeds and the carrying amount is recognised as a gain or loss in the Statement of Profit and Loss in the period of derecognition.

b. Depreciation

Depreciation on investment property (buildings) is provided on a straight-line basis over the estimated useful lives prescribed under Schedule II of the Companies Act, 2013 or based on technical assessment by management, whichever is appropriate.

- Land is not depreciated
- Useful lives, residual values, and depreciation methods are reviewed at each reporting date and adjusted prospectively, if required.

3.4 Inventories

Inventories are valued at lower of cost and net realizable value and for this purpose cost is determined on weighted average basis. The aforesaid items are valued below cost if the finished products in which they are to be incorporated are expected to be sold at a loss.

Cost includes direct material cost, direct labour cost, non-refundable taxes and duties, freight, other direct expenses and an appropriate proportion of variable and fixed overhead expenditure.

Cost of the purchased inventory are determined after deducting rebates and discounts. Provision is made for obsolete, non-moving and defective stocks, wherever necessary.

3.5 Impairment of Non-Financial Asset

The Company assesses at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating units (CGU) fair value less costs of disposal and its value in use. Recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets of the Company. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

3.6 Employee benefits - Retirement benefit costs and termination benefits**3.6.1 Defined Contribution Plans**

Payment to defined contribution retirement benefit plans i.e. Provident

Fund, Employee state insurance are recognised as an expense in the Statement of Profit and Loss when an employees have rendered service entitling them to the contributions.

3.6.2 Defined Benefit Plans

The Company has a defined benefit gratuity plan. Every employee who has completed five years or more of service gets a gratuity on post employment at 15 days salary (last drawn salary) for each completed year of service as per the rules of the Company. The aforesaid liability is provided for on the basis of an actuarial valuation on projected unit credit method made at the end of the financial year. The scheme is unfunded.

Remeasurement, comprising actuarial gains and losses and the return on plan assets (excluding net interest), is reflected immediately in the balance sheet with a charge or credit recognised in other comprehensive income (OCI) in the period in which they occur. Remeasurement recognised in other comprehensive income is reflected immediately in retained earnings and is not reclassified to Statement of Profit and Loss.

Past service cost is recognised in Statement of profit and loss in the period of a plan amendment. Net interest is calculated by applying the discount rate at the beginning of the period to the net defined benefit liability or asset. Defined benefit cost are categorised as follows:

- Service cost (including current service cost, as well as gains and losses on curtailments and settlement)
- Net interest expense or income
- Remeasurement

The company presents the first two components of defined benefit cost in profit or loss in the line item 'employee benefit expense'. Curtailment gains or losses are accounted for as past service cost.

The retirement benefit obligation recognised in the Balance Sheet represents the actual deficit or surplus in the company's defined benefit plans. Any surplus resulting from this calculation is limited to the present value of any economic benefits available in the form of refunds from the plans or reductions in future contributions to the plans.

3.6.3 Short term benefits

The costs of all short-term employee benefits (that are expected to be

settled wholly within 12 months after the end of the period in which the employees render the related service) are recognised during the period in which the employee renders the related services. The accruals for employee entitlements of benefits such as salaries, bonuses and annual leave represent the amount which the Company has a present obligation to pay as a result of the employees' services and the obligation can be measured reliably. The accruals have been calculated at undiscounted amounts based on current salary levels at the Balance Sheet date.

3.7 Financial Instruments

3.7.1 Financial Assets

a) Initial Recognition and Measurement

All financial assets are initially recognized at fair value except trade receivables which do not contain a significant financing component are measured at transaction price according to Ind AS 115. Transaction costs of financial assets not at Fair Value through Profit or Loss are added to the fair value of financial asset. Purchase and sale of financial assets are recognised using trade date accounting.

b) Subsequent Measurement

For purposes of subsequent measurements, 'debt instrument' is measured at the amortised cost if both the following conditions are met:

- a) The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
- b) Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

This category is the most relevant to the company. After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in finance income in the profit or loss. The losses arising from impairment are recognised in the profit or loss. This category generally applies to trade and other receivables.

c) Impairment of financial assets

The Company assesses at each Balance Sheet date whether there is

objective evidence that a financial asset or a group of financial assets is impaired. A financial asset or a group of financial assets is impaired and impairment losses are incurred only if there is objective evidence of impairment as a result of one or more events that occurred after the initial recognition of the asset (a 'loss event') and that loss event (or events) has an impact on the estimated future cash flows of the financial asset or group of financial assets that can be reliably estimated.

In accordance with Ind-AS 109 – Financial Instruments, the Company follows 'simplified approach' for recognition of impairment loss allowance on trade receivables which do not contain a significant financing component.

The application of simplified approach does not require the Company to track changes in credit risk. Rather, it recognises impairment loss allowance based on lifetime Expected Credit Losses at each Balance Sheet date, right from its initial recognition.

d) Derecognition of Financial Assets

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognised (i.e. removed from the Company's balance sheet) when:

- The rights to receive cash flows from the asset have expired, or
- The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either:
 - (a) the Company has transferred substantially all the risks and rewards of the asset, or
 - (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

3.7.2 Financial Liabilities

a) Initial Recognition and Measurement

Financial liabilities are measured at amortised cost using Effective Interest Rate (EIR) method. For trade and other payable maturing within one year from the Balance Sheet date, the carrying value approximates fair value due to short maturity.

b) Subsequent Measurement

Financial liabilities are carried at amortized cost using the EIR method. For trade and other payables maturing within one year from the balance sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

c) Loans and borrowings

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost using the EIR method. Gains and losses are recognised in profit or loss when the liabilities are derecognised as well as through the EIR amortisation process.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR.

The EIR amortisation is included as finance costs in the Statement of Profit and Loss. This category generally applies to borrowings.

d) Derecognition of Financial Liabilities

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the Statement of Profit and Loss.

f) Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet only if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

g) Equity instruments

An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by the Company are recognized at the proceeds received, net of direct issue costs.

Repurchase of the Company's own equity instruments is recognized and deducted directly in equity. No gain or loss is recognized in Statement of Profit and Loss on the purchase, sale, issue or cancellation of the Company's own equity instruments.

3.8 Fair Value measurement

The Company measures financial instruments, such as, derivatives at fair value at each balance sheet date on a portfolio basis.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

'All assets and liabilities for which fair value is measured or disclosed in the Financial Statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities
- Level 2 — Valuation techniques for which the lowest level input that is

significant to the fair value measurement is directly or indirectly observable

- Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognised in the Financial Statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

This note summaries accounting policy for fair value. Other fair value related disclosures are given in the relevant notes.

- Quantitative disclosures of fair value measurement hierarchy
- Financial instruments (including those carried at amortised cost)

3.9 Leases and ROU

Company as Lessee

Lease contracts entered by the Company majorly pertains for buildings taken on lease to conduct its business in the ordinary course.

The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Company recognises lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.

The Company determines the lease term as the non-cancellable period of a lease, together with both periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option; and periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option. In assessing whether the Company is reasonably certain to exercise an option to extend a lease, or not to exercise an option to terminate a lease, it considers all relevant facts and circumstances that create an economic incentive for the Company to exercise the option to extend the lease, or not to

exercise the option to terminate the lease. The Company revises the lease term if there is a change in the non-cancellable period of a lease.

The Company used the following practical expedients when applying Ind AS 116 :

- Applied a single discount rate to a portfolio of leases with similar characteristics.
- Applied the exemption not to recognise right-of-use assets and liabilities for leases with less than 12 months of lease term and leases of low value.
- Excluded initial direct costs from measuring the right-of-use asset at the date of initial application.
- Used hindsight when determining the lease term if the contract contains options to extend or terminate the lease.

(i). Right-of-use assets

The Company recognises right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognised, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are depreciated on a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets.

If ownership of the leased asset transfers to the Company at the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the asset.

(ii). Lease liabilities

At the commencement date of the lease, the Company recognises lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of

penalties for terminating the lease, if the lease term reflects the Company exercising the option to terminate. Variable lease payments that do not depend on an index or a rate are recognised as expenses (unless they are incurred to produce inventories) in the period in which the event or condition that triggers the payment occurs.

3.10 Revenue Recognition:

The Company has adopted Ind AS 115 'Revenue from Contracts with Customers' which introduces a five-step approach to measuring and recognising revenue from contracts with customers. Under Ind AS 115, revenue is recognised at an amount that reflects the consideration to which an entity expects to be entitled in exchange for services to a customer. The Company has elected to use the practical expedient that there is no financing component involved when the credit period offered to customers is less than 12 months (also refer Credit Risk).

Rendering of Services

Revenue from sale of services is recognised in accordance with the terms of the relevant agreements as accepted and agreed with the customers. Upfront non-refundable payments received are deferred and recognised as revenue over which the related services are performed.

Revenue from minimum guarantee clauses, cost conversion mechanisms, price escalation provisions, and other contractual adjustments is treated as variable consideration. Such revenue is recognized only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the consideration is subsequently resolved.

Where the realization of such variable consideration is contingent upon customer confirmation, negotiation, or other contractual uncertainties, the Company constrains the recognition of such amounts and records revenue only when there is sufficient objective evidence to support both entitlement and recoverability.

Interest income

Interest on deposits is recognized on the time proportion method using the underlying interest rates.

3.11 Taxation

Income tax expense comprises current tax expense and the net

change in the deferred tax asset or liability during the year. Current and deferred tax are recognised in Statement of Profit and Loss, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax are also recognised in other comprehensive income or directly in equity, respectively.

(i) Current tax:

Current Tax expenses are accounted in the same period to which the revenue and expenses relate. Provision for current income tax is made for the tax liability payable on taxable income after considering tax allowances, deductions and exemptions determined in accordance with the applicable tax rates and the prevailing tax laws.

Current tax assets and current tax liabilities are offset when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle the asset and the liability on a net basis.

(ii) Deferred tax:

Deferred income tax is recognised using the Balance Sheet approach. Deferred income tax assets and liabilities are recognised for deductible and taxable temporary differences arising between the tax base of assets and liabilities and their carrying amount in financial statements, except when the deferred Income tax arises from the initial recognition of goodwill, an asset or liability in a transaction that is not a business combination and affects neither accounting nor taxable profits or loss at the time of the transaction.

Deferred income tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carry forward of unused tax credits and unused tax losses can be utilised.

Deferred tax liabilities are generally recognized for all taxable temporary differences.

The carrying amount of deferred tax assets is reviewed at each Balance Sheet date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the deferred income tax asset to be utilised.

Deferred tax liabilities and assets are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realized, based on tax rates (and tax laws) that have been enacted or substantively enacted by the Balance Sheet date.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis.

3.12 Cash Flow Statement

Cash flows are reported using the indirect method, whereby, profit before tax is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows are segregated into operating, investing and financing activities.

3.13 Earnings per share

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. Partly paid equity shares are treated as a fraction of an equity share to the extent that they are entitled to participate in dividends relative to a fully paid equity share during the reporting period. The weighted average number of equity shares outstanding during the period is adjusted for events such as bonus issue, bonus element in a rights issue, share split, and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding, without a corresponding change in resources.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

ARUNJYOTI BIO VENTURES LIMITED

Notes to the Financial Statements for the Year ended March 31, 2026

(All amounts in lakhs of Indian Rupees except share data and where otherwise stated)

Note 3(a): Property, Plant and Equipment.

Particulars	Land	Building	Plant and Equipment	Furniture and Fixtures	Vehicles	Electrical Installations	IT Equipment	Total
Gross Block at Cost/ Deemed Cost								
As at 31st March 2024	51.52	544.90	3,090.41	-	119.42	381.34	3.53	4,191.12
Adjustments:								
Additions	4.20	173.52	104.81	0.56	7.94	293.77	2.51	587.31
Disposals								-
As at 31st March 2025	55.72	718.42	3,195.22	0.56	127.36	675.11	6.04	4,778.43
Adjustments:								
Additions	169.15	40.27	71.40	-	-	8.63	1.61	291.06
Disposals	-	-	26.67	-	-	-	-	26.67
As at 31st March 2026	224.87	758.69	3,239.95	0.56	127.36	683.74	7.65	5,042.82
Accumulated Depreciation and Impairment								
As at 31st March 2024	-	11.70	149.49	-	5.31	25.01	0.64	192.15
Adjustments:								
Depreciation charge during the year	-	19.98	209.58	0.03	14.54	48.47	1.73	294.33
Disposals	-	-	-	-	-	-	-	-
As at 31st March 2025	-	31.68	359.07	0.03	19.85	73.48	2.37	486.48
Adjustments:								
Depreciation charge during the year	-	23.04	216.72	0.05	15.13	63.40	2.35	320.69
Disposals	-		4.66					4.66
As at 31st March 2026	-	54.72	571.13	0.08	34.98	136.88	4.72	802.51
Net Book Value								
As at 31st March 2025	55.72	686.74	2,836.15	0.53	107.51	601.63	3.67	4,291.95
As at 31st March 2026	224.87	703.97	2,668.82	0.48	92.38	546.86	2.93	4,240.31

ARUNJYOTI BIO VENTURES LIMITED

Note 3(b): Investment Property

Particulars	Land	Building	Total
Gross Block at Cost/ Deemed Cost	-	-	-
As at 31st March 2024	-	-	-
Adjustments:			
Additions	-	-	-
Disposals	-	-	-
As at 31st March 2025	-	-	-
Adjustments:			
Additions	52.51	223.81	276.32
Disposals	-	-	-
As at 31st March 2026	52.51	223.81	276.32
Accumulated Depreciation and Impairment	-	-	-
As at 31st March 2024	-	-	-
Adjustments:			
Depreciation charge during the year	-	-	-
Disposals	-	-	-
As at 31st March 2025	-	-	-
Adjustments:			
Depreciation charge during the year	-	4.87	4.87
Disposals	-	-	-
As at 31st March 2026	-	4.87	4.87
Net Book Value			
As at 31st March 2025	-	-	-
As at 31st March 2026	52.51	218.94	271.45
Fair Value as at 31st March 2026	52.51	218.94	271.45

Information regarding income and expenditure of Investment property

Particulars	31-Mar-26	31-Mar-25
Rental income derived from investment properties	34.48	-
Other than rental income	26.60	-
Direct operating expenses (including repairs and maintenance) generating rental income	0.23	-
Direct operating expenses (including repairs and maintenance) that did not generate rental income	-	-
Profit arising from investment properties before depreciation and indirect expenses	60.85	-
Less – Depreciation	4.87	-
Profit arising from investment properties before indirect expenses	55.98	-

ARUNJYOTI BIO VENTURES LIMITED

3(c)-Right-of-use Assets

Particulars	Building
Gross block	
At March 31, 2024	71.38
Additions during the year	-
Disposals/transfer	-
At March 31, 2025	71.38
Additions during the year	-
Disposals/transfer	-
At March 31, 2026	71.38
Amortisation	
At March 31, 2024	8.40
Amortisation charge for the year	8.40
Disposals	-
At March 31, 2025	16.80
Amortisation charge for the year	8.40
Disposals	-
At March 31, 2026	25.20
Net Book Value	
As at March 31, 2025	54.58
As at March 31, 2026	46.18

ARUNJYOTI BIO VENTURES LIMITED

Note 4: Intangible Assets

Particulars	Software	Total
Gross block at cost/Deemed cost as at March 31, 2024	5.95	5.95
Additions	-	-
Disposals	-	-
As at March 31, 2025	5.95	5.95
Additions	-	-
Disposals	-	-
As at March 31, 2026	5.95	5.95
Amortisation		
As at March 31, 2024	0.89	0.89
Charge for the year	1.85	1.85
Disposals	-	-
As at March 31, 2025	2.74	2.74
Charge for the year	1.85	1.85
Disposals	-	-
As at March 31, 2026	4.59	4.59
Net Book Value		
As at March 31, 2025	3.21	3.21
As at March 31, 2026	1.36	1.36

Note 5. Other Non-current Financial Assets

Particulars	As at March 31, 2026	As at March 31, 2025
Deposits with Government, public bodies		
-Considered good	101.02	66.88
Fixed Deposits with Banks (Under Lien)	86.66	82.34
Others	0.15	0.35
Total	187.83	149.57
Less: Provision for doubtful assets	-	-
Total Other Non-current Financial Assets	187.83	149.57

ARUNJYOTI BIO VENTURES LIMITED

Note 6: Deferred Tax Assets

The balances comprises temporary differences attributable to :

Particulars	As at March 31, 2026	As at March 31, 2025
Deferred Tax Asset on account of:		
a) Depreciation	(225.01)	(169.45)
b) Carry Forward Business Losses and Unabsorbed Depreciation	318.49	206.50
c) Leases	1.47	-
d) Provision for Gratuity	2.50	-
Total Deferred tax assets	97.45	37.05

Note 7: Inventories

Particulars	As at March 31, 2026	As at March 31, 2025
Consumables	10.53	244.56
Stores & Spares	-	1.01
Total Inventories	10.53	245.57

Note 8: Trade receivables- Current

Particulars	As at March 31, 2026	As at March 31, 2025
Trade receivables considered good-Secured	-	-
Trade receivables considered good-Unsecured	383.73	396.51
Trade receivables which have significant increase in credit risk	-	-
Trade receivables-credit impaired	-	-
Total	383.73	396.51
Less : Allowance for credit impaired	-	-
Total Trade Receivables	383.73	396.51

Refer Note 8(a) for Trade Receivables ageing schedule.

ARUNJYOTI BIO VENTURES LIMITED

Note 8(a): Trade receivables- Current

External Trade Receivable	As at March 31, 2026							
	Outstanding for following periods from due date of receipt							
	Not due	Unbilled	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed Trade receivables – considered good	-	60.58	295.06	-	-	28.09	-	383.73
(ii) Undisputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-	-	-
(iii) Undisputed Trade Receivables – credit impaired	-	-	-	-	-	-	-	-
(iv) Disputed Trade Receivables–considered good	-	-	-	-	-	-	-	-
(v) Disputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-	-	-
(vi) Disputed Trade Receivables – credit impaired	-	-	-	-	-	-	-	-
Total external trade receivables	-	60.58	295.06	-	-	28.09	-	383.73

External Trade Receivable	As at March 31, 2025							
	Outstanding for following periods from due date of receipt							
	Not due	Unbilled	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed Trade receivables – considered good	-	115.11	109.08	82.64	31.94	57.74	-	396.51
(ii) Undisputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-	-	-
(iii) Undisputed Trade Receivables – credit impaired	-	-	-	-	-	-	-	-
(iv) Disputed Trade Receivables–considered good	-	-	-	-	-	-	-	-
(v) Disputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-	-	-
(vi) Disputed Trade Receivables – credit impaired	-	-	-	-	-	-	-	-
Total external trade receivables	-	115.11	109.08	82.64	31.94	57.74	-	396.51

ARUNJYOTI BIO VENTURES LIMITED

Note 9: Cash and cash equivalents

Particulars	As at March 31, 2026	As at March 31, 2025
Balances with banks		
- in current accounts	6.79	41.27
Cash on hand	5.88	17.95
Total Cash and Bank Balances	12.67	59.22

Note 10: Loans

Particulars	As at March 31, 2026	As at March 31, 2025
Unsecured, considered good		
Loans to related parties*	65.99	0.27
Loans which have significant increase in credit risk	-	-
Loans-credit impaired	-	-
Total	65.99	0.27
Less : Allowance for credit impaired	-	-
Total Loans	65.99	0.27

*Refer Note 37 for related party loan

Note 11 : Other Financial Assets (Current)

Particulars	As at March 31, 2026	As at March 31, 2025
Salary Advance to employees	0.90	0.37
Total Other Financial Assets (Current)	0.90	0.37

ARUNJYOTI BIO VENTURES LIMITED

Note 12: Current Tax Assets (Net)

Particulars	As at March 31, 2026	As at March 31, 2025
TDS Receivable	62.22	48.11
TCS Receivable	-	3.30
Total Current Tax Assets	62.22	51.41

Note 13: Other current assets

Particulars	As at March 31, 2026	As at March 31, 2025
Unsecured, considered good		
Balance with Statutory Authorities	-	239.44
Advance to Vendors	19.51	609.61
Prepaid expenses	16.16	-
Total Other Current Assets	35.67	849.05

Note 14: Equity

Particulars	As at March 31, 2026		As at March 31, 2025	
	No. of shares	Value	No. of shares	Value
Authorised				
Equity shares of Rs.1/- each	19,00,00,000	1,900.00	19,00,00,000	1,900.00
Total	19,00,00,000	1,900.00	19,00,00,000	1,900.00
Issued, Subscribed and Fully Paid-up				
Equity shares of Rs.1/- each	18,63,81,000	1,863.81	18,63,81,000	1,863.81
Total	18,63,81,000	1,863.81	18,63,81,000	1,863.81

(a) Reconciliation of the equity shares capital amount outstanding at the beginning and at the end of the reporting year

Particulars	As at March 31, 2026		As at March 31, 2025	
	No. of shares	Value	No. of shares	Value
Equity shares				
At the beginning of the year	18,63,81,000	1,863.81	2,07,09,000	207.09
Issued during the year	-	-	16,56,72,000	1,656.72
Outstanding at the end of the year	18,63,81,000	1,863.81	18,63,81,000	1,863.81

*During the previous year, the Company subdivided its equity shares from face value of ₹10 each to ₹1 each.

ARUNJYOTI BIO VENTURES LIMITED

(b) Terms/rights attached to equity shares

The Company has a single class of equity shares. Accordingly, all equity shares rank equally with regard to dividends and share in the Company's residual assets. The equity shares are entitled to receive dividend as declared from time to time. On winding up of the Company, the holders of equity shares will be entitled to receive residual assets of the Company, remaining after distribution of all preferential amounts in proportion to the number of equity shares held by the shareholders.

(c) Shares held by Promoters

Particulars	As at March 31, 2026		As at March 31, 2025		% Change during the year
	No. of shares	Value	No. of shares	Value	
Equity shares of Rs. 1/- each					
Pabbathi Badari Narayana Murthy	3,58,76,078	358.76	3,58,76,078	358.76	0.00%
Dathvik Pabbathi .	4,30,04,890	430.05	4,30,04,890	430.05	0.00%
Ponnuru Siva Ratna Maha Lakshmi Prasanna	99,05,040	99.05	99,05,040	99.05	0.00%
Total	8,87,86,008	887.86	8,87,86,008	887.86	

(d) Details of shareholders holding more than 5% shares in the company

Particulars	As at March 31, 2026		As at March 31, 2025		% Change during the year
	No. of Shares	% of holding in the class	No. of Shares	% of holding in the class	
Pabbathi Badari Narayana Murthy	3,58,76,078	19.25%	3,58,76,078	19.25%	0.00%
Dathvik Pabbathi .	4,30,04,890	23.07%	4,30,04,890	23.07%	0.00%
Ponnuru Siva Ratna Maha Lakshmi Prasanna	99,05,040	5.31%	99,05,040	5.31%	0.00%

- (e) The Company has not allotted any fully paid equity shares by way of bonus shares nor has bought back any class of equity shares during the period of five years immediately preceding the balance sheet date nor has issued shares for consideration other than cash.

ARUNJYOTI BIO VENTURES LIMITED

Note 15: Other Equity

Particulars	As at March 31, 2026	As at March 31, 2025
Reserves & Surplus		
Capital Reserve	23.34	23.34
Securities premium	1,656.72	1,656.72
Retained Earnings	(672.06)	(218.45)
Total Reserves & Surplus	1,008.00	1,461.61
Capital Reserve		
Opening Balance	23.34	23.34
Additions	-	-
Closing Balance	23.34	23.34
Securities Premium		
Opening Balance	1,656.72	-
Rights issue	-	1,656.72
Closing Balance	1,656.72	1,656.72
Retained Earnings		
Opening balance	(218.45)	(53.77)
Adjustment for restatement	-	(67.06)
Net profit / (loss) for the period	(453.61)	(27.62)
Remeasurements of post-employment benefit obligation, net of tax (OCI)	-	-
Expenses related to rights issue	-	(70.00)
Closing Balance	(672.06)	(218.45)
Total Reserves & Surplus	1,008.00	1,461.61

Nature and purpose of each reserve

Securities premium - The amount received in excess of face value of the equity shares is recognised in securities premium. It is utilised in accordance with the provisions of the Companies Act, 2013

Capital Reserve - Reserve of capital nature taken to this head under the erstwhile GAAP

Retained Earnings - This reserve represents undistributed accumulated earnings of the company as on balance sheet date.

ARUNJYOTI BIO VENTURES LIMITED

Note: 16(a) Non Current borrowings

Particulars	As at March 31, 2026	As at March 31, 2025
<u>Secured</u>		
Term Loans from Bank*	1,150.05	1,579.66
<u>Unsecured</u>		
Total non current borrowings	1,150.05	1,579.66
Non current borrowings	1,150.05	1,579.66

Note: 16(b) Current Borrowings

Particulars	As at March 31, 2026	As at March 31, 2025
<u>Secured</u>		
Current maturities of Term loans from Bank*	480.20	444.48
Working Capital Loan	499.87	469.00
<u>Unsecured</u>		
Current maturities of loan from Director	45.00	68.77
Current borrowings	1,025.07	982.25

*During the year, there was a delay of 1 day in repayment of loan instalments and interest in few months due to administrative and operational timing factors and such delay doesn't make the loan repayable on demand. The amount was subsequently repaid, and there were no continuing defaults as at the reporting date.

Notes

Loan	Term Loan-1	Term Loan-2	Working Capital Loan	Vehicle Loan	Loan from Director
Loan term	Dec. 2023 to Nov 2029	Dec. 2024 to Sep 2029	NA	Dec 2023 to Nov 2030	Jan 2023 to Dec 2026
Amount	20,00,00,000	4,00,00,000	5,00,00,000(Limit)	1,00,10,987	45,00,000
Interest rate	Repo+3.15%	Repo+3.15%	Repo+3.15%	8.5% p.a	0% p.a
Security	The facility is secured by equitable mortgage over factory land and buildings, hypothecation of the Company's unencumbered fixed assets, and mortgage over collateral immovable properties. The facility is further backed by a lien on fixed deposits	The facility is secured by equitable mortgage over factory land and buildings, hypothecation of the Company's unencumbered movable fixed assets, and mortgage over collateral immovable properties. The facility is further backed by a lien on fixed deposits	The Cash Credit facility is secured by hypothecation of the entire current assets of the Company, mortgage over factory land and buildings and specified collateral immovable properties.	Secured by hypothecation of the vehicle financed under the loan arrangement	No security
Guarantee	Personal guarantees of Mr. Pabbathi Badari Narayana Murthy, Mr. Dathvik Pabbathi and Mrs. Pabbathi Mahalakshmi Prasanna and a corporate guarantee of M/s MSRM International Trading Private Limited.	Personal guarantees of Mr. Pabbathi Badari Narayana Murthy, Mr. Dathvik Pabbathi and Mrs. Pabbathi Mahalakshmi Prasanna and a corporate guarantee of M/s MSRM International Trading Private Limited.	Personal guarantees of Mr. Pabbathi Badari Narayana Murthy, Mr. Dathvik Pabbathi and Mrs. Pabbathi Mahalakshmi Prasanna and a corporate guarantee of M/s MSRM International Trading Private Limited.	No guarantee	No guarantee
Terms of repayment	72 monthly instalments after a 12-month moratorium	57 monthly instalments after a 12-month moratorium	On Demand	7th of every month (84 monthly installments)	31st December 2026

ARUNJYOTI BIO VENTURES LIMITED

Note: 16(c) Changes in liability arising from financing activities

Particulars	1st April 2025	Cashflows			31st March 2026
		Receipts	Interest	Payments	
Current borrowings	982.25	1,291.92	78.25	1,327.35	1,025.07
Non-current borrowings	1,579.66	-	121.51	551.12	1,150.05
Lease Liabilities	59.06	-	4.98	12.00	52.04
Total	2,620.97	1,291.92	204.74	1,890.47	2,227.16

Particulars	1st April 2024	Cashflows			31st March 2025
		Receipts	Interest	Payments	
Current borrowings	831.25	1,839.54	85.98	1,774.52	982.25
Non-current borrowings	4,244.12	-	167.32	2,831.78	1,579.66
Lease Liabilities	65.49	-	5.57	12.00	59.06
Total	5,140.86	1,839.54	258.87	4,618.30	2,620.97

Note: 17(a) Lease Liabilities- Non Current

Particulars	As at March 31, 2026	As at March 31, 2025
Lease Liabilities	45.01	52.03
Total other financial liabilities	45.01	52.03

Note: 17(b) Lease Liabilities- Current

Particulars	As at March 31, 2026	As at March 31, 2025
Lease Liabilities	7.03	7.03
Total	7.03	7.03

Note 18 (a): Provisions - Non current

Particulars	As at March 31, 2026	As at March 31, 2025
	Non-Current	Non-Current
Provision for Gratuity (Refer Note 18(c))	9.89	-
Total	9.89	-

Note 18 (b): Provisions - Current

Particulars	As at March 31, 2026	As at March 31, 2025
	Current	Current
Provision for Gratuity (Refer Note 18(c))	0.04	-
Total	0.04	-

Note 18 (c):

a) Employee Benefits

Particulars	As at March 31, 2026	As at March 31, 2025
Amount recognised as expense in the statement of Profit and Loss		
- Provident Fund Contribution	44.64	15.56

b) Gratuity (Unfunded)

The Company has a defined benefit gratuity plan governed by the Payment of Gratuity Act, 1972. Every employee who has completed 5 year or more of service is entitled to gratuity on departure at 15 days last drawn salary for each completed year of service or part thereof in excess of six months.

ARUNJYOTI BIO VENTURES LIMITED

Changes in defined benefit obligation

Particulars	As at March 31, 2026	As at March 31, 2025
Projected benefit obligation at the beginning of the year	-	-
Past Service Cost	6.26	-
Current Service Cost	3.67	-
Interest Cost	-	-
Actuarial (gain)/ loss on obligation	-	-
Benefits paid	-	-
Projected benefit obligation at the end of the year	9.93	-

Break up of the Provision for Gratuity into Current & Non-current

Particulars	As at March 31, 2026	As at March 31, 2025
Current Liability	0.04	-
Non-Current Liability	9.89	-
Total	9.93	-

Expense recognised in the Statement of Profit and Loss

Particulars	As at March 31, 2026	As at March 31, 2025
Past Service Cost	6.26	-
Current Service Cost	3.67	-
Interest Cost	-	-
Net Gratuity Costs	9.93	-

ARUNJYOTI BIO VENTURES LIMITED

Summary of Actuarial Assumptions

Particulars	As at March 31, 2026	As at March 31, 2025
Attrition Rate	35.00%	0.00%
Discount rate	6.50%	0.00%
Salary escalation rate	5.00%	0.00%

Mortality

Age (Years)	Rates (p.a)
20 years	0.09%
25 years	0.09%
30 years	0.10%
35 years	0.12%
40 years	0.17%
45 years	0.26%
50 years	0.44%
55 years	0.75%
60 years	1.12%
65 years	1.59%
70 years	2.41%

Maturity profile of the defined benefit obligation

Particulars	As at March 31, 2026	As at March 31, 2025
Weighted average duration of defined benefit obligation (in years)	4.00	-
Expected benefit payments for the year ending		
Not later than 1 year	0.04	-
Later than 1 year and not later than 5 years	9.35	-
Later than 5 year and not later than 10 years	3.33	-
Above 10 years	0.55	-

ARUNJYOTI BIO VENTURES LIMITED

Remeasurement of the net defined benefit liability recognised in other comprehensive income

Particulars	As at March 31, 2026	As at March 31, 2025
Remeasurement for the period - Obligation (gain)/loss arising from		
– change in demographic assumptions	-	-
– change in financial assumptions	-	-
– experience variance	-	-
Amount recognised in OCI	-	-

Sensitivity analysis of significant actuarial assumptions

Particulars	31-Mar-26 Decrease	31-Mar-26 Increase	31-Mar-25 Decrease	31-Mar-25 Increase
Discount Rate (- / + 1%)	10.35	9.53	-	-
(% change compared to base due to	4.30%	-4.00%	-	-
Salary Growth Rate (- / + 1%)	9.52	10.36	-	-
(% change compared to base due to	-4.10%	4.30%	-	-
Attrition Rate (- / + 50% of attrition rates)	14.46	6.14	-	-
(% change compared to base due to	45.60%	-38.20%	-	-
Mortality Rate (- / + 10% of mortality rates)	9.93	9.93	-	-
(% change compared to base due to sensitivity)	0.00%	0.00%	-	-

Note 19: Trade Payables

Particulars	As at March 31, 2026	As at March 31, 2025
Trade payables (including accruals)		
The above amount includes		
Total outstanding dues of micro and small enterprises	4.23	0.71
Trade payables dues of creditors other than micro and small enterprises	175.37	140.62
Total Trade Payables	179.60	141.33

Refer Note 19(a) for Trade Payables ageing schedule and 19(b) for MSME Disclosure

Note 19(a): Trade Payables

Trade Payable	As at March 31, 2026					
	Outstanding for following periods from due date of payment					
	Unbilled Dues	Not due	Less than 1 year	1-2 years	2-3 years	More than 3 years
Undisputed dues						
MSME	-	-	4.23			4.23
Others	8.25	-	162.54	1.26	3.32	-
Disputed dues						
MSME	-	-	-	-	-	-
Others	-	-	-	-	-	-
Total Trade payables	8.25	-	166.77	1.26	3.32	-
						179.60

Trade Payable	As at March 31, 2025					
	Outstanding for following periods from due date of payment					
	Unbilled Dues	Not due	Less than 1 year	1-2 years	2-3 years	More than 3 years
Undisputed dues						
MSME	-	-	0.71	-	-	0.71
Others	5.24	-	130.60	3.72	-	1.06
Disputed dues						
MSME	-	-	-	-	-	-
Others	-	-	-	-	-	-
Total Trade payables	5.24	-	131.31	3.72	-	1.06
						141.33

Note 19(b) : Disclosures required under section 22 of the Micro, Small and Medium Enterprises Development Act, 2006

Particulars	As at March 31, 2026	As at March 31, 2025
(i) Principal amount remaining unpaid to any supplier as at the end of the accounting year	4.23	0.71
(ii) Interest due thereon remaining unpaid to any supplier as at the end of the accounting year	-	-
(iii) the amount of interest paid in terms of section 16 of the Micro, Small and Medium Enterprises Development Act, 2006 (27 of 2006), along with the amount of the payment made to the supplier beyond the appointed day during each accounting year	-	-
(iv) the amount of interest due and payable for the period of delay in making payment (which has been paid but beyond the appointed day during the year) but without adding the interest specified under the Micro, Small and Medium Enterprises Development Act, 2006	-	-
(v) the amount of interest accrued and remaining unpaid at the end of each accounting year	-	-
(vi) Interest remaining due and payable to supplier disallowable as deductible expenditure under Income tax Act, 1961 for the current year	-	-
(vii) the amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under section 23 of the Micro, Small and Medium Enterprises Development Act, 2006	-	-

ARUNJYOTI BIO VENTURES LIMITED

Note 20: Other financial liabilities - Current

Particulars	As at March 31, 2026	As at March 31, 2025
Payable to employees	39.01	30.62
Directors' Remuneration Payable	8.00	8.00
Employee related liabilities	34.34	1.78
Total	81.35	40.40

Note 21: Other Current Liabilities

Particulars	As at March 31, 2026	As at March 31, 2025
Statutory liabilities	46.44	10.64
Total Other current liabilities	46.44	10.64

Note 22 :

(a): Revenue from operations

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Sale of Products	-	640.44
Sale of services	2,648.93	2,138.39
Sub-Total (a)	2,648.93	2,778.83

ARUNJYOTI BIO VENTURES LIMITED

(b): Other Operating Income

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Income from Investment Property	61.08	-
Other Operating Income	65.43	9.58
	-	-
Sub-Total (b)	126.51	9.58
Total (a+b)	2,775.44	2,788.41

Note 23: Other income

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Interest Income	11.80	28.13
Total	11.80	28.13

Note 24: Purchase of Stock in Trade

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Raw materials, Packing materials, Consumables at the beginning of the year		
Add : Purchases	-	376.91
Less: Raw materials and Packing materials at the end of the year	-	-
Total Purchase of Stock in Trade	-	376.91

ARUNJYOTI BIO VENTURES LIMITED

Note 25: Changes In Inventories of Finished Goods, Work-In-Progress And Stock-In-Trade

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Opening Balance		
Finished Goods	-	134.72
Spares And Consumables	-	-
Inventories At The Beginning Of The Year	-	134.72
Closing Balance		
Finished Goods	-	-
Spares And Consumables	-	-
Total Closing Balance		-
Total Changes In Inventories of Finished Goods, Work-Inprogress And Stock-In-Trade	-	134.72

Note 26: Employee benefits Expense

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Salaries, wages and bonus	900.00	719.99
Managerial Remuneration	137.19	121.76
Contribution to provident fund and other funds	44.64	15.56
Gratuity expenses (Refer Note 18)	9.93	-
Staff welfare expenses	31.73	35.81
Total	1,123.49	893.12

Note 27: Finance Costs

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Interest on Term Loan	147.18	205.10
Interest on Working capital loan	41.65	38.81
Interest on Vehicle Loan	6.78	7.78
Interest on Lease Liabilities	4.97	5.57
Others	4.15	1.61
Total	204.73	258.87

ARUNJYOTI BIO VENTURES LIMITED

Note 28 (a): Other Expenses

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Consumption of stores & spares (Refer Note 28(c))	503.16	11.29
Repairs & Maintenance	66.78	56.29
Rent- Plant & Machinery	13.86	-
Rent- Others	-	7.31
Freight, Loading And Unloading Charges	56.82	44.64
Security Services	14.28	12.41
Telephone Expense & Postage	2.25	1.40
Rent- Office	-	4.80
Rates And Taxes	13.54	13.01
Travelling & Conveyance Expenses	24.54	15.16
Miscellaneous Expenses	2.33	4.47
Legal and professional	27.70	24.10
Director's Sitting Fee	3.15	3.85
Software Charges	0.57	3.36
Printing & Stationery	3.56	3.07
Bad Debts	8.50	-
Advertisement & Business Promotion Expenses	0.48	0.58
Land Development	1.65	1.80
Insurance Charges	1.38	3.56
Office and general maintenance	7.31	11.26
Loss on sale of fixed assets	11.93	-
Right Issue Expense	-	38.49
Power and Fuel Expense	590.29	620.45
Auditors Remuneration (Refer Note(i))	9.50	1.13
Total	1,363.58	882.43

ARUNJYOTI BIO VENTURES LIMITED

Note (i)

Details of payments to auditors

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Payment to auditors		
As Statutory auditor:	6.00	1.00
In other capacities:		
Certificates fees		
Tax Audit fees	2.00	-
Limited review fees	1.50	-
Other services	-	0.13
Out of pocket expenses	-	-
Total payment to auditors	9.50	1.13

Note : 28 (b) Exceptional Items

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Trade Advances write off	102.72	-
Trade receivables Write off	170.93	-
Total	273.65	-

Note : 28 (c) Consumption of Spares

Certain operational bottlenecks and process inefficiencies during the current quarter resulted in abnormal consumption of inventory amounting to Rs. 241 lakhs, which has been recognised under consumption of stores and consumables for the year ended March 31, 2026.

ARUNJYOTI BIO VENTURES LIMITED

Note 29 :Revenue from contracts with customers

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Contract with customers Details of revenue from contracts with customers recognised by the Company, net of indirect taxes in its statement of Profit and loss.		
Revenue from operations		
<u>Revenue from contract with customers</u>		
a) Sale of Products	-	640.44
b) Sale of Services		
Co-packing services	2,648.93	2,138.39
Total Revenue from Operations	2,648.93	2,778.83

Disaggregation of Revenue from Co-packing Services

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Fixed Consideration	2,413.03	2,052.80
Variable Consideration	235.90	85.59
Revenue from Co-packing services	2,648.93	2,138.39

Movement in Contract Balances

Contract Balance	Year ended March 31, 2025	Additions	Utilised/ Reversal	Year ended March 31, 2025
Unbilled Revenue (included in Trade Receivables)	115.11	60.58	115.11	60.58
Total Contract Balances	115.11	60.58	115.11	60.58

ARUNJYOTI BIO VENTURES LIMITED

Note 30:

Income Tax

The major components of income tax expense for the years ended 31 March 2026 and 31 March 2025 are:

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Statement of Profit and Loss:		
Current tax	-	-
Prior period tax	-	-
Deferred Tax	(60.41)	(6.47)
Income tax expense reported in the statement of profit & loss	(60.41)	(6.47)

Reconciliation of tax expense

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Accounting Profit before tax (after exceptional items) (a)	(514.02)	(34.09)
Income Tax Rate (b)	25.168%	25.17%
Calculated taxes based on above without any adjustments for deductions [(a) x (b)]	(129.37)	(8.58)
Adjustments:		
DTA not recognised on losses	68.87	-
Others	0.09	2.11
Income tax expense reported in the statement of profit & loss	(60.41)	(6.47)

ARUNJYOTI BIO VENTURES LIMITED

Reconciliation of deferred tax asset (net)

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Opening balance as of April 1, 2025	37.05	30.58
Tax income / (expense) during the year recognised in profit or loss	60.40	6.47
Closing Balance as at 31 March, 2026	97.45	37.05

Note 31: Earnings Per Share

Basic EPS amounts are calculated by dividing the profit for the year attributable to equity holders of the company by the weighted average number of Equity shares outstanding during the year. Diluted EPS amounts are calculated by dividing the profit attributable to equity holders of the company by the weighted average number of Equity shares outstanding during the year plus the weighted average number of Equity shares that would be issued on conversion of all the dilutive potential Equity shares into Equity shares.

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Profit attributable to equity shareholders (Rs. in lakhs)	(453.61)	(27.62)
Weighted average number of equity shares used for computing basic and diluted earning per share (No of shares)	18,63,81,000	17,76,06,058
Face value of equity shares (Rs.per share)	1.00	1.00
EPS- basic and diluted (in Rs.)	(0.24)	(0.01)

Note 32(a): Fair Value Measurement

Particulars	31-Mar-26			31-Mar-25		
	FVTPL	FVTOCI	Amortised Cost	FVTPL	FVTOCI	Amortised Cost
Financial Assets						
Trade Receivables	-	-	383.73	-	-	396.51
Cash and cash equivalents and Bank Balances	-	-	12.67	-	-	59.22
Loans	-	-	65.99	-	-	0.27
Other Financial Assets - Non Current	-	-	187.83	-	-	149.57
Other Financial Assets - Current	-	-	0.90	-	-	0.37
Total Financial Assets	-	-	651.12	-	-	605.94
Financial Liabilities						
Borrowings	-	-	2,175.12	-	-	2,561.91
Trade payables	-	-	179.60	-	-	141.33
Lease Liabilities	-	-	52.04	-	-	59.06
Other Financial liabilities- Current	-	-	81.35	-	-	40.40
Other Financial liabilities- Non Current	-	-	-	-	-	-
Total Financial Liabilities	-	-	2,488.11	-	-	2,802.70

Note 33: Financial Risk Management**A) Credit Risk**

Credit risk is the risk that the counterparty to a financial instrument or customer contract will fail to discharge its contractual obligations, resulting in a financial loss to the Company. The Company is exposed to credit risk primarily from its financial assets and liabilities, such as trade receivables, loans, and cash and cash equivalents and borrowings.

The Company's exposure to credit risk on trade receivables is mainly from its customer Tata Consumer Products Limited (TCPL), which constitutes the principal trade receivable. The Company continuously evaluates the creditworthiness and past payment history of TCPL and has historically not experienced any defaults. Based on management's assessment and past experience, the credit risk associated with trade receivables is considered low. Accordingly, the Company has assessed the expected credit loss (ECL) on trade receivables and does not consider any provision necessary as at the reporting date.

For cash and cash equivalents, the credit risk is limited as these balances are maintained with reputed banks and financial institutions having high credit ratings, thereby ensuring strong credit quality and negligible risk of default.

The Company has established internal control systems and periodic monitoring mechanisms for review of trade receivables and other financial assets. These include regular monitoring of recoverability and timely identification of any significant credit deterioration, if any, to ensure appropriate risk mitigation actions are taken.

Based on current assessment, the Company considers its overall exposure to credit risk to be low.

B) Liquidity Risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting its financial obligations as and when they become due.

Maturities of financial liabilities

The tables below analyse the Company's financial liabilities into relevant maturity groupings based on their contractual maturities for all non-derivative financial liabilities.

There are no derivatives financial liabilities for the company.

The amounts disclosed in the table are the contractual undiscounted cash flows. Balances due within 12 months equal their carrying balances as the impact of discounting is not significant.

ARUNJYOTI BIO VENTURES LIMITED

Contractual Maturities as at 31st March, 2026	On Demand	Due in 1st year	Due in 2nd to 5th year	More than 5 years	Total
Non derivatives					
Borrowings	545.37	543.84	1,290.89	-	2,380.10
Obligations under finance lease	-	12.00	48.00	6.00	66.00
Trade payables	-	179.60	-	-	179.60
Other financial liabilities	-	81.35	-	-	81.35
Total non-derivative liabilities	545.37	816.79	1,338.89	6.00	2,707.05

Contractual Maturities as at 31st March, 2025	On Demand	Due in 1st year	Due in 2nd to 5th year	More than 5 years	Total
Non derivatives					
Borrowings	478.78	599.86	1,869.96	-	2,948.60
Obligations under finance lease	-	12.00	48.00	18.00	78.00
Trade payables	-	141.33	-	-	141.33
Other financial liabilities	-	40.40	-	-	40.40
Total non-derivative liabilities	478.78	793.59	1,917.96	18.00	3,208.33

ARUNJYOTI BIO VENTURES LIMITED

The Company has a net current liability position as at the reporting date, which may indicate potential liquidity constraints in meeting its short-term obligations. Management has assessed the situation and is confident of meeting its liabilities through operational cash flows and by raising additional funds through available financing arrangements.

C) Market Risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises three types of risk: interest rate risk, currency risk and other price risk, such as equity price risk and commodity risk. Financial instruments affected by market risk include loans and borrowings and derivative financial instruments. The company is not affected by currency risk and other price risk based on its nature of business.

(a) Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to the risk of changes in market interest rates relates primarily to the Company's short-term debt obligations with fixed & floating interest rates.

Sensitivity Analysis of the Interest Rate

Profit or loss is sensitive to higher/lower interest expense from borrowings as a result of change in interest rates.

Particulars	Basis points	Effect on profit before tax in Rs. Lakhs	
		31-Mar-26	31-Mar-25
INR	100bp Increase	21.02	24.77
INR	100bp Decrease	(21.02)	(24.77)

The assumed movement in basis points for the interest rate sensitivity analysis is based on the currently observable market environment, showing a significantly higher volatility than in prior years.

ARUNJYOTI BIO VENTURES LIMITED

Note 34 : Capital Management

The company's objectives when managing capital are to:

- > Safeguard their ability to continue as a going concern, so that they can continue to provide returns for shareholders and benefits for other stakeholders, and
- > Maintain an optimal capital structure to reduce the cost of capital.

In order to maintain or adjust the capital structure, the Company may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt.

The Company monitors its capital structure through gearing ratio to maintain an optimal mix of debt and equity. The gearing ratio is calculated as net debt divided by total equity. Net debt includes total borrowings less cash and cash equivalents.

Particulars	As at 31 March, 2026	As at 31 March, 2025
Total Borrowings	2,175.12	2,561.91
Less: Cash and Cash Equivalents	12.67	59.22
Net Debt	2,162.45	2,502.69
Total Equity	2,871.81	3,325.42
Gearing Ratio	0.75	0.75

Note 35: Operating Segment Disclosure

Arunjyoti Bio Ventures Limited is engaged in a single business activity, namely co-packing, and operates as a single operating segment. Accordingly, separate segment information as required under Ind AS 108 "Operating Segments" is not presented.

However, in accordance with the entity-wide disclosure requirements of Ind AS 108:

Geographical Information:

The Company's revenue is derived predominantly within India and all non-current assets are located within India.

Major Customer Disclosure:

Revenue from one customer constitutes more than 10% of the Company's total revenue. During the year, revenue derived from TCPL (Tata Consumer Products Limited) accounted for a substantial portion of the Company's total revenue.

The amount of revenue from this customer is Rs. 2,775.44 lakhs (previous year: Rs. 2,778.41 lakhs).

Note 36: Interests in other entities

a) Subsidiaries- Nil

b) Interest in Associates and Joint Ventures- Nil

Note 37: Related party transactions**(A) Details of related parties:**

Directors who held the office during the year:

Pabbathi Badari Narayana Murthy, Wholetime Director

Vishal Nadimpalli, Wholetime Director & CFO

Dathvik Pabbathi, Wholetime Director

Srikar Ranga, Independent Director

Vijaya Rama Lakshamana Murthy Mylavarapu, Independent Director

Dhanalakshmi Guntaka, Independent Director

Key Management Personnel (KMP):

Swati Jain, Company Secretary and Compliance officer

Entities in which Directors are interested with whom transactions were carried out in current / previous year

MSRM International Trading Pvt. Ltd

Miryalguda Rice Industries Pvt. Ltd

Pasura Xpress LLP

Relative of Director

Pabbathi Siva Ratna Mahalakshmi Prasanna

(B) Transactions with related parties:

Particulars	Directors and other relatives		Key Management Personnel (KMP)		Entities in which directors are interested	
	31-Mar-26	31-Mar-25	31-Mar-26	31-Mar-25	31-Mar-26	31-Mar-25
Sitting fees	3.15	3.85	-	-	-	-
Purchase of Investment Property (Land & Building) & Land- Dathvik Pabbathi, Wholetime Director	222.74	-	-	-	-	-
Purchase of Investment Property (Land & Building) & Land - Pabbathi Siva Ratna Mahalakshmi Prasanna	222.74	-	-	-	-	-
Office Rent	12.00	16.80	-	-	-	-
Interest on Loan given	-	-	-	-	4.53	-
Loans taken	23.71	5.77	-	-	-	11.03
Loan repayments made	29.65	1,469.42	-	-	17.83	-
Loans given**	-	-	-	-	80.72	47.26
Loans repayment received	-	-	-	-	19.09	47.26
Remuneration - Pabbathi Badari Narayana Murthy, Wholetime Director*#	85.71	85.13	-	-	-	-
Remuneration - Vishal Nadimpalli, Wholetime Director & CFO*#	51.48	36.63	-	-	-	-
Remuneration - Swati Jain, Company Secretary and Compliance officer*	-	-	2.54	2.54	-	-

ARUNJYOTI BIO VENTURES LIMITED

* Long term benefits have not been disclosed since the liability for such benefits have been derived by the actuary for entity as a whole.

**The Company has granted loan of Rs. 80.72 Lakhs (Amount outstanding as on 31st March 2026 is Rs. 65.99 Lakhs) to LLP in which directors are interested, which is subject to approval by the shareholders through special resolution under Section 185 (2) and the management is proposing to place it before the ensuing AGM for members approval.

During the year, managerial remuneration exceeded the remuneration approved by the shareholders by ₹25.19 lakhs due to the approval being granted on a net remuneration basis. The Company proposes to obtain shareholders' approval/ratification for the excess remuneration at the ensuing Annual General Meeting.

(C) Balances outstanding at the year end

Particulars	Directors and other relatives		Key Management Personnel (KMP)		Entities in which directors are interested	
	31-Mar-26	31-Mar-25	31-Mar-26	31-Mar-25	31-Mar-26	31-Mar-25
Office Rent	0.90	1.26	-	-	-	-
Remuneration	8.00	8.00	-	-	-	-
Trade Advance	-	-	-	-	1.44	1.44
Loans given	-	-	-	-	61.91	0.27
Interest receivable on loan given	-	-	-	-	4.08	-
Loans taken	45.00	50.94	-	-	-	17.83
Advance given for purchase of land	-	308.21	-	-	-	-

Note 38: Contingent assets and liabilities

(i). Contingent liabilities: Nil (31st March 2025 - Nil)

(ii) Contingent assets: Nil (31st March 2025 - Nil)

(iii) Commitments: Nil (31st March 2025 - Nil)

Note 39: Leases

The Company has elected not to apply the requirements of Ind AS 116 "Leases" to short-term leases of all assets that have a lease term of 12 months or less and leases for which the underlying asset is of low value. The lease payments associated with these leases are recognized as an expense on a straight-line basis over the lease term except inflation adjustment.

Ind AS 116 has resulted in an increase in cash inflows from operating activities and an increase in cash outflows from financing activities on account of lease payments.

ARUNJYOTI BIO VENTURES LIMITED

a. Set out below are the carrying amounts of lease liabilities and the movements during the year:

Particulars	31-Mar-26	31-Mar-25
Opening Balance	59.06	65.49
Additions during the year	-	-
Disposal during the year	-	-
Accretion of interest	4.98	5.57
Payment of lease liabilities	(12.00)	(12.00)
Reversal lease liability due to termination	-	-
Total	52.04	59.06
Current Lease liabilities	7.03	7.03
Non Current Lease liabilities	45.01	52.03

b. Payments recognised as expenses

Particulars	Year ended 31st March 2026	Year ended 31st March 2025
Short term leases and low value assets	13.86	7.31

c. Maturity analysis of lease liabilities (undiscounted value)

Particulars	Year ended 31st March 2026	Year ended 31st March 2025
Within one year	12.00	12.00
After one year but not more than five years	48.00	48.00
More than five years	6.00	18.00
Total	66.00	78.00

Note 40: Restatement of Deferred Tax Expense

During the year, the Company identified and corrected a prior period error relating to deferred tax on depreciation differences and recognition of previously unavailed tax benefit on unabsorbed depreciation. In accordance with Ind AS 8, the comparative figures have been restated. The adjustment is non-cash in nature and has no impact on the Company's operating performance or cash flows. Following is the impact of the above in Statement of Assets and Liabilities and Statement of Profit and loss.

Particulars	31 March 2025			01 April 2024		
	As previously reported	Restatement adjustment	As restated	As previously reported	Restatement adjustment	As restated
Deferred tax (asset) / liability	50.43	(87.48)	(37.05)	(97.63)	67.06	(30.57)
Other Equity	1,374.13	87.48	1,461.61	(30.43)	(67.06)	(97.49)

ARUNJYOTI BIO VENTURES LIMITED

Amounts in the Statement of Profit and Loss for the respective periods / year published in the above results increased / (decreased) by:

Particulars	Year ended 31.03.2025
Deferred tax charge / (credit)	(154.53)
Profit After Tax	154.53
Earnings per Share – in Rs. (Both Basic and Diluted)	0.09

Note 41: Social Security

The Government of India notified on November 21, 2025, four Labour Codes - the Code of Wages 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating existing labour laws. Based on management's assessment, the Company's existing employee compensation structures and benefit practices are largely aligned with the requirements of the Labour Codes and hence there is no impact on the financial results for the period under review. The Company will continue to monitor developments relating to implementation of the Labour Codes and evaluate any impact, if any, in future periods.

Note 42: Financial Ratios

Ratio	Numerator	Denominator	31-Mar-26	31-Mar-25	% variance	Remarks
Current Ratio(times)	Current Assets	Current Liabilities	0.43	1.36	-69%	Due to decrease in Current Assets.
Debt - equity Ratio(times)	Total Debt	Shareholder's Equity	0.76	0.77	-2%	No significant change
Debt Service Coverage Ratio(times)	Earnings available for debt service	Debt service	0.01	0.11	-88%	Due to decrease in earnings available for debt service.
Return On Equity(%)	Net profit after taxes	Average Shareholder's Equity	-15%	-1.61%	810%	Due to decrease in Net profit after taxes.
Inventory Turnover Ratio(times)	Revenue from operations	Average Inventory	21.67	10.35	109%	Due to consumption of Inventory the average inventory has been decreased.
Trade Receivables Turnover Ratio(times)	Revenue from operations	Average trade receivables	7.11	8.33	-15%	No significant change
Trade payable Turnover Ratio(times)	Net credit Consumables purchase	Average trade payables	3.14	1.59	98%	Due to decrease in Trade payables.
Net Capital Turnover Ratio	Revenue from operation	Working Capital	(3.61)	6.63	-155%	Due to decrease in Current Assets.
Net Profit Ratio(%)	Net profit after taxes	Revenue from operations	-16%	-0.99%	1550%	Due to decrease in Net profit after taxes.
Return On Capital Employed(%)	Profit before tax and finance costs	Capital employed	-6%	4%	-260%	Due to decrease in Profit before tax and finance costs.

Note 43: Other Statutory Information

- a). No proceeding have been initiated or pending against the Company under the Benami Transactions (Prohibitions) Act, 1988 (45 of 1988) and the Rules made thereunder.
- b). The Company has not traded or invested in crypto currency or virtual currency during the financial year.
- c). The Company does not have any transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).
- d). The Company has not been declared wilful defaulter by any bank or financial institution or government or any other government authorities.
- e). The company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
 - i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
 - ii) provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries.
- f). The company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the company shall:
 - i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
 - ii) provide any guarantee, security or the like on behalf of the ultimate beneficiaries.
- g). The Company does not have any transactions with struck off companies.

ARUNJYOTI BIO VENTURES LIMITED

- h). The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.
- i). The Company has complied with the number of layers prescribed under clause (87) of section 2 of the Act read with the Companies.

(Restriction on number of Layers) Rules, 2017

- j). For the year ended March 31, 2026, the company is not required to transfer any amount into the Investor Education & Protection Fund.
- k). The differences between the quarterly return of inventories and receivables submitted to the banks and the books of account, did not affect the required security cover computed in accordance with the sanctioned terms.
- l). The Company has granted loans or advances in the nature of loans to related parties (as defined under the Companies Act, 2013), which are repayable on demand and/or without specifying any terms or period of repayment. The details of such loans outstanding as at the balance sheet date are as follows:

Type of Borrower	Amount of loan or advance in the nature of loan outstanding (in Lakhs)	Percentage to the total Loans and Advances in the nature of loans
Related Parties	65.99	100%

- m). No Scheme of Arrangements has been approved by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013.
- n). The company has not revalued its property, plant and equipment (including right-of-use assets) or intangible assets or both during the current or previous year.

ARUNJYOTI BIO VENTURES LIMITED

- o). All the title deeds of immovable properties included in property, plant and equipment are held in the name of the Company.

Note 44:

The Company has used accounting software during the year which has the audit trail feature enabled throughout the year. Post publication of ICAI implementation guide in February 2024, direct database level changes were also included in audit trail scope, which was not enabled for application used for maintaining books of accounts.

Note 45:

Previous year's figures have been regrouped, wherever necessary, to confirm to current year's grouping.

Note 46:

The financial statements were approved by the board of directors on May 13, 2026.

As per our Report of even date attached
for PKF Sridhar & Santhanam LLP
Chartered Accountants
Firm Registration Number: 003990S/S200018

Sd/-
Viswanadh VNSS Kuchi
Partner
Membership No.: 210789

Place: Hyderabad
Date: 13th May 2026

for and on behalf of the Board of Directors of
Arunjyoti Bio Ventures Limited
CIN: L01400TG1986PLC062463

Sd/-
Pabbathi Badari Narayana Murthy
Wholetime Director
DIN:01445523

Sd/-
Vishal Nadimpalli
Wholetime Director Cum CFO
DIN:02745303

Sd/-
Swati Jain
Company Secretary
Membership No.:A58986

If undelivered please return to :

ARUNJYOTI BIO VENTURES LIMITED

Door No.1-98/1/JSIC/6F/604-B6th Floor,
Jain Sadhguru Capital Park, Beside Image Gardens,
Madhapur, Shaikpet, Telangana - 500081